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Tissue Factor (TF; CD142) is the principal initiator of the coagulation cascade. This
45kDa protein is constitutively expressed in extravascular cells and as such forms a
protective haemostatic envelope surrounding the vasculature ready to initiate
coagulation on vascular injury. When bound to its cofactor factor Vll/VIIa in the
normal bloodstream, it forms a highly catalytic complex (TF/VIIa) which triggers the
activation of factors IX and X and ultimately the formation of a fibrin clot. Peripheral
blood cells do not, in a resting state, express TF allowing maintenance of the fluidity
of the blood. However, agonists such as bacterial lipopolysaccharide (LPS) and
immune complexes, if present in the bloodstream can induce the expression of TF on
monocytes resulting in activation of the clotting process. This induction ofmonocyte
TF has been clearly implicated in the pathology of various disease processes such as
disseminated intravascular coagulation (DIC) following endotoxaemia,
thromboembolic disease and atherosclerosis. I have characterised a whole blood
model to investigate the induction of TF on monocytes, and have developed a highly
specific and sensitive flow cytometric technique to measure the TF protein on the cell
surface of activated monocytes. I have shown that there is a reproducible dose
dependent induction of TF on monocytes in whole blood by LPS (1 Opg/ml-1 OOpg/'ml)
after a 2 h incubation. Antisense therapy is aimed at the specific inhibition of a
particular target protein by preventing the translation of its mRNA. Antisense (AS)
oligodeoxynucleotides (ODNs) are short single stranded lengths of reverse
complementary DNA which can be designed to specifically hybridize to a target
mRNA, through Watson and Crick base pairing laws, arresting translation of the
protein. I have investigated the potential of ASODNs to inhibit specifically the
nascent induction of TF in monocytes in response to LPS. I have characterised the
uptake kinetics of a fluorescently labelled 25 base phosphorothioate oligonucleotide
GEM-91 (Gene Expression Modulator number 91) into peripheral blood leukocyte
subtypes. I have shown that the uptake of GEM-91 is dose and time dependent and is
not saturated at concentrations of up to 1 Op,M for 4 hours. I have also shown that
monocytes internalize 2 and 4 fold higher levels of oligonucleotide than neutrophils
or lymphocytes respectively. Monocytes internalized approximately 200fg GEM-
91/cell after 0.5 hours in culture rising to 800fg/cell after 4 hours. This apparently
selective and efficient uptake of ODNs in monocytes suggests that they may be an
attractive target for antisense therapy. It has been suggested that ODNs enter cells by
the active process of receptor mediated endocytosis. A number of groups have
alluded to the identity of the putative antisense receptor. I have investigated the
involvement of two monocyte cell surface receptors in the uptake of ODN, and have
concluded that both the Mac-1 (CD 1 lb/CD18) and CD14 receptors may be involved
to differing extents in the uptake of ODN into monocytes. I then went on to
investigate the potential of three different antisense ODNs to TF to reduce the
induction of TF by E. coli 0111 :B4 LPS in monocytes in whole blood. I have shown
that certain ODNs actually induce TF on monocytes and that as a result an equilibrium
may exist between TF induction by ASODNs and its inhibition. 1 have concluded that
ASODN offer great potential as an anti-TF therapy in monocytes, but much work
needs to be done to improve their specificity, delivery and intracellular bioavailability.
The TF inducing ability of a range of LPS molecules from different bacterial sources
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has also been investigated. The experiments described "have shown that LPS structure
and bacterial source are important in determining the potency of LPS at inducing TF.
In addition, I have concluded that LPS from the ubiquitous gut bacterium Bacteroides
fragilis is less potent at inducing TF than E. coli LPS and have also shown that this
LPS is capable of reducing the potency of the E. coli LPS at inducing TF. This may
have protective implications. In summary, the studies reported in this thesis aimed to
investigate the expression and control of TF in peripheral blood monocytes. The
therapeutic potential of ASODNs at inhibiting this expression has been investigated.
Particular attention has been paid to the uptake kinetics of ASODNs into peripheral
blood leukocyes and the possible mechanisms involved. The possible protective effect
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The ability of tissues, or their extracts, to induce the clotting of blood was first
reported by Thackrah in 1819 and was later confirmed by de Blainville in 1834 when
he noted that the infusion of a suspension of brain into animals produced widespread
coagulation within blood vessels and subsequent death. Schmidt (1892) believed that
the tissues contained a substance that directly converted prothrombin to thrombin
resulting in clot formation. Consequently, much of the work done in the early 1900s
was concerned with identifying the nature of this procoagulant activity present in the
tissues. It was argued that the responsible substance was either a lipid, a protein, an
unknown activator of prothrombin, or thrombin itself (Howell 1912; Mills, 1921;
McLean, 1916). In 1921, as part of his doctoral thesis, Mills sites Wooldridge as
having demonstrated that the procoagulant activity of tissues required both
phospholipid and protein and was thus due to a lipid/protein complex. In his research,
he went on to demonstrate that the protein and lipid fractions of tissues could be
separated, resulting in loss of procoagulant activity, but that these components, when
recombined, possessed 250-fold more activity than the individual fractions.
Subsequent studies went on to demonstrate that the potent procoagulant activity in
tissues was an apolipoprotein (Chargaff, 1944,1948) and that it required both a
protein and a phospholipid portion for full procoagulant activity (Kuhn and Cleese
1957; Hvatum and Prydz, 1969; Deutsch et al., 1964, Nemerson, 1968). It is now
accepted that the potent procoagulant property of tissues is due to tissue factor (TF)
(factor III, thromboplastin) or more accurately the tissue factor apoprotein complexed
with membrane phospholipids (Carson, 1984; Mann et al., 1988; Bach, 1988;
Nemerson, 1988; Broze, 1992; Roberts, 1992).
1.1.1 The Coagulation System
In 1905, Morawitz summed up the previous century's work leading to a theory of
blood coagulation involving the interaction of four factors. Three factors
prothrombin, calcium ions and fibrinogen, were present in plasma whilst the fourth,
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thrombokinase (tissue factor) was believed to be contained within the platelets and
leukocytes. When blood came into contact with tissues, platelets and leukocytes were
thought to aggregate and liberate TF. The released TF was then thought to react with
prothrombin in the presence of calcium ions to generate thrombin which converted
fibrinogen into the fibrin strands of a blood clot. Destroyed cells were believed to
provide a second source of TF , which caused the blood to clot more rapidly at the
site of a wound. By the middle of the century, as new clotting factors were
discovered, it became apparent that blood coagulation could be initiated in at least
two ways. Finally in 1964, Macfarlane and Davie & Ratanoff had developed the
cascade hypothesis of coagulation, separating the known clotting factors into two
pathways; the intrinsic and the extrinsic converging at the activation of factor X. In
the intrinsic pathway the exposure of the contact factors (factor XII, high molecular
weight kininogen and prekallikrein) in plasma led to the activation of factor XI with
susequent activation of factor IX which, in the presence of factor VIII cleaved factor
X to factor Xa. In the extrinsic pathway, coagulation was triggered by the binding of
plasma factor VII to TF, with susequent activation of factor Xa. Factor Xa then
converted prothrombin to thrombin, which induced the formation of cross linked
fibrin from fibrinogen monomers and finally a blood clot.
1.1.2 TF /TFPI in Haemostasis
The catastrophic bleeding of haemophiliacs, who are deficient in factor VIII but have
an intact extrinsic pathway initially led investigators to believe that the intrinsic
pathway initiated coagulation during haemostasis. However, the fact that patients
deficient in one of the contact factors required to initiate the intrinsic system are
asymptomatic (Hathaway et al., 1965; Nemerson & Furie 1980; Kaplan & Silverberg
1987) whereas individuals deficient in factor VII bleed abnormally (Ragni et al 1981;
Triplett et al 1985), and the obsevations by 0sterud & Rappaport (1977) that factor
Vila/tissue factor can activate factor IX of the intrinsic pathway as well as factor X
led to a resurgence of interest in the extrinsic pathway in the 1980s. The recent
discovery of an endogenous inihibitor of TF, Tissue Factor Pathway Inhibitor (TFPI),
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a novel, endogenous, kunitz-type inhibitor of TF mediated coagulation, led to the
reorganisation of the system placing TF as the prime initiator of coagulation. The first
step which occurs upon the exposure of blood to extravascular tissues is the binding
of VII to TF, its cell surface receptor and cofactor. The resulting TF/factorVII
complex is activated by trace amounts of factor Xa present in blood or the
extravascular space, forming the highly active enzyme complex TF/factorVIIa. This
in turn activates both factor IX and factor X. Factor Xa then converts prothrombin to
thrombin, which finally induces the formation of fibrin from fibrinogen monomers
resulting in a blood clot (Fig. 1.1). Consequently, today coagulation is divided into
two stages rather than two pathways: an 'initiation' stage which is handled by the TF-
dependent pathway, and an 'augmentation' stage, which is handled by the components
of the previous intrinsic pathway. Both pathways are able to generate fibrin, but the
TF pathway is shut off by TFPI, soon after initiation. By this time, however,
sufficient thrombin will have been generated to activate factors V, VIII, and XI. The
second augmentation stage of the pathway will then ensure prolonged activation of
the coagulation cascade (Fig 1.1). This model suggests that TF is responsible for
activation of the coagulation cascade whilst the intrinsic components are required for






FIGURE 1.1 The Role of Tissue Factor in Coagulation
Haemostasis is initiated when factor VII or factor Vila comes into contact with TF at a site of blood
vessel injury. Limited quantities of factor IXa and factor Xa are generated before there is feedback
inhibition of the factor VIIa/TF complex mediated by TFPI and factor Xa. The generation of factor
Xa is then amplified through the action of factor Villa and factor IXa; the latter produced initially by
factor VIIa/TF and supplemented by factor XIa. Factor XI activation may be produced by thrombin
and autoactivation by factor XIa.
Feedback Inhibition
Feedback Augmentation
Adapted from Broze et al., 1992
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1.2 Tissue Distribution of TF
The distribution of TF activity in different tissues of the human body was studied by
Asrup in 1965. TF activity was found at highest levels in brain, lung and kidney.
More recent studies with specific mono- and polyclonal antibodies have allowed the
more precise, cell specific localization of TF antigen by immunohistochemical studies,
to the vascular adventitia, organ capsules, epithelium of skin and mucosa (Faulk et al.,
1990; Fleck et al., 1990; Flossel et al., 1994), Bowman's capsule of glomeruli in the
kidney (Flossel et al., 1994) astrocytes in the brain (Flossel et al., 1994; Delzoppo et
al., 1992; Eddleston et al., 1993). TF antigen has also been detected in stromal cells
of the human endometrium (Lockwood et al., 1993) suggesting that TF serves to
promote preimplantation endometrial haemostasis. Unperturbed endothelium and
peripheral blood cells did not express TF and fibroblasts showed variable staining
patterns. This strategic anatomical localization of TF has led to the hypothesis that
TF provides a 'haemostatic envelope', initiating rapid activation of coagulation in the
event of vessel damage, whilst at the same time remaining separate from the cells in
the circulation to prevent aberrant thrombosis formation. Further support for the
hypothesis that TF forms a lining to protect against haemorrhage is the high level of
TF antigen in placental tissue, and the observation that oestradiol induced the
production of TF mRNA in stromal endometrium in immature rats (Quirk et al.,
1995). It is also known that TF is expressed early in human and murine development
prior to formation of the circulation (Luther et al., 1996). In addition, during the
early stages of TF expression there was no detectable expression of factor VII. This,
combined with the recent discovery that TF is a true receptor, (Rottingen et al., 1995)
suggests the possibility of other ligands for TF outside the coagulation system. This
will be more fully discussed later. TF is thought to be responsible for the continuous
generation of small amounts of factors IXa and Xa occurring under basal conditions
(Bauer et al., 1990; Bauer et al., 1989a). Such basal activation of coagulation could
result from exposure of blood to the trace amounts of TF detectable in normal plasma
(Francis et al., 1995) or could occur at extravascular sites where, due to the presence
6
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of factor VII in the interstitial fluids, TF/VII complexes can always be present on cells
constitutively expressing TF (Rapaport et al., 1995).
Atherosclerotic plaques were found to contain many cells synthesizing TF including
macrophages and intimal cells. The necrotic core of plaques contained cell-free TF
protein. These deposits of TF may be involved in the promotion of thrombosis on or
in athersclerotic vessel segments. This topic will be discussed later in the context of
TF in disease.
1.3 Physiology and Physical Properties of TF
1.3.1 TF Protein
Tissue factor protein was fully purified from bovine brain in 1981 by Bach et al., and
was further characterised simultaneously by Broze and by Nemerson (Broze et al.,
1985; Guha et al., 1986) and has recently been assigned the designation CD142. It is
a 45kDa, single chain, transmembrane protein, synthesised as a 295 amino acid
polypeptide. It consists of two immunoglobulin-like domains associated through an
extensive, novel interdomain interface region. In its mature form, TF consists of 263
amino acids organized into a 219 amino acid extracellular domain, which is
responsible for binding VH/VIIa, a 23 amino acid transmembrane segment and a 21
amino acid cytoplasmic tail (Morrissey, 1987) (Fig. 1.2) It bears sequence homology
to the interferon gamma receptor and so has been classified as a member of the
cytokine superfamily of receptors (Bazan, 1990). Unlike other protein cofactors of




FIGURE 1.2 Structure of the TF Protein. Based on sequence homology with other members of the
cytokine/interferon receptor family of proteins, the extracellular region of TF is depicted as two
domains that form a V-shaped, ligand-binding trough. The predicted transmembrane domain
traverses the plasma membrane on a cell and is followed by a short cytoplasmic tail. The single
letter amino acid code is used.
^ ^ denotes sites of carbohydrate attachment
denotes palmitate or stearate.
The three Trp-Lys-Ser sequences are shown in bold. Site of introns in the TF gene are labelled with
capital letters .
Taken from Broze in Flaemostasis and Thrombosis, Third Edition, 1994 Volume I. Eds Bloom, et
al. Chapter 15 pp351
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1.3.2 TF as a Receptor
As well as acting as a cofactor for Vila, TF has now been shown to act as a true
receptor by two different groups. To act as a true receptor, a protein must elicit an
intracellular signal upon ligand binding. Masuda et al., demonstrated that binding of
factor Vila to cell surface TF on four-day cultured human monocytes could induce
transient tyrosyl phosphorylation of intracellular proteins, in particular a 70-kD
polypeptide (Masuda et al., 1996). This phosphorylation reached a maximum by 30
seconds with dephosphorylation being complete within a few minutes. This study also
reports that TF was co-localised with the 14kDa y-chain homodimer from the IgEFc
receptor. This is a signal transducing element homologous to the zeta chain
associated with many other cytokine receptor complexes. Roy et al., 1991 have
shown that TF can be cross-linked to both a 70kDa and a 14kDa polypeptide on the
cell surface, neither of which have yet been identified. Rottingen et al., 1995 have
demonstrated that the binding of factor Vila can induce transient cytosolic calcium
increases in 4 different cell lines: induced HUVECs, constitutive TF producers like
Madine-Darby Canine Kidney (MDCK) cells and the human bladder carcinaoma cell
line J82, and transfected COS-1 cells. In contrast to the observations of Masuda,
Camerer et al., 1996 further noted that this response ofMDCK cells was dependent
on the proteolytic functionality of factor Vila and while being inhibited by U73122, a
specific inhibitor of phosphoinositol-specific phospholipase C, was not inhibited by a
number of tyrosine kinase inhibitors (Camerer et al., 1996a). In this report, the
authors also note that the calcium oscillations observed can be triggered by factor Xa
as well as Vila. Both inactivated factor Xa and inactivated factor Vila show
homologous desensitization of receptor function, indicating that the proteins bind to
distinct separate receptors on the cell surface. They suggest that the role of TF in the
phosphatidyl inositol-specific phospholipase C-mediated Ca2+ signalling pathway may
be to anchor factor Vila to the cell surface allowing it to cleave an as yet unidentified
protease activated receptor, analagous to the thrombin receptor, rather than itself
mediating any transmembrane signal. These studies have been carried out on either
cell lines or cultured cells which are likely to behave differently to cells in vivo and are
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sensitive to culture contaminants. For these reasons it is still not clear as to what class
of receptor TF might belong, or indeed if TF actually functions as a signal
transduction molecule in vivo.
1.3.3 The TF Gene
The human TF gene is 12.4 kbp in length and is located on the short arm of
chromosome 1 (Carson et al., 1985; Scarpati et al., 1987; Kao et al., 1988). It is
organised into 6 exons which are separated by 5 introns. Exon 1 encodes the N-
terminal signal peptide that is removed during processing of the protein. Exons 2-5
encode the extracellular portion of the TF molecule, and exon 6 encodes both the
transmembrane and cytoplasmic domains as well as a long 3' untranslated region
(Mackman et al., 1989). The 5' untranslated region of the TF transcript is 123 bp in
length and the transcription start site is located 26bp downstream from a TATA
promoter element. The TF promoter is spanned by a CpG island (Bird, 1986),
suggesting that methylation of this region may prevent expression of the TF gene in
various cell types including T and B lymphocytes. When serum starved fibroblasts are
stimulated with growth factors, TF mRNA expression typically increases and reaches
a maximum 1-2 hours after stimulation in the absence of de novo protein synthesis
(Taby et al., 1996; Bloem et al 1989). This confirms the classification of TF as an
'immediate early' or 'primary response' gene along with c-myc although it is not
induced as early as c-fos (Lau et al., 1987).
1.4 Regulation of TF Expression
The TF promoter appears to allow at least three modes of regulation and it is
apparent that TF gene expression is regulated differently in different cell types. In
most extravascular cell types, the TF gene is constitutively expressed. However, in
some of these cell types TF synthesis is turned off by serum/growth factor starvation,
and may be induced by reintroduction of these compounds to the medium. In cells
such as monocytes, macrophages and endothelial cells the TF gene is not
10
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constitutively expressed but may be induced by a variety of agonists including
bacterial lipopolysaccharide (LPS) and Tumour Necrosis Factor-a (TNF-a) (Tables
1-3). Comparison of promoter sequences from human (Mackman et al., 1989)
murine (Mackman et al 1992 ) and porcine (Moll et al., 1995) TF genes reveals
conservation ofDNA binding sites for several transcription factors that regulate gene
expression. These include four Spl sites (Kadonaga et al., 1986) Egr-l (Berg et al.,
1992), AP-1 (Lee et al., 1987), and NF-kB (Singh et al., 1988). All these conserved
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1.4.1 Regulation of Basal Expression
(Monocytic Cells, Vascular Endothelial Cells, Vascular Smooth Muscle Cells,
Epithelial -Like cells)
To analyze functional expression of the TF promoter, various 5' flanking regions of
the TF gene were cloned upstream of the firefly luciferase reporter gene (Mackman et
al., 1990). Initial studies using transiently transfected COS-7 cells, a simian virus 40-
transformed monkey kidney cell line which constitutively expresses TF, demonstrated
that the TF promoter directs expression of the luciferase reporter gene. Deletion of
the promoter from -2106 to -383 did not change the basal transcription of the gene.
However, further deletion of the promoter, from -383 to -279 increased the basal
transcription, indicating the presence of a negative regulatory element in this region.
Subsequent deletion of the region between -278 and -112, which contains both AP-1
sites, the NFkB and a putative Spl site decreased basal transcription. However,
mutation of the Ap-1 and kB sites indicates that they do not contribute to basal
promoter activity. The role of the putative Sp-1 site remains to be determined. These
initial studies by Mackman determined that the 'minimal' TF promoter required for
basal expression of TF contains three Sp-1 binding sites and spans a region between -
111 and +14 bp relative to the start site of transcription. Mutational analysis of this
region in HeLa cells suggests that the Spl sites are synergistic and that at least two
must be retained to maintain a basal level of transcription (Cui et al., 1994).
1.4.2 Induced TF Expression.
Consistent with its potent coagulant activity and immunohistochemical localization, it
is apparent that TF is necessarily not normally expressed by intravascular cells. It can,
however, be induced in vitro in monocytes and endothelial cells by a number of
exogenous and physiological stimuli (Tables 1-4). These include endotoxin (LPS)
(Rivers et al., 1975), tumour necrosis factor (Bevilacqua et al., 1986), interleukin-
l(Nawroth et al., 1986) , immune complexes (Prydz et al., 1979) or phorbol esters
(Romberg et al., 1982). Other reports indicate that gamma interferon (Moon et al.,
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1988) or granulocyte -macrophage colony stimulating factor (Zuckerman et al., 1989)
can act synergistically with LPS to induce macrophage associated TF.
1.4.2.1 Serum Growth Factor and Phorbol Ester (PMA) Induction of TF Gene
Expression.
Stimulation of quiescent murine and human fibroblasts with serum or mitogens rapidly
(1-2 hours) induced TF mRNA without the requirement for de novo protein synthesis
(Lau et al., 1987; Hartzell et al., 1989; Bloem et al., 1989; Ranganathan et al., 1991).
In quiescent rat vascular smooth muscle cells (Taubman et al., 1993) and in human
epithelial cells (Cui et al., 1994), TF synthesis was induced by PMA as well as by
serum growth factors. Induction both by serum and by PMA requires calcium,
whereas only PMA induction requires protein kinase C (Taubman et al., 1993; Cui et
al., 1994), suggesting that serum and PMA induction of TF expression is mediated by
different signalling pathways. Mackman has suggested that the serum response region
(SRR) of the TF gene is located between residues -111 to +14 on the TF promoter
and is unrelated to the c-fos serum response element. Mutational analysis of this
region in HeLa cells, demonstrated a redundancy in this element: deletion of
individual Sp-1 sites failed to inhibit induction indicting that no individual element was
absolutely required for the induction of TF expression, rather several distinct DNA
elements may act in concert to regulate serum and PMA induction. (Cui et al., 1994).
Gel shift mobility assays were subsequently used to analyze the binding of nuclear
proteins to radiolabeled oligonucleotides spanning the SRR between -111 and +14 bp
(Cui et al., 1994). These studies revealed constitutive binding of Sp-1 to all three
Sp-1 sites in the SRR. In addition, serum or PMA stimulation of HeLa cells induced
de novo expression of Egr-1 that bound to three sites that overlapped the three Sp-1
sites. Erg-1 is an immediate early gene that is transiently expressed in fibroblasts and
epithelial cells in response to stimulation with serum growth factors (Madden et al.,
1993). Interestingly, induction of Erg-1 mRNA and protein precedes induction of TF
mRNA in serum stimulated fibroblasts (Hartzell et al., 1989). Recent studies in HeLa
cells using plasmids containing mutations in both the Sp-1 and the Egr-1 sites have
14
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indicated that both the Sp-1 and the Egr-1 recognition sites are involved in the
regulation of the serum induction of the TF gene (Cui et al., 1996).
1.4.2.2 LPS and Cytokine Monocytic Cell TF Induction
Recent observations have indicated that thrombosis may be triggered by the aberrant
expression of TF on the surface of activated peripheral blood monocytes (Barstad et
al., 1995). Inhibition of protein or RNA synthesis inhibits the expression of TF
procoagulant activity in stimulated monocytes suggesting that there is not an
intracellular pool of presynthesised TF and that de novo synthesis is required for
monocytes to express procoagulant activity (Gregory et al., 1989; Crossman et al.,
1990). In vitro, bacterial LPS, cytokines and PMA are among the agonists that
induce TF expression in monocytes. TF synthesis is generally induced by agents
which increase the levels of cytosolic calcium, and suppressed by agents which
increase the levels of cyclic AMP (Lyberg et al., 1983; Prydz et al., 1980). There are
at least three cell surface receptors for LPS, CD14 (Wright et al., 1990), CD11/CD18
(Wright et al., 1986) and a 80kDa protein (Bright et al., 1990), and occupancy and
involvement of these is possibly dependent on the amount of LPS applied (Ternisien
et al., 1995). Difficulties in transfecting primary monocytes have precluded the direct
analysis of the TF promoter in these cells. Studies by Mackman et al., have focused
on a human monocytic cell line, THP-1, which is derived from an acute human
monocytic leukaemia and which induces TF gene expression in a manner similar to
peripheral blood monocytes, to investigate regulation of the human TF gene (Brand et
al., 1991). The region of the TF promoter responsible for activation of TF synthesis
by LPS and cytokines appears to be distinct from the serum response region.
Deletion analysis of the TF promoter in human monocytic cells allowed Mackman et
al., to restrict the LPS response to a distal enhancer (LRE), a 56 bp region from -227
to -172 containing the two AP-1 like motifs and one NF-kB like motif (Mackman et
al., 1991). Recent functional studies by Mackman et al., using THP-1 cells show that
LPS induction of the LRE is abolished by mutation of either of the AP-1 sites or the
kB site (Oeth et al., 1994; Parry et al., 1995). Upon stimulation with LPS through
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the CD 14 receptor, the TF promoter binds c-Jun, Fos being constitutively bound
(Groupp et al., 1996) suggesting that the initiation complex involves an interaction
between c-Rel/p65 on the NFkB site and c-Jun/Fos on the API site (Mackman et al,
1995; Stein et al., 1993). Prior to LPS stimulation, the c-Rel-p65 complex is retained
in the cytosol in complex with the inhibitor IkBo. (Oeth et al., 1994; Parry et al.,
1995). Activation of the complex requires dissociation and proteolytic degradation of
the inhibitor before nuclear translocation of the complex (Mackman et al., 1994;
Henkel et al., 1993). MAD3, an IkB protein that has been shown to be involved in
downregulation of NFkB translocation to the nucleus (Zabel et al., 1993) is
phosphorylated in THP-1 cells upon LPS stimulation (Cordle et al., 1993). This
suggests that upregulation of TF expression upon LPS stimulation may be due to
phosphorylation and degradation of the inhibitor IkB (Finco et al., 1995), allowing
the translocation of the c-Rel-p65 complex to the nucleus and subsequent binding to
the TF promoter. A number of studies have suggested that LPS can induce NFkB
activation via a number of different mechanisms. In CHO cells (which do not
normally respond to LPS) transfected with a CD 14 expressing plasmid and RAW
264.7 cells (Delude et al., 1994) NFkB nuclear translocation does not require tyrosine
kinase activity. However, NFkB activation by LPS was inhibited in c6 glicoma cells
by incubation with the tyrosine kinase inhibitor herbimycin A (Nishiya et al., 1995).
1.4.2.3 Endothelial Cell TF Induction
Vascular endothelial cells have also been shown to express TF in cell culture when
stimulated by LPSs (Colluci et al., 1983), thrombin (Brox et al., 1984), IL-1
(Bevilacqua et al,. 1986) and TNF-a (Bevilacqua et al., 1986). Cytokine and LPS
induction of the human and porcine TF promoters transfected into human, porcine
and bovine endothelial cells is mediated by the binding of transcription factors to the
two AP-1 sites and the NFkB site within the LRE (Bierhaus et al., 1995; Bierhaus et
al., 1995; Moll et al., 1995; Parry et al., 1995) in a manner similar to human
monocytic cells. In addition, over expression of the inhibitor IkBoc dramatically
reduces TF expression in stimulated porcine endothelial cells (Wrighton et al., 1996),
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confirming a role for c-Rel-p65 in inducible TF expression in these cells. Mackman et
al, have also shown that PMA induction of the TF promoter in human umbilical vein
endothelial cells (HUVEC) is mediated by the LRE and a second PMA response
element containing three Egr-1 sites (Parry et al., 1995). Unpublished data by
Mackman et al., have shown that PMA induces Egr-1 in HUVECs suggesting that
Egr-1 may contribute to the induction of TF gene expression in endothelial cells as
has been shown in monocytic cells. However, it is widely believed that TF induction
in endothelial cells is an in vitro phenomenon as expression of TF in the endothelium
has been observed only rarely in vivo. Saphenous veins and internal mammary
arteries from coronary bypass surgery and athersclerotic plaques from carotid
endarterectomy specimens failed to show TF expression (Wilcox et al., 1989).
Furthermore, immunocytochemical studies of E. coli induced DIC in baboons
revealed endothelial TF expression associated only with the endothelium in the splenic
microvasculature (Drake et al., 1993). TF has, however, been found in
subendothelium in ballooned human and rabbit arteries (Weiss et al., 1989), and after
ex vivo TNFa stimulation of segments of bovine aorta (Ryan et al., 1992) but not
after ex vivo LPS or thrombin stimulation of isolated intact human saphenous veins
(Solberg et al., 1990). In humans, TF is expressed in vascular endothelial cells within
tumours of patients with invasive breast cancer (Contrino et al., 1996). Limited
activity seen in some studies may be caused by the presence of TFPI. Lack of
immunological detection may be caused by sensitivity limitations, as the level of
induced TF expression in endothelial cells is lower than the constitutive expression in
other cell types (Diquelou et al., 1995). It is also possible that there is heterogenous
expression of TF in endothelial cells (Kirchhofer et al., 1994; Mackman et al., 1995)
or that repressor systems might limit the expression of TF in endothelial cells in vivo.
0sterud, 1995b has also proposed that the endothelium is not procoagulant in itself
but it may support reactions that enhance TF generation in the vascular system, such
as the binding and activation of neutrophils and monocytes and their interactions with
platelets. Alternatively, it may still be possible that TF is expressed in endothelial cells
in vivo, but that the induction is more tightly controlled or more difficult to detect
than in the cell culture situation.
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Inducing Agent Monocyte Endothelial Cell
Lineage Lineage
Bacterial Lipopolysaccharide Rivers etal., 1975 Lyberg etal., 1981
Rickettsia rikettsii Sporn et al., 1994
Rickettsia conorrii Teysseireetal., 1992
N.Meningitdis 0sterud et al., 1983
M. leprae/M. bovis Lyberg etal., 1982
Serum from P.falciparum malaria Hemmer et al., 1991
patients
Antiphospholipid sera Branch & Rodgers, 1993
Monoclonal anticardiolipin Romberg et al., 1994
antibodies
Mouse hepatitis virus Levy etal., 1981
Lectins Lyberg et al., 1980
Phorbol ester Lyberg etal., 1981 Lyberg etal., 1981
Calcium ionophores Prydz et al., 1990
Diacylglycerol Petterson etal., 199
Amines Dean etal., 1983
TABLE 1.1 Induction of TF Synthesis by Exogenous Agents.
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Bevilacqua et al., 1986,
Carlsen et al 1988
Clauss et al., 1990
Celi et al 1994
Prydz etal., 1979
Prydz et al., 1977
Cermaketa/., 1993
Schuff-Wenier et al., 1989
Lesnik et al., 1992
Faucette et al., 1992
Kornberg et al., 1990
Crutchley et al., 1995
Siegbahn et al., 1995
Siegbahn etal., 1995
Brox etal., 1984, Gladal etal., 1985
Carlsen et al 1988
Carlsen et al 1988
Bevilacqua et al., 1986;Nawroth et
al., 1986; Carlsen et al 1988
Clauss etal., 1990





TABLE 1.2. Induction of TF Synthesis by Physiological Agents
Adapted from Camerer et al., 1996
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Inducing Condition Monocyte Endothelial Cell
Lineage Lineage
Allogenic lymphocytes Carlsen et al., 1989 Lyberg et al., 1983;Carlsen et al., 1989
Monocyte adherence Lo etal, 1995
activated EC
Platelet adherence Niemetz & Marcus 1974 Johnsen et al., 1983
Hypoxia Gertler et al., 1991
Phagocytosis Dean etal., 1983
TABLE 1.3. Induction of TF Synthesis by Cell Interaction and Other Conditions
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1.4.3 Control of TF Synthesis
It has been reported that TF procoagulant activity is greater in lysed cells than in
intact cells (Carson et al., 1986; Maynard et al., 1975). However, it has been
variously shown that TF protein is entirely expressed on the cell surface ofmost cells.
Therefore, it appears that the catalytic activity of the TF/VIIa complex on most intact
cells is markedly less than that in cell lysates suggesting that alterations in membrane
lipids may be a means of regulating TF procoagulant activity. Treatment of cells with
calcium or an ionophore can mimic the TF increase seen with cell disruption,
suggesting that there may be a calcium associated physiological control of membrane
activity at this level (Bach et al., 1990). The complex pattern of TF expression in
different tissues and cell types suggests that regulation of TF procoagulant activity
involves different regulatory mechanisms. In monocytes, LPS treatment induces
transient de novo transcription of the TF gene resulting in a transient increase in TF
activity (Gregory et al., 1989; Mackman et al., 1990). Therefore, it is apparent that
the primary level of regulation in the monocyte is at the level of transcription.
However, it has also been shown that TF can be regulated by post transcriptional
mechanisms. A report by Brand et al. 1991 has demonstrated that TF mRNA stability
changes after LPS stimulation. One hour after LPS treatment, the half-life of TF
mRNA was greater than 120 minutes, whereas 2 hours after treatment, the half life
declined to 25 minutes. It has also been reported that high concentrations of PMA
can induce a rapid decrease in membrane associated TF in peripheral blood
monocytes, which suggests that TF can be modulated at the level of the plasma
membrane (Brozna et al., 1988). From these experiments it is apparent that TF
activity is regulated by several different mechanisms that modulate turnover of
membrane associated TF, stability of TF mRNA, TF gene transcription or translation
of TF mRNA.
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The first level of control after transcription lies in the stabilization/destabilization of
the primary transcript. Transcription of the TF gene begins within 15 minutes of
treatment with LPS and reaches a maximum level after 1 hour. Tissue factor mRNA
transcripts accumulate to maximum levels within 4 hours and then decrease rapidly
(Gregory et al., 1989). In monocytes, the transient increase in TF mRNA levels
correlates with a transient increase in TF procoagulant activity which is maximal 4-6
hours after LPS treatment. It is, therefore apparent that expression of TF
procoagulant activity is dependent on continuous TF mRNA synthesis, since when TF
mRNA synthesis ceases, TF procoagulant activity declines. The major TF transcript
is 2.2 kb in length, but in several cell types and tissue from placenta, a small
proportion of longer transcripts (3.1 - 3.4 kb) is seen (Scarpati et ai, 1987). In LPS
stimulated monocytes, the longer transcript arises from an alternative splicing
including 955 bp on intron 1 (Vanderlogt et al, 1992; Brand et al., 1991). As intron
1 contains an inframe stop codon, no protein is produced from this transcript. During
the stimulation of THP-1 cells, only the smaller (2.2-kb) transcript was detected
initially, but after 4 hours the larger 3.4 kb transcript was present and appeared to be
more stable (Brand et al., 1991).
1.4.3.2 Posttranslational Control of TF Expression
After production of the mature protein, the next step in the regulation of TF
expression is its cellular localisation. In order to serve as a receptor/cofactor for
factor VII, TF must be present on the cell surface in a suitable configuration to initiate
coagulation. It has been reported that not all of the TF/VII complexes on the cell
surface are capable of supporting coagulation (Le et al., 1992) in that TF may be
present but not functional. TF may be active but not functional if expressed in a
region where it is unavailable to the plasma clotting factors except on cell lysis. TF
activity increases dramatically following cell lysis, the surface activity being typically
20% of the activity observed after lysis (Drake et al., 1989; Le et al., 1992; Rao et
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al., 1992). Binding of neutralizing monoclonal antibodies to intact monocytes
resulted in more than 90% inhibition of the TF activity in lysed cells, suggesting that
TF is predominantly surface expressed (Drake et al., 1989). This was also observed
in the human ovarian carcinoma cell line OC-2008 (Rao et al., 1992). In contrast to
these results, TF antigen has been found in subendothelial vesicles of HUVECs and
not on the apical surface (Ryan et al., 1992). Tissue factor activity is thought to be
greater in lysed cells due to a component of the plasma membrane which is
unavailable on the cell surface but exposed on cell disruption. This component is
thought to be phosphatidylserine (PS), which is crucial for TF activity (Bach et al.,
1986; Bjorklid & Storm, 1977) In fibroblasts calcium ionophores have been shown to
rapidly increase surface TF activity without changing antigen levels (Bach et al.,
1990). Conversely, thrombin stimulation, whilst increasing cytosolic calcium, did not
produce the same effect as ionophores (Carson et al., 1994) These studies concluded
that there is a limiting amount of PS in the outer leaflet of the plasma membrane, and
that cell lysis increased TF activity by increasing the amount of PS available to the
TF/VIIa complex. They also suggest that redistribution or 'flip-flopping' of
membrane PS may be a way of modulating TF activity or by cell lysis to modulate TF
activity. Recently, two groups have reported that TF is localized to specific regions
of the plasma membrane (Sevinsky et al., 1996; Mulder et al., 1996). Sevinsky et al.,
1996 have shown that subsequent to TF/factorVIIa complexes forming on the
endothelial cell surface, they are actively transported to membrane domains called
caveolae. Futhermore, Mulder et al., have demonstrated that on smooth muscle cells
TF is localized to caveolae without the formation of enzyme/substrate complexes. It
has been reported that caveloae are deficient in anionic phospholipid binding sites
(Simionecu et al., 1981a; Simionecu et al., 1981b) but are rich in signalling molecules
including 1,4,5,-triphosphosphate receptors and protein kinase C (Smart et al., 1995).
Therefore, TF in caveloae could be speculated to be either a latent pool of
procoagulant activity (Mulder et al., 1996) or a downregulation of function (Sevinsky
et al., 1996). Another mode of regulation of TF activity is the surface turnover of the
protein. The activity of transmembrane proteins is often controlled by internalization,
recycling or exocytosis from intracellular pools. Zioncheck et al., 1992, have
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reported that although there are no endocytosis motifs in the cytoplasmic domain of
the TF molecule there is a conserved serine/threonine phosphorylation site which
might be a good candidate for control of membrane localization. This group also
reported that staurosporine inhibited this phosphorylation. As staurosporine has also
been reported to block downregulation of TF (Brozna et al., 1994) it might be
concluded that this phosphorylation is related to stabilization of the TF molecule on
the cell surface.
1.5 Tissue Factor in Disease
In recent years numerous studies have focused on the in vivo expression of TF in
health and disease. The selective perivascular, cell-specific distribution of TF and the
lethal effects of TF knockouts have added support to the view that TF plays a pivotal
role in the initiation of blood coagulation during physiological haemostasis.
Inappropriate in vivo expression of TF, particularly by intravascular cells that do not
express TF under normal circumstances (monocytes, macrophages and endothelial
cells), has been widely documented and is accepted to be responsible for aberrant clot
formation in a variety of pathological conditions including sepsis associated
disseminated intravascular coagulation (DIC) and thromboembolic disease. In
malignancy, in vivo expression of TF by tumour cells and/or by host cells has been
implicated not only in intratumoral and systemic activation of blood coagulation but
also in tumour growth and metastasis. Some of these disease states will be discussed
in detail below.
1.5.1 Endotoxaemia/DIC
Disseminated intravascular coagulation (DIC) arises due to inappropriate and
excessive activation of the coagulation process. Increased fibrin formation may lead
to diffuse microvascular thrombosis resulting in impairment of bloodflow, ischaemia,
multiple organ failure and subsequent death. Many different underlying diseases are
associated with DIC, including septicaemia, obstetric complications, severe trauma
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and malignancy (Bell et al., 1994). Exposure of TF to the peripheral bloodstream is
believed to be a common factor in the initiation of aberrant coagulation in D1C. This
may be due to direct exposure of preformed TF (during obstetric accidents or severe
trauma) or to induction of TF expression on the surface of activated monocytes such
as in sepsis (Brozna et al., 1990). In cancer, tumour cells may synthesize excessive
amounts of TF which may result in intravascular coagulation (Edwards et al., 1981).
Infusion of recombinant TF initiates DIC in rabbits, strongly suggesting that TF is able
to cause the disease (Warr et al., 1990). Disseminated intravascular coagulation
following gram negative septicaemia is the clearest model for the pathophysiological
significance of the aberrant expression of TF in cells in contact with the blood. To
establish the role ofTF in DIC, several animal models of lethal intravenous infusion of
bacteria have been utilized in rabbits, mice, baboons and chimpanzees. In rabbits,
mononuclear macrophages from various origins (blood, peritoneal cavity, pulmonary
alveoli, bone marrow and spleen) and aortic endothelium obtained after endotoxin
infusion express strong TF activity (Semeraro et al., 1981; Rothberger et al., 1983;
Montemurro et al., 1985; Semeraro et al., 1993). Furthermore, in mice treated with
endotoxin, TF mRNA was elevated in lung and kidney. In situ hybridization studies
further localized the mRNA to alveolar type II cells in the lung and tubular epithelial
cells in the kidney, whereas endothelial cells were negative (Mackman et al., 1995;
Mackman et al., 1993b). In baboons with E. coli septic shock, TF antigen was
detected in the splenic endothelial cells and macrophages as well as in lung alveolar
epithelial cells and glomerular epithelial cells (Drake et al., 1993). These experiments
coupled with the earlier observations that a normal number of leukocytes is required
for endotoxin induced DIC to occur, and that passive transfer of TF expressing
leukocyes into normal animals causes DIC (Muller-Berghaus et al., 1978) support the
concept that mononuclear phagocytes play a key role in endotoxin induced DIC. In
addition, monocytes from endotoxin resistant animals show a marked reduction in TF
expression when treated with endotoxin (Semeraro et al., 1992). Furthermore, both
TF neutralizing antibodies (Warr et al., 1990; Taylor et al., 1991; Levi et al., 1994),
factor VH/VIIa neutralizing antibodies (Biemond et al., 1995), TFPI (Day et al.,
1990; Creasey et al., 1993) and more recently active-site inhibited factor Vila (Taylor
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et al., 1997), reverse the lethality of endotoxin infusion in primate models, indicating
that TF dependent initiation of coagulation is responsible for the diseased state.
Moreover, depletion of TFP1 in a rabbit model sensitized the animals to DIC (Sandset
etal., 1991a; Sandset et al., 1991b).
Activation of coagulation is almost invariably observed in human sepsis However, the
pathophysiological mechanisms involved have been more difficult to elucidate than in
animals. As a result, human studies have been restricted to analysis of plasma or
circulating monocytes/macrophages. In severe infectious diseases such as
meningococcal infection and bacterial peritonitis peripheral blood monocytes
exhibited a significant increase in TF activity (0sterud et al., 1983; Almdahl et al.,
1987). Interestingly, the highest levels of cellular TF were seen in patients with lethal
outcome suggesting a prognostic value for this measurement. A substantial increase
in TF activity has also been reported in peritoneal macrophages from patients with
peritonitis (Almdahl et al., 1987), and in the bronchiolar lavage fluid of patients with
adult respiratory distress syndrome secondary to sepsis (Idell et al., 1989). Tissue
factor can also be found in plasma from patients with DIC (Takahashi et al., 1994;
Wada et al., 1994). Taken together, these studies demonstrate an important role for
TF in the initiation of coagulation in DIC.
It is of note that studies investigating LPS induction of clotting activity most often
utilize E. coli LPS. It is clear, however, that LPSs are a complex set of molecular
species the activities and functionality of which vary greatly and are dependent on
their structures and bacterial source. One of the most common causes of human
sepsis is bacterial infection following peritonitis. It is known that bacteria from the
Bacteriodes species outnumber E. coli in the gut by 1000 fold (Delahooke et al.,
1995), and so it is likely that these bacteria will be the major cause of infection in
disease complications involving gut rupture. It is, therefore, important to consider the
different TF inducing potential of these different bacterial LPSs. This is addressed
further in chapter 7
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1.5.2 Athersclerosis and Arterial Thrombosis
Thrombosis is linked to the development and progression of atherosclerosis. Acute
thrombosis can occur spontaneously leading to arterial blockage resulting in
myocardial infarction, unstable angina, stroke and sudden death (Fuster et ah, 1992).
Recent studies suggest that the accumulation of TF in atherosclerotic plaques plays a
major role in determining plaque thrombogenicity. TF is also rapidly induced in the
vessel wall as a consequence of acute arterial injury. Both phenomena may be
important in the thrombotic complications of atherosclerotic heart disease.
Monocytes are instrumental in the development of athersclerotic lesions. When
differentiated to macrophages in the vessel wall, they are scavengers of oxidised LDL.
Thus they are transformed into foam cells, an early event in the atherogenic process.
Studies in cell culture systems have demonstrated that most key cellular elements
within an atherosclerotic plaque, including endothelial cells, mononuclear
macrophages and smooth muscle cells, are able to synthesize TF in response to a
number of atherogenic molecules including cytokines, growth factors, modified low
density lipoproteins and cell interactions. Furthermore, in perfusion models of
thrombogenesis, TF-expressing monocytes and endothelial cells, when exposed to
nonanticoagulated blood under flow conditions, could elicit fibrin deposition and
thrombus formation (Clozel et ah, 1989; Barstad et al., 1995). These studies
prompted the investigation of in vivo TF expression in these cells and their role in
arterial thrombosis both in animals and in humans. In rabbit atherosclerotic lesions,
induced by cholesterol rich diets, TF antigen and activity were detected in foamy and
non-foamy macrophages and smooth muscle cells but not by endothelial cells (Kato et
al., 1996). In rabbits fed an atherogenic diet for six weeks, spleen mononuclear
phagocytes expressed increased basal TF activity, and exhibited an enhanced
procoagulant response to endotoxin both in vitro and in vivo (Semeraro et al., 1990).
Studies using a rat balloon injury model, Marmur et al., 1993, demonstrated a rapid
induction ofTF mRNA and activity in medial smooth muscle cells of aorta in response
to balloon dilatation. In addition, Speidel et al., 1995, observed that TF caused
prolonged procoagulant activity associated with the luminal surface of balloon injured
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rat aortas. Several studies have also examined the expression of TF in human
atherosclerosis. Wilcox et al., 1989 first reported that, in atherosclerotic plaques
from patients undergoing carotid endartectomy, TF mRNA and protein were
expressed in macrophage foam cells, monocytes, smooth muscle cells but not in
endothelial cells. TF protein was also present in the extracellular matrix of the
necrotic core, possibly shed from the surface of adjacent TF expressing cells.
Consistent with these findings, macrophages isolated from carotid atherectomy
patients expressed markedly increased TF activity (Tipping et al., 1989). Patients
with a history of recent embolic complications of carotid vascular disease, had TF
levels far exceeding those of plaque macrophages from asymptomatic patients. Annex
et al., 1995, first demonstrated the presence of TF antigen in coronary lesions using
immunohistochemical staining of coronary atherectomy specimens. The detection
rate was higher in patients with unstable coronary syndromes than in patients with
stable disease. In contrast, Marmur et al., 1996 used a specific functional assay and
Thiruvikraman et al., 1996 a novel method based on the binding of labelled factors
Vila and X to show that TF was present in variable amounts in virtually all of the
plaques tested, but was not correlated to clinical severity. Within the plaque, TF was
particularly abundant in the relatively acellular lipid-rich core and was also located in
the surrounding smooth muscle cells. In contrast to other studies, the endothelium
overlying the plaques was found to be often positive for TF (Thiruvikraman et al.,
1996). Taken together, these studies strongly suggest that the prognosis for plaque
rupture is determined by expressed TF which causes rapid thrombus formation. The
importance of TF in this regard has been further demonstrated by the preventative
effect of TFPI on arterial reocclusion (Haskel et al., 1991). An increased capacity to
produce TF has been reported also in circulating monocytes from patients with
coronary disease and in particular those with active unstable angina (Neri et al., 1992;
Jude et al., 1994; Leatham et al., 1995) possibly reflecting a specific inflammatory
process, that leads to increased TF expression, thrombin generation and thrombus
formation and may contribute to plaque instability. Most recently, it has been shown
that extracts from human atheromatous plaques express constitutive TF activity and




Although it is known that activation of blood coagulation, in combination with blood
stasis is an essential pathogenic factor in venous thrombosis the precise initiation
event is still unclear (Thomas, 1994). One possibility is that activation of coagulation
is caused by the release of TF from injured tissues into the bloodstream.
Alternatively, thrombus formation in areas of stasis could be initiated by the exposure
of blood to locally available TF, possibly as a result of vessel wall damage, endothelial
cell activation or recruitment of activated monocytes (Thomas, 1994). Vessel wall
lesion, exposing preformed TF, does not appear to play a major role except in the
case of severe vascular trauma. In a rabbit jugular vein stasis model, the injection of
TF-expressing blood mononuclear cells induced thrombus formation more quickly
than a rabbit thromboplastin preparation (Scagnol et al., 1991). Moreover, the
administration of low doses of endotoxin 4 hours before stasis potentiated venous
thrombosis in normal but not leukopenic rabbits (Bernat et al., 1994). Thus,
monocyte-initiated coagulation could contribute to thrombus formation in areas of
blood stasis. In humans, evidence linking in viva expression of monocytes TF to the
pathogenesis of venous thrombosis remains inconclusive. An augmented monocyte
TF activity has been reported in conditions known to be associated with venous
thromboembolism, including major surgery and trauma (Miller et al., 1981; Blakowski
etal., 1986; Ollivier et al., 1989).
1.5.4 Malignancy
The tendency to thrombotic complications in various types of malignant disease is
thought to be partly due to a constitutive or induced expression of TF. Several
tumours express TF constitutively (Callander et al., 1992a; Sturm et al., 1992; Zhang
et al., 1994), and there is also strong evidence to suggest that local activation of
coagulation and fibrin deposition occurs at sites of tumour growth (Dvorak et al.,
1994). Several in vivo studies on the expression of TF in human malignancy have
shown that in both haematological disease (Tanaka et al., 1993) and in solid tumours
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(Callander et al., 1992; Costantini et al., 1993; Hamada et al., 1996), TF antigen,
activity and mRNA have been detected. As many tumour cells express TF, systemic
haemostatic abnormalities may result from malignant cell entry into the circulation
during the course of metastasis or from TF expressing membrane vesicles shed from
tumour cells. Alternatively, coagulation may be activated by release of tumour or
host cell derived mediators that stimulate monocytes and endothelial cells to express
TF. The fact that patients with malignant disease show increased circulating
monocyte TF which often correlates with markers of activated coagulation (Morgan
et al., 1988; Semeraro et al., 1994; Montemurro et al., 1995) lends support to this
view. In addition, high plasma and urinary levels of TF have been frequently reported
in cancer patients (Kakkar et al., 1995; Levi et al., 1993). Recent studies have also
demonstrated the involvement of TF in tumour angiogenesis. In a study using meth-
A-sarcoma cells which had been induced to either over or under express TF, it was
shown that TF may contribute to the angiogenic properties of tumour cells by altering
the production of growth regulatory molecules. Furthermore, TF has been localized
to the vascular endothelial cells within invasive breast cancer tumours (Contrino et al.,
1996).
1.5.5 Surgical Trauma (Cardiopulmonary Bypass)
During cardiopulmonary bypass (CPB) surgery there is an extensive activation of the
extrinsic coagulation pathway. Experimental observations have attributed this to the
widespread circulation, during cardiac surgery, of inflammatory mediators such as
tumour necrosis factor and interleukin-1 as well as LPS which can induce the
expression of TF on monocytes and endothelial cells. These observations are
supported by the fact that many of the features of CPB-associated coagulopathy can
be induced in animals by infusion of LPS or cytokines (Nawroth et al., 1986; Bauer et
al., 1989b). During CPB there is the potential for massive widespread TF expression
throughout the entire extravascular space due to the systemic exposure of monocytes
and endothelial cells to inflammatory mediators. If left unchecked, this would result
in intravascular coagulation and widespread fibrin deposition in the microvascular
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circulation. There are a variety of therapies directed at attenuating the effects of
widespread thrombin generation during CPB. Systemic heparinization is intended to
stop the progression of the coagulation cascade. However, thrombin generation
increases after the neutralization of heparin with protamine sulphate, and continues to
be elevated significantly 24 hours post-operatively (Kestin et al., 1993). In addition,
heparin does not directly inhibit the formation of thrombin and, therefore, cannot
prevent widespread microvascular thrombosis. Other agents such as serine protease
inhibitors and platelet inhibitors have also been used but like heparin, they focus on
inhibiting coagulation distal in the cascade, once endothelial cells have been activated,
TF has been expressed, and widespread thrombin generation has occurred.
1.6 Therapeutic Potential of TF Inhibition
The predictable way in which TF is expressed in a variety of disease states where
aberrant coagulation plays a role, suggests that strategies aimed at inhibition of TF
may be useful as novel anti-thromboembolic therapies. Studies have been performed
in animal models that demonstrate the importance of TF in the initiation and
progression of thrombotic complications and illustrate the protective effect of TF
inhibition at the protein, intracellular and molecular level in these conditions.
1.6.1 Monoclonal Antibodies to TF
The infusion of monoclonal antibodies to TF has been shown to be beneficial in a
number of animal models of DIC and arterial thrombosis. Intravenous infusion of E.
coli at a lethal dose into a baboon is associated with coagulopathy, vasomotor
collapse, organ failure and death (Coalson et al., 1979). Injection of either the IgG or
Fab of anti-TF monoclonal antibody TF9-5B7 protected baboons from the effects of
this lethal dose of E. coli. Infusion of small amounts of this monoclonal antibody
before E. coli challenge attenuated the septic coagulopathy, cardiovascular collapse
and cell injury involved in DIC resulting in 100% survival rate (Taylor et al., 1991).
In another study injection of a polyclonal anti-TF antibody into mice 2 hours before
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intraperitoneal injection of LPS, resulted in a reduction in the mortality rate compared
to saline infused controls (Dackiw et al., 1996). Inhibition of TF using monoclonal
antibodies has also been shown to prevent acute coronary and vascular thrombosis.
Three animal studies have addressed the posibility of inhibiting vascular thrombosis by
the use of anti-TF antibodies. Jang et al., 1992, exposed adventitial TF to the
bloodstream in an eversion graft model of rabbit femoral artery. A 2 hour infusion of
a neutralizing anti-TF monoclonal antibody prevented thrombosis in 80% of the
animals. Furthermore, in a rabbit model of carotid artery thrombosis, administration
of a monoclonal antibody against rabbit TF (AP-1) resulted in complete inhibition of
intravascular thrombus formation (Pawashe et al., 1994). In a subsequent study the
same antibody also improved the performance of the thrombolytic agent tissue
plasminogen activator (TPA). Administration of the antibody shortened the TPA clot
lysis time and lowered the reocclusion rate when TPA infusion was stopped compared
with control rabbits (Ragni et al., 1996). In a third study, Speidel et al., 1995
observed inhibition of coagulation on the intimal surface of the balloon injured rabbit
aorta by an anti-TF antibody. These studies demonstrate the importance of TF
inhibition as an antithrombotic therapy. However, infusion of monoclonal antibodies
in a human clinical setting is a far from ideal solution. The infusion of murine protein
may cause immunological problems and, in addition, monoclonal antibodies are unable
to discriminate between the extravascular constitutively expressed TF and the induced
TF expressed in monocytes. This highlights the need for a neater more specific
therapy.
1.6.2 Tissue Factor Pathway Inhibitor (TFPI)
Tissue factor pathway inhibitor is an endogenous multivalent kunitz-type proteinase
inhibitor expressed primarily by the microvascular endothelium. It is thought to be
the major physiologic inhibitor of TF-induced coagulation, producing factor Xa-




Animal studies have shown that the immunodepletion of endogenous TFPI sensitizes
rabbits to DIC induced by TF or endotoxin infusion (Sandset et al., 1991a, 1991b).
Conversely, infusion of high, therapeutic concentrations of TFPI in rabbits inhibits the
intravascular coagulation induced by TF in rabbits and prevents mortality in a baboon
model of E. coli sepsis (Day et al., 1990; Creasey et al., 1993). As discussed
previously, induced TF expression underlies the pathology of many coagulation
disorders. However, it has been shown that in the cell types thought to demonstrate
abnormal TF expression TFPI expression is either absent (Werlin et al., 1993) or
delayed (Bajaj et al., 1996; Bajaj et al., 1993). Furthermore, although plasma TFPI
levels in patients with these diseases are generally normal or high, a number of
subjects have been found to have low plasma levels (Girard, 1997). Despite the
presence of 2-fold elevated plasma TFPI levels in several clinical conditions with TF
induced coagulopathy, several observations have indicated the potential for
therapeutic administration of exogenous TFPI to inhibit the TF/VIIa complex. Firstly,
relatively high concentrations of TFPI are required to inhibit the TF/VIIa complex
without the need to initially generate factor Xa (Callander et al., 1992b) allowing the
inhibition of TF/VIIa induced coagulation before it has been initiated Secondly, the
plasma TFPI levels achieved during a severe coagulopathy are in a much lower range
than might be needed to have a totally therapeutic effect (Girard 1997). In addition,
the TFPI released due to endothelial damage may be C-terminally truncated and,
therefore, a less powerful anticoagulant (Broze et al., 1995; Broze et al., 1994;
Nordfang et al., 1991). Two forms of recombinant TFPI are currently available for
therapeutic purposes: full length rTFPI and the two domain rTFPI in which the third
Kunitz domain and the C-terminal region have been deleted. These two forms have
different pharmacokinetic and activity profiles making each one suitable for different
conditions. Full length rTFPI binds to factor Xa at a much faster rate than the two
domain rTFPI resulting in faster inhibition of the TF/VIIa complex (Broze et a/.,
1995; Nordfang et al., 1991) making it more useful when rapid inhibition of TF
induced coagulation is required. In addition, full length rTFPI is cleared more rapidly
from the circulation and so is only useful if targeted to a focal area of injury by an
indwelling catheter. In contrast, the two domain rTFPI persists in the circulation for a
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longer period (Hoist et al., 1996) making it potentially more useful when a more
generalized anticoagulant effect is required such as in sepsis. It has been shown by
Bregengard et al., 1993 that infusion of two domain rTFPI inhibited endotoxin
induced DIC in rabbits. In a baboon model of E. coli sepsis administration of full
length rTFPI decreased 11-6 levels and decreased mortality (Creasey et al.. 1993; Carr
et al., 1995). Full-length rTFPI is currently being used in clinical trials in patients
with sepsis and DIC and in those following microvascular surgery. It could also be
used in other diseases complicated by TF-induced coagulation such as unstable angina
and to prevent thrombosis following fibrinolysis.
1.6.3 Active Site Inhibited Factor Vila
Active site inhibited factor Vila (VIlai) competes efficiently with factor Vila for
binding to TF (Sorensen et al., 1997), thereby inhibiting the initiation of coagulation.
Therefore, factor VIlai is a potential inhibitor of TF/VIIa initiated thrombosis. The
anti-thrombotic effect of factor VIlai has been demonstrated in animal models. In
baboons recovering from femoral artery balloon angioplasty factor VIlai abolished
thrombus formation at sites of vascular injury (Harker et al., 1995; Harker et al.,
1996). In addition, in an athersclerotic rabbit arterial injury model, factor VIlai was
shown to reduce angiographic restenosis and neointimal hyperplasia (Jang et al.,
1995) Furthermore, topical administration of factor VIlai was seen to increase
arterial patency rated in a rabbit model of arterial thrombosis (Arnlijots et al., 1997)
1.6.4 Molecular Inhibition of TF
The main problem with the strategy of generalised inhibition of the mature TF protein,
may be the lack of complete understanding of the in vivo distribution of TF under
normal and pathological conditions. In addition, its physiological roles beyond
cofactor function in coagulation are poorly understood. As previously mentioned, the
TF structure bears strong similarity to the cytokine family of receptors and therefore,
it is possible that TF may be involved in immunologic responses of unknown nature
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(Edgington et ah, 1992). In addition, the brain contains very large amounts of TF,
and it is possible that uncontrolled, generalised inhbition of TF activity may result in
excess bleeding. Insights into the molecular mechanisms that regulate TF expression
are of interest in the pursuit of novel therapies to attenuate aberrant generation of
thrombin. Specific inhibition of induced TF in monocytes at the genetic level, may
provide a more specific means of blocking intravascular TF production.
1.6.4.1 Transcriptional Inhibition
Elucidation of the molecular mechanisms that regulate TF gene expression,
particularly in monocytes and macrophages, may permit the development of
therapeutic strategies that will inhibit inducible TF expression associated with various
thrombotic diseases. The expression of TF on the surface of monocytes and
endothelial cells requires transcriptional activation of the TF gene and translation of
TF specific mRNA transcripts into protein that is translocated to the plasma
membrane (Edgington et ah, 1991). Intervention at the level of transcription provides
a more precise method of specifically inhibiting the TF gene. Strategies aimed at
blocking activation of the transcription factor NF-kB, involved in control of TF
expression, are being explored in the context of cardiopulmonary bypass surgery
(Boyle et ah, 1996). In addition, LPS induction of TF can be inhibited in monocytes
and macrophages by immunosupressive agents such as 11-4 (Ramani et al., 1993a) and
11-10 (Ramani et ah, 1993b), and also by agents which increase the level of cAMP
such as dibutyryl cAMP (Prydz et ah, 1980; Ollivier et ah, 1993; Mackman et ah,
1994; Galdal et ah, 1984). It is thought that the increase in cAMP may reduce TF
mRNA levels by reducing the rate of gene transcription (Ollivier et ah, 1993; Ollivier
et ah, 1996)
1.6.4.2 Antisense Oligonucleotides (ASODNs)
Perhaps the most specific method of inhibiting the induced expression of TF in
monocytes/macrophages is at the level of translation. Antisense oligonucleotides
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(ASODN) are short, traditionally 15-25 bases long, single stranded DNA fragments,
which are designed to specifically hybridize to a target mRNA and temporarily
prevent its translation into protein. Sequence specific interference with mRNA
function by complementary oligonucleotides was first proposed over two decades ago
by Belikova et al., 1973. The first example of specific inhibition of gene expression
by an ODN was reported by Zamecnik and Stephenson in 1978, who demonstrated
that a short ODN inhibited Rous-sarcoma-virus replication in cells culture. Since
then, many groups have investigated the potential for inhibition of a range of specific
proteins by antisense oligonucleotides. The majority of these studies have focused on
viral or cancer targets for ASODN therapy. To date, only one group has investigated
the possibility of inhibiting TF induction using antisense oligonucleotides. Stephens
and Rivers, 1998 have shown that co-addition of an ASODN to the TF mRNA and
LPS to isolated human monocytes results in a 80% inhibition in TF activity when
compared to control ASODNs. This study, although promising, did not attempt to
directly measure a reduction in TF protein levels. The authors also found it necessary
to conjugate their ASODN to a CD 14 antibody to specifically target monocytes.
During the course of this thesis, we have further investigated the potential of naked,
unconjugated ASODN targeted to the TF mRNA, at inhibiting induction of TF
protein in monocytes in a whole blood model.
1.6.4.3 Transgenic Knockouts of TF
In contrast to the other proteins involved in coagulation, no congenital deficiency of
TF has been reported, suggesting that it is essential in development. The development
of Transgenic Knockout (TKO) technology has made it possible to specifically
inactivate a chosen gene and examine the consequences of its absence in a murine
model. Complete inactivation of the TF gene was lethal, virtually all TF deficient
embryos dying in utero between 9.5 and 10.5 days post coitum (Bugge et al., 1996;
Carmeliet et al., 1996). In a separate study, approximately 15%of embryos survived
past day 10, but none completed gestation (Toomey et al., 1996). Inactivation of the
TF gene results in abnormal circulation from the yolk-sac to the embryo beyond day
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8.5 (Carmeliet et al., 1996). The fatal effects of TF gene disruption along with the
fact that TF is expressed early in organogenesis before the appearance of detectable
amounts of factor Vila (Luther et al., 1996) suggest that TF has other, as yet
unknown roles aside from initiator of coagulation.
1.7 Aims of the Thesis
The importance of TF at initiating the coagulation cascade and the role of induced TF
expression on monocytes in producing aberrant clot formation in a variety of
pathophysiological processes has so far been discussed. In addition, the therapeutic
benefit of carefully controlled TF inhibition has been described. There is an obvious
need for more specific and localized therapeutic inhibition of TF at the cellular level.
Therefore, the experiments discussed in this thesis aim to characterize the LPS
induced expression of TF on monocytes in whole blood. Initial experiments used E.
colt LPS but in chapter 7, TF induction by a variety of bacterial LPSs including
Bactericides fragilis LPS (the most prevalent bacteria in the gut) was investigated.
Ultimately, the work outlined in this thesis, investigates the potential of the monocyte
as a target for antisense inhibition of LPS-indcued TF, with the view to producing a






2.1.1 Principle of Flow Cytometry
The flow cytometer, analyses cells as they travel in a pressurised moving stream past a
fixed laser beam. As a cell passes in front of the laser, several measurements are made
based on the physical characteristics of the cell. Using an Optical-to-Electronic
system, the flow cytometer records how a cell interacts with a focused laser beam in
terms of the cell's ability to scatter the incident light and emit fluorescence. This
information is collected and transmitted to the computer. The size and granularity of
the cell can be determined by virtue of its light scattering properties. The larger the
cell, the greater its forward light scattering abilities (FSC) and the more granular or
complex the cell, the greater its side light scattering ability (SSC) (Fig 2.1). The light
scattering ability of the cells is displayed as a characteristic 'dot-plot' pattern (Fig 2.2).
FIGURE 2.1 Light Scattering Properties of Cells
The size and granularity of cell can be determined by its light scattering properties and
detected by flow cytometry. Forward light scatter is proportional to cell surface area whilst
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In addition to the size and shape of cells, the flow cytometer can detect fluorescent
molecules within the cell or on the cell surface. In staining, the cell will bind a
fluorescent dye and/or a fluorochrome conjugated antibody in an amount proportional
to the quantity of the binding constituent (eg cell surface antigen). Alternatively the
cell may internalise quantities of fluorescently labelled molecules . The cell's emitted
fluorescence intensity will then be proportional to the fluorescing cellular constituent.
The fluorochrome absorbs energy from the incident laser light source and
subsequently releases it by emitting photons of a longer wavelength called
fluorescence (Fig 2.3). This fluorescence is detected on one of three channels (FL1,
FL2 or FL3) depending on the wavelength.
2.1.2 Cell-Type Detection
Peripheral blood leukocytes (PBLs) display a characteristic dot-plot pattern when
analysed by flow cytometry. Lymphocytes are small, agranular cells with an
uncomplex interior and thus appear on the dot plot with a low forward and side
scatter (Fig 2.3). Neutrophils are large complex cells with large granular, lobed nuclei
and, as such, appear on the dot plot with a high forward and side scatter pattern (Fig
2.3). Monocytes are also large cells but with smaller more regular lobed nuclei.
Therefore, they have an easily distinguishable position on the dot-plot appearing with
a high forward scatter, and a side scatter somewhere between that of a lymphocyte
and a neutrophil (Fig 2.3). Consequently, a particular cell type can be singled out by
virtue of its position on the dot-plot screen and 'gated' so that its particular
fluorescence characteristics can be examined. During the course of experimentation,
certain treatments may cause certain cell types, in particular monocytes, to change
shape and move outwith their gate. In these situations it is necessary to adjust the
gate settings to 'keep track' of the monocytes.
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2.1.3 Cell Analysis
Having identified and gated the cell population of interest, the fluorescence profile of
these cells is displayed as a fluorescence histogram, whereby the cell count is plotted
against the fluorescence intensity of the cells. The relative fluorescence characteristics
of the cells can then be quantified in one of two ways:
1. Geometric Mean Fluorescence. As the fluorescence intensity is often plotted on a
log scale, the 'Geometric Mean Fluorescence' (GMF) is a measure of the overall
mean fluorescence of the cells selected taking into account the logarithmic scale.
(Fig. 2.4)
2. Percentage Positive Ceils. This analysis method has been used by Leatham, et al.,
1995 and Amirkosravi et al., 1996. Using an isotype control antibody (an antibody
which does not bind to the protein of interest but is of the same isotype as the test
antibody) or an unlabelled analogue of the fluorescent molecule to be tested, a
fluorescence histogram is created and a marker set so that this marker contains a
known percentage of cells. In the experiments to follow, this positive delineator is
set so that 3% of isotype control labelled cells are counted as positive and this is
designated 'background'. Thus, when the true molecule or antibody is used, the
percentage of cells falling inside the marker (percent positive cells) can be
determined. (Fig 2.4).
The percentage positive cells method was used to measure TF antigen on monocytes
as recommended by Amirkosravi et al., 1997. This method enables a permanent
'background' delineator to be set (in this case 3% positive cells). This delineator can
then be used as a template for all subsequent experiments. Cells in the monocyte gate
were periodically checked for CD 14 positivity and were found to be >95% CD 14
positive each time they were tested. A dual staining method for simultaneous
measurement of GEM-91 fluorescence and CD 14 antigen was not practical in this
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case as the FAM-label fluorescence was of an intensity that consistently quenched the
CD14-PE label.
All flow cytometric experiments were carried out on a Fluorescence Activated Cell
Scanner (FACScan) benchtop flow cytometer using FACSFlow™ optimized sheath
fluid (Becton Dickinson Immunocytometry Systems, San Jose, California, USA)
Analysis was carried out using the Macintosh driven Cell Quest™ sofware specially
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2.1.4 Fluorescence Conjugates Used
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Some antibodies and ODNs used were conjugated to a fluorochrome for detection by
flow cytometry. The fluorochromes used are listed below. Suppliers of the
conjugates are listed in the text.
2.1.4.1 FITC (Fluorescein IsoThioCyanate)
This fluorochrome absorbs light at the 488nm wavelength and emits in the green
530nm wavelength. It is, therefore, detected using the FL-1 channel on the flow
cytometer
2.1.4.2 FAM (Fluorescein Addition Monomer)
Like FITC, FAM aborbs light at the 488nm wavelength and emits in emits in the
green 530 nm range and so can be detected in the FL-1 channel on the flow
cytometer.
2.1.4.3 R-Phycoerythrin (R-PE)
Like FITC and FAM, R-PE excites at 488nm but it emits fluorescence in the orange
range (575nm). Therefore, it is detected using the FL-2 channel.
2.1.4.4 Quantum Red (PE-Cy5)
Quantum red is a tandem fluorochrome in which a small organic dye, Cy5 is
covalently linked to R-Phycoerythrin. The PE absorbs light energy at 488 nm and
emits in the excitation range ofCy5 which acts as the acceptor dye. The complex
then emits at 670 nm. This can be detected in the red FL-3 channel.
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Blood samples were collected from healthy, consenting volunteers (staff at the
Department ofHaematology, Royal Infirmary ofEdinburgh) by clean venepuncture
into heparin-coated tubes (300ul heparin per 3ml blood) or citrated vacutainers. The
red blood cells were lysed by the addition of 4-10 volumes of red cell lysis buffer
(150mM ammonium chloride, lOmM potassium bicarbonate, 0. ImM EDTA) for 3-5
minutes at room temperature. Cells were then centrifuged at lOOOg for 5 minutes at
4°C and the cell pellet resuspended in 5 volumes of red cell lysis solution. After a
final centrifugation step, (400g for 5 minutes), cells were finally resuspended in
culture medium (QBSF51, Sigma Chemical Company, Poole, UK), counted in the
presence of trypan blue, and plated out at a final density of lxl 06 cells per ml of
culture medium. All incubations were carried out in a humidified atmosphere of 95%
air, 5% C02.
2.1.6 Immunostaining
The concentrations of all antibodies used were suggested by Prof. T. Edgington,
Scripps Research Institute, La Jolla, and were checked by titration experiments in
both isolated monocytes and monocytes in whole blood. The primary TF mab was
used at a concentration of 10pg/ml in a final volume of lOOpi lOOpl of a 1/20
dilution in PBS of phycoerythrin conjugated rabbit anti-mouse IgG fab(2') fragment
(RAMPE) (Dako, Ltd) was used as the detection antibody.
2.1.6.1 Direct Immunostaining (Isolated Cells)
A lOOpl aliquot of cells (lxl 07) was placed in a sterile polypropylene tube and to it
was added the appropriate monoclonal antibody preconjugated to its fluorochrome.
This was incubated for 30 minutes at 4°C in the dark. The cells were then washed
twice in washing solution; 10ml fetal calf serum, 25ml 4% sodium azide in 465ml
Phosphate Buffered Saline(PBS), (made by dissolving 2 tablets in 400ml distilled
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water), and resuspended in 300pl washing solution before being immediately analysed
by flow cytometry. All reagents were purchased from Sigma Chemical Company
unless otherwise stated.
2.1.6.2 Direct Immunostaining (Whole Blood)
lOOpl ofwhole blood was placed in polypropylene tubes containing the appropriate
preconjugated monoclonal antibody and incubated at 4°C for 30 minutes in the dark.
The red blood cells were lysed by the addition of 4ml of red cell lysis solution as
above, washed twice in washing solution (as above), and fixed overnight by the
addition of 300pl 1% paraformaldehyde in PBS and 300pl washing solution. The
cells taken from whole blood incubations post red-cell lysis were fixed in
paraformaldehye overnight as this removed any red blood cell contamination
and improved the separation of the cell populations on the FACS plot. In contrast,
isolated cultured cells were not fixed as they were less robust than cells from whole
blood incubations and changed morphology so as to be unrecognisable on the FACS
plot. There was no difference in the fluorescence characteristics between fixed and
unfixed cells (Fig 2.5).
2.1.6.3 Indirect Immunostaining (Isolated Cells)
A lOOpl aliquot of cells (lxl07/ml) was placed in a sterile polypropylene tube and to it
was added the appropriate primary monoclonal antibody. This was incubated for 30
minutes in the dark at 4°C and was then washed twice in washing solution as above.
The cells were then resuspended in lOOpl of 1/20 dilution in PBS of phycoerythrin
conjugated rabbit anti-mouse IgG fab(2') fragment (RAMPE) (Dako, Ltd) detection
antibody. The fab(2') fragment was used to minimalise binding to fc receptors on the
monocytes and neutrophils in the cell suspension. This was incubated for 30 minutes
at 4°C in the dark. The cells were finally washed twice in washing solution and
resuspended in 300pl ofwashing solution before being analysed by flow cytometry.
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2.1.6.4 Indirect Immunostaining (Whole Blood)
1OOpl ofwhole blood was placed in polypropylene tubes containing the appropriate
primary monoclonal antibody. This was incubated a 4°C for 30 minutes in the dark.
The whole blood was then lysed by the addition of 4mls red blood cell lysis solution
(as above) for 3-5 minutes at room temperature before being centrifuged for 10
minutes at 400g at 4°C. The cell pellet was then washed twice in washing solution at
4°C before being incubated with the detection antibody RAMPE as above. The cells
were then washed twice in washing solution and fixed with 300pl 1%
paraformaldehyde solution in PBS and 300pl washing solution overnight.
2.1.7 Statistical Analysis
The raw data from all paired experiments were analysed by a repeated measures
analysis of variance (ANOVA) followed by an appropriate post test. If each test
condition was being compared with one control a Dunnett's post test was used. If test
groups were being compared with each other a Bonferroni post test for multiple
comparisons was used. If experiments were not paired as when sample size differed,
raw data was not used and group means were compared by a one way ANOVA
followed by an appropriate post test. All statistical analyses were performed using the
Graph-Pad Instat programme, and statistical advice was given by Ms Kay Penny,
University of Edinburgh, Medical Statistics Department.
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3.1.1 The Antisense Strategy
The concept of the antisense (AS) strategy is a straightforward one: inhibition of a
particular target protein using single stranded oligodeoxynucleotides (ODNs) of a
sequence complementary to that of the specific messenger RNA (mRNA) (Fig 3.1)
This strategy is so called due to its reliance on the formation of reverse
complementary (antisense) Watson-Crick base pairing between the antisense construct
and the mRNA to be inhibited (Fig 3.1). It is the specificity of this base pairing that
allows the potentially selective targeting of a particular mRNA. Helene and Toulme
declare that the sequence specificity of the antisense technique is based on the fact
that a sequence of about 13 bases in RNA is unique in the human genome (Helene &
Tolume, 1990). However, although the probability of a 13 base sequence reoccurring
in the genome as a whole is low, in view of the non-random nature of the human
genome, sequences of bases are more likely to reoccur in DNA coding for proteins in
the same class, such as in receptor families. There is, therefore, the possibility of an
antisense molecule having more than one target. The idea that gene expression may
be modulated by the use of exogenous nucleic acid derivatives was first alluded to by
Paterson et al in 1977 when they used single stranded DNA to inhibit translation of a
complementary RNA in a cell-free system. The first indication that the antisense
mechanism might be used therapeutically came in 1978 when Zamecnik and
Stephenson demonstrated that a 13 nucleotide DNA molecule complementary to the
Rous sarcoma virus could inhibit viral replication in culture. In the 1980s, Simons
and Kleckner, 1983 and Mizuno et a/., 1984, demonstrated the existence of naturally
occurring antisense RNAs in prokaryotes and showed that these molecules were
involved in regulating expression of their corresponding genes. Furthermore, in
eukaryotic cells, naturally occurring antisense transcripts also exist which are involved
in physiological gene regulation (Farrell and Lukens, 1995; Kimelman and Kirschner,
1989). These observations suggested that the use of reverse complementary antisense
molecules might be of use therapeutically. Recently, synthetic antisense molecules
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have been artificially introduced into cells to inhibit gene function (Zhang et al.,
1996), and it has been shown that antisense ODNs microinjected into the cytoplasm of
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3.1.2 Antisense ODNs
Antisense oligodeoxynucleotides (ASODNs) are short, typically 10-30 base, single
stranded lengths of DNA which are designed to hybrize to a specific mRNA and
prevent translation of a single target protein (Fig 3.1). Antisense
oligodeoxynucleotides need to meet certain physical requirements to make them
useful. Firstly, they need to cross cell membranes and secondly they must be able to
hybridise with their intended target. The ability of an ODN to form a stable hybrid is
a function of its binding affinity and sequence specificity. Binding affinity is a function
of the number of hydrogen bonds formed between the ODN and its target mRNA.
Thus, as the G-C base pairing utilises 3 hydrogen bonds as opposed to the two
between C and T, it may be concluded that hybridisation stability will increase with G-
C content of the ASODN. At physiologic conditions, it has been estimated that at
least 12 bp need to form in order to form a stable hybrid with a phosphodiester
backbone (Khan et al., 1993). While increased length increases oligo affinity for its
target, it is thought that the non-specific effects of ASODNs, such as protein aptamer
binding or hybridization to random base sequences increase with increasing G-C
content and ODN length. Unmodified phosphodiester ODNs were the first generation
molecules to be investigated and have been investigated for use in vitro and in vivo.
However, they are extremely sensitive to attack by endogenous nucleases, the half life
of phosphodiesters in growth medium containing 10% calf serum being about 30
minutes (Crooke et al., 1992). Next generation antisense molecules were
subsequently designed so that the internucleotide link was more resistant to attack.
This was accomplished by replacing one of the non-bridging oxygen atoms in the
phosphate group with either a sulphur or a methyl group (Fig. 3.2). This type of
modification results in a phosphorothioate (Zon., 1995) or a methylphosphonate
(Crooke., 1991) respectively (Fig. 3.2). It has been the phosphorothioate molecules
that have been most extensively investigated both in the laboratory and in several
clinical trials (Gewirtz et al., 1996; de Fabritis et al., 1995; Webb et al., 1997). In
addition to being resistant to nuclease attack, the phosphorothioates are negatively
charged molecules and so are water soluble. Furthermore, they permit RNase H
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activity when in the duplex (see below). However, the polyanionic nature of these







x = OH Phosphodiester
x = OCH 3 Methyl Phosphonate
x = S Phosphorothioate
Common Sugar Modifications:
2'-0- methyl groupfas shown)
2'-0-methyoxyethoxy-group
FIGURE 3.2. Common Chemical ODN Modifications. Common modifications of the
phosphodiester linkage and sugar moieties are shown.
Adapted from Gewirtz et at., 1998
3.1.3 Cellular Uptake of Phosphorothioate ODNs
Finding effective methods to induce efficient uptake of ODNs into cells is an active
area of current research, and is crucial to the success of any ODN based
pharmacology (Gerwitz et al., 1998). In addition to spontaneous uptake of naked
DNA ( Nestle et al., 1994), many different strategies have been employed to increase
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ASODN uptake Microinjection of ODNs has been used successfully by many
laboratories (Dagle et al, 1991; Kola et al., 1995; Leonetti et al., 1991) but is
obviously of little use clinically, except perhaps in in vitro fertilization. Other
commonly employed strategies may be classified as those which are aimed at
modifying the target cell, typically by permeabilizing the cell membrane, and those
which seek to directly or indirectly modify the permeation properties of the ODN.
Physical disruption of target cell membranes has been carried out by electroporation
(Bergan et al., 1996; Flanagan and Wagner, 1997) or by the use of chemical agents
which permeablize the cell membrane such as streptolysin (Giles et al., 1995; Bergan
et al., 1996; Flanagan and Wagner, 1997). Both of these methods are physically
destructive to cells and so are of little use in vivo. They are, however useful in ex vivo
therapies such as bone marrow purging. Calcium has also been used in recent studies
to assist uptake ofASODNs into the cell (Wu-Pong et al., 1994). An alternative, less
physically extreme strategy for improving delivery ofODNs into cells is to modify the
permeation characteristics of the ODN by packaging the DNA in an artificial vector.
Such vectors can be cationic lipids which can be manufactured to contain the DNA
within a lamelar structure called a liposome, or coat the DNA by charge interaction
(Lewis et al., 1996; Juliano et al., 1992; Behr, 1994). However, these lipid carriers
often prove to be more cytotoxic than naked DNA. Finally the ODN itself can be
modified. One such strategy is to conjugate the ODN either directly or indirectly to a
ligand specific for a receptor resident on the target cell type. For example, ODNs
have been conjugated to folate, mannose, asialoglycoproteins and tumour-specific
antibodies to target haematopoietic, pulmonary alveolar (Liang et al., 1996;) hepatic
and a variety of tumour cells (Kuijpers et al., 1993) specifically. Technical problems
with this sort of technology have been encountered such as dissociation of the ODN
and the carrier (Lu et al., 1994) rapid clearance of antibody conjugated material or
biological sequestering in the endosome compartment (Liang et al., 1996; Bonfils et
al., 1992) which also limit the effectiveness to this approach.
Despite much research in this field, there is as yet no consensus on the best method of
delivery, which may vary between the cell lines or cells used and depend on the
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specific modifications made to the ODN. Studies have yielded conflicting results in
that different methods, cell lines and ODNs have been used for evaluating
internalization of ODN. The one consistent finding has been that all mammalian cells
investigated are capable of internalizing phosphorothioate ODNs by an active process.
However, the intracellular fate of the ODN is controversial. Some studies suggest
that ODNs are internalised by a receptor mediated or adsorptive endocytosis pathway
in which the ODN is retained within membrane bound intracellular vesicles (Loke et
al., 1989; Stein et al., 1993; Bennett et al., 1993), whilst other studies suggest that
the ODN either uses alternative methods for gaining entry into cells such as fluid
phase pinocytosis, or escapes from the cytoplasmic vesicles (Wu-Pong et al., 1994;
Nestle et al., 1994; Noonberg et al., 1993). More recently it has been proposed that
the mechanism of cellular uptake of exogenously administered ODNs occurs by a
combination of different mechanisms depending on the concentration of the ODN. It
is believed that at ODN doses higher than 1 pM, fluid phase endocytosis is responsible
whereas at sub micromolar concentrations receptor mediated endocytosis plays a
more important role (Beltinger et al., 1995; Benimetskya et al., 1997). So far, the
majority of studies have concentrated on uptake of ODNs into cell lines (Iversen et
al., 1992; Stein et al., 1993; Temsamani et al., 1994; Tonkinson et al., 1994, Vlassov
et al., 1994) which are thought to incorporate ODNs more efficiently than primary
cells. Despite its implication for in vivo studies, information about spontaneous
uptake of naked DNA in primary peripheral blood leukocytes is limited. Currently,
only 4 studies examining the uptake of ODN into PBLs have been documented,
(Marti et al., 1992, Iversen et al., 1992, Pirruccello et al., 1994, Zhao et al., 1996).
Leukocytes are currently important target cells in clinical studies testing antisense
ODNs as therapeutics for inflammatory disease including rheumatoid arthritis and
Crohn's disease (Bradbury, 1997), for chronic myelogenous leukaemia and
myelodysplastic syndrome (Bayever et al.. 1993; Nichols, 1995; Skorski et al., 1994)
and for human immunodeficiency virus infection (Zhang et al., 1995). It is our hope
to utilize ASODNs to modulate the expression of monocyte TF, and so an
understanding the uptake mechanisms and intracellular availability of ODNs in
peripheral blood leukocytes is important if these molecules are to be used effectively
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as a therapy. We have, therefore, investigated the spontaneous uptake kinetics of a
naked 25 base pair phosphorothioate antisense molecule, GEM-91, into peripheral
blood leukocyte subtypes to assess the feasibility of using a naked, and thus more




3.2 Materials and Methods
3.2.1 ODNs
Biotin-, Fluorescein Addition Monomer (FAM) and 35S labelled GEM-91 (3xlOJ
dpm/pg) were supplied by Hybridon. Polybead carboxylate microspheres
(Polysciences Inc. Warrington, PA) were conjugated to MEG (a 25-base ODN
complementary to GEM-91 synthesized with a 5' primary amine group) which was
supplied by Oswel DNA services, Southampton, UK. This conjugation utilised 1-
ethyl-3-(dimethylaminopropyl) carbodiimide hydrochloride (EDC) (Pierce, Chester,
UK) in order to generate an amine reactive intermediate on the microspheres (Staros
etal., 1986)
3.2.2 Hybridisation of GEM-91 and Calibration of Label Fluorescence
In order to quantify the amount of ODN binding to cells it was first necessary to
calibrate the system using 35S labelled GEM-91 (specific activity 940cpm/pg) and
MEG-labelled microspheres. MEG is the reverse complementary sequence of GEM.
The following protocol was used:
1. Increasing concentrations (0.01-10,000pg) of 35S labelled GEM-91 (940cpm/pg)
were added to lOOpl aliquots of MEG conjugated microspheres (20,000
spheres/ml) to detect the point of saturation, where all available MEG sites on all
spheres were occupied by 35S-labelled GEM-91 (Fig. 3.3). It can be seen from
Fig.3.3 that the binding capacity of the spheres was 100,000cpm per lOOpl (2000
spheres). Specific activity of 35S-labelled GEM-91 was 940cpm, therefore
100,000/940 = 106pg GEM-91/lOOp.l suspension. There were 2000 spheres/100pl
solution so 53fg GEM-91 bound per sphere.
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2. Spheres were then hybridised with an excess (lpg) of FAM or Biotin-
Streptavadin-phycoerythrin- labelled GEM-91 in the same way. The fluorescence
intensity (GMF)of the spheres hybridised with FAM or biotin labeled GEM-91 was
measured by flow cytometry in triplicate (Table 3.1). FAM labeled GEM-91 was
detected on the FL-1 channel and Streptavadin-PE was detected on the FL-2
channel.
Label Used GMF of Spheres in Respctive Channels
1 2 3 Mean SEM
FAM (FL-1) 175 185 171 177 4.2
Biotin/Streptavadin-PE (FL-2) 814 804 827 815 6.7
Table 3.1 Calibration of Label Fluorescence. GMF of microspheres bound with saturating
concentrations of FAM-labeled and Biotin/Streptavadin-labeled GEM-91.
Therefore,
GMF (FL-1) 177 = 53fg/sphere. 53/177 = 0.3. GMF units*0.3 = fg/sphere.
GMF (FL-2) 815 s 53fg/sphere. 53/815 = 0.065. GMF units*0.065 = fg/sphere.
It has been assumed in the experiments to follow that human cells bind ODN in a
comparable manner to microspheres. Therefore, on the basis of these calibration
experiments, it can be concluded that GMF values recorded in the FL1 (FAM)
channel must be multiplied by the correction factor 0.3 and in the FL-2 (PE) channel
by 0.065 to determine the amount ofGEM-91 in fg/cell.
To determine whether hybridisation efficiencies to MEG-conjugated microspheres of
all GEM-91 species used were equal, aliquots of each labelled species were denatured
at 95°C for 5 minutes before being spun to remove the spheres. The concentration of
ODN in the supernatant was then measured by reading its optical density at 260nm.
The mean (± standard error mean) concentration of ODN in each supernatant was
found to be 30.5±1.4, 30.5±0.8, 29.8±l.lng per 103 spheres for 35S , biotin and FAM
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labelled GEM-91 (n=6). It was, therefore, concluded that there were no differences
in hybridisation efficiency between the differently labelled ODNs.
3.2.3 Blood Cell Collection and Culture
Blood samples from nine healthy volunteers were collected by clean venepuncture
into heparin-coated tubes (300ul heparin per 3ml blood). The mononuclear cells were
isolated as described in chapter 2 and were plated out on sterile tissue culture plates
(Costar) at a final density of lxlO6 cells per ml of culture medium (QBSF51, Sigma
Chemical Company, Poole, UK) in a final volume of 5ml. All incubations were
carried out in a humidified atmosphere of 95% air, 5% C02 at 37°C.
3.2.4 Uptake Studies
3.2.4.1 Preparation of GEM-91 for use in Uptake Studies
Filter sterilised stocks of all GEM-91 solutions were prepared in PBS (Phosphate
buffered saline tablets were supplied by Sigma; addition of 1 tablet to 200ml of
distilled water produced 0.01M phosphate buffer, 0.0027M potassium chloride and
0.137M sodium chloride, pEl 7.4) and stored at -20°C such that the final
concentration in the culture could be obtained by the addition of the same volume of
drug. Therefore, in all cases, lOpl of GEM-91 was added per 500gl of culture
medium.
3.2.4.2 Uptake Methodology and Preparation of Cells for Flow Cytometric
Analysis
Uptake of GEM-91 into peripheral blood leukocytes was measured using two
methods: Biotin labelled GEM-91 in conjunction with PE-conjugated streptavadin
was used to measure extracellular binding of the ODN to the cell surface. Biotin
labelled ODN is able to enter the cell whilst the streptavadin is not. Therefore, the
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PE-conjugated streptavadin bound only to the cell-surface associated QDN The
original intention of the study was to use FAM labelled GEM-91 to measure total
association of ODN with the cell and to subtract the extracellular association as
determined by the biotin-streptavadin experiments to derive the intracellular
concentrations ofODN. However, during the course of the study it became apparent
that the inclusion of the viability stain propidium iodide (PI) in the FAM experiments
completely quenched the cell surface associated fluorescence of the FAM label.
Sixteen cell samples were chosen at random and incubated with lp.M GEM-91 for 4
hours. The internalised GEM-91 was then measured directly by PI quenching of cell
surface bound GEM-91, and was also calculated by subtracting the external GEM-91,
as measured by the biotin-streptavadin method, from the total fluorescence. The two
different methods were found to give comparable results (Fig.3.4 and Append. 1).
This enabled the FAM labelled ODN (with the addition of PI) to be used as a direct
measure of intracellular ODN uptake. This phenomenon has also been reported for
ethidium bromide quenching of cell surface associated fluorescence (Fattorossi et al.,
1989) and has been further confirmed for PI quenching of FAM label by experiments
by Cunningham, 1997 (personal communication)
For the subsequent uptake studies, cells from three separate individuals were
incubated in the presence of a range of doses of FAM labelled or biotin labelled
GEM-91 (0, 0.1, 1.0, lOpM) for up to 4 hours. At set times throughout this culture
period (30, 60, 90, 120, and 240 minutes) and at the end of the culture period, cell
samples (5x10s cells) were taken. Cells were centrifuged at lOOOg for 5 minutes,
washed in 1.5ml PBS, centrifuged and resuspended in fresh PBS. An aliquot of cells
treated with FAM-labelled GEM-91 was analysed by flow cytometry followed by an
aliquot treated with 40p.l 0.25% PI (Sigma Chemical Co) per ml of sample. The
geometric mean channel fluorescence value (GMF) was recorded for each sample.
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3.3.1 Extracellular Uptake ofGEM-91 into Cells
3.3.1.1 Total Leukocyte Population
Extracellular uptake in the total leukocyte population was found to be dose-dependent
and non-saturating within the range of doses (0.1 to lOpM GEM-91) studied (Fig.
3.3). The highest levels of extracellular association were detected at the earlier
timepoints (<lh), with significant decreases being observed over time. In the
presence of lOpM GEM-91, the mean concentration of GEM-91 in unfractionated
peripheral blood leukocytes after 30 minutes of culture was 425±112 fg GEM-91/cell
with a maximum individual value of 643fg GEM-91/cell. After 4 hours in culture, the
mean concentration of GEM-91 had decreased to 115±30 fg GEM-91/cell with a
minimum individual value of 80fg GEM91/cell. (Fig 3.3)
3.3.1.2 Lymphocytes
Lymphocytes had lower levels of cell surface associated GEM-91 than the
unfractionated PBLs. The mean concentration of GEM-91 was approximately 70fg
GEM-91/cell at the highest dose (10p.M) after 0.5 h in culture. However, unlike
monocytes and neutrophils, lymphocytes showed no measurable decrease in
extracellular binding over the timecourse measured (up to 4 hours). (Fig 3.4).
3.3.1.3 Monocytes
Monocytes showed the greatest proportion of total GEM-91 extracellular association.
The mean concentration of GEM-91 on the monocyte cell surface was approximately
500fg GEM-91/cell after 0.5 hours of culture in the presence of 10p,M GEM-91. This
concentration dropped dramatically to approximately 60fg GEM-91/cell after 4 hours,




Neutrophils showed a high level of extracellular GEM-91 binding. The mean
concentration of GEM-91 on the neutrophil cell surface was approximately 350fg
GEM-91/cell after 0.5 hours of culture in the presence of lOpM GEM-91. This
concentration decreased to approximately 135fg GEM-91/cell after 4 hours. This
decrease was less marked than in monocytes (Fig 3.6).
Raw data for extracellular binding in all cell types can be found in Appendix B1.
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Cell Surface Binding ofGEM-91 to Total
Leukocytes
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FIGURE 3.5 Cell Surface Binding of GEM-91 to Total Peripheral Blood Leukocytes. PBLs
were incubated with 3 different concentrations of biotin-labelled GEM-91 for 4h. Surface
bound ODN was detected by addition of PE-labelled streptavadin. which cannot penetrate cells
and so binds only to cell-surface associated ODN. It can be seen that after a 30 min incubation
with lOpM GEM-91 PBMCs bound approximately 425fg GEM-91/cell. This concentration




Cell Surface Binding of GEM-91 to Lymphocytes
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FIGURE 3.6 Cell Surface Binding of GEM-91 to Lymphocytes. Cells were incubated with 3
different concentrations of biotin-labelled GEM-91 for 4 hours. Cell surface bound GEM-91
was detected by the addition of PE-labelled streptavadin which cannot penetrate cells and so
binds only to cell surface associated ODN. After a 1 hour incubation with lOpM GEM-91
lymphocytes bound approximately 75fg GEM-91/cell. There was no measurable decrease in
extracellular associated ODN over the 4 hour incubation period. Points are the mean of 3
separate experiments +/- sem.
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Cell Surface Binding of GEM-91 to Monocytes
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FIGURE 3.7 Cell Surface Binding ofGEM-91 to Monocytes. Cells were incubated with 3
different concentrations of biotin-labelled GEM-91 for 4 hours. Cell surface bound ODN was
detected by incubation with PE-labelled streptavadin which cannot penetrate cells and so binds
only to cell suface bound ODN. It can be seen that after 30 minutes in culture with lOpM
GEM-91 monocytes bound approximately 500fg GEM-91/cell. This dropped dramatically to
60fg/cell after 4 hours despite the continued presence of GEM-91 in the cultures. Points are
the mean of 3 separate experiments +/- sem.
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Cell Surface Binding of GEM-91 to Neutrophils








FIGURE 3.8 Cell Surface Binding of GEM-91 to Neutrophils. Cells were incubated with 3
concentrations of biotin-labelled GEM-91 for 4 hours. Surface-bound ODN was detected by
the addition of PE-labelled streptavadin which cannot penetrate cells and so detects only
surface bound ODN. After 30 minutes in the presence of lOpM GEM-91 neutrophil cell
surface bound ODN had reached approx. 350fg/cell decreasing to 135fg/cell after 4 hours.
Points are the mean of 3 separate experiments +/- sem.
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3.3.2 Intracellular Uptake of GEM-91 into Peripheral Blood Leukocytes
3.3.2.1 Total Leukocyte Population
Intracellular uptake of GEM-91 was dose- and time- dependent, and was not
saturated at concentrations of GEM-91 up to 10pM for 4 hours. By 4 hours of
incubation, intracellular concentrations had reached levels equivalent to extracellular
concentrations achieved in the first hour (Fig. 3.7).
3.3.2.2 Lymphocytes
At the lowest concentration of GEM-91 (0.1 |iM), no detectable level of uptake of the
ODN into lymphocytes was measurable at timepoints < 4 hours. At this dose, the
level ofGEM-91 measured after 4 hours was 3.7fg GEM-91/cell. At the intermediate
concentration ofGEM-91 (l.OpM), there was no change in the ODN uptake over the
first 4 hours of culture. The level of GEM-91 measured between 30 minutes and 4
hours in culture remained constant at approximately 15fg GEM-91/cell. At the
highest concentration of GEM-91 (10pM), the peak value of ODN uptake was
approximately 94fg GEM-91/cell after 2 hours (Fig 3.8).
3.3.2.3 Monocytes
As with the extracellular studies, monocytes exhibited the highest levels of GEM-91
uptake, with approximately 2- and 4- fold higher levels of GEM-91 than that
measured in neutrophils and lymphocytes respectively. At the highest dose, (10pM),
the mean concentration of GEM-91 within monocytes was approximately 200fg
GEM-91/cell after 0.5 hours in culture. This concentration increased to




Neutrophils also showed a high level of intracellular GEM-91. At the highest dose
(lOpM), the mean concentration of GEM-91 within neutrophils was approximately
130fg GEM-91/cell after 0.5 hours in culture. This concentration increased to
approximately 460fg GEM-91/cell after 4 hours. As in the extracellular studies, this
increase was less marked than that measured for monocytes (Fig 3.10).
Raw data for intracellular binding in all cell types can be found in Appendix B2.
Finally, it should be noted that the uptakes observed for the various cell populations
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FIGURE 3.9 Intracellular Uptake ofGEM-91 into Total Leukocytes. PBLs were incubated
with 3 concentrations of FAM-labelled GEM-91 for 4 hours after which they were treated
with 0.25% propidium iodide (PI). This compund quenched the cell surface FAM-labeled
GEM-91 enabling the intracellular GEM-91 to be measured directly. ODN uptake was time
and dose dependent, and after 4h in culture intracellular concentrations reached levels
equivalent to extracellular concentrations achieved in the first hour. Points are the mean of 3
separate experiments +/- sem.
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Intracellular Uptake of GEM-91 into Lymphocytes
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FIGURE 3.10 Intracellular Uptake of GEM-91 into Lymphocytes. Cells were incubated with
3 concentrations of FAM-labelled GEM-91 for 4 hours after which they were treated with
0.25% PI to quench the cell surface FAM-labeled GEM-91 enabling the intracellular GEM-91
to be measured directly. At the lower doses of ODN tested there was very little internalization
of ODN. After 2h in culture with lOpM GEM-91 lymphocyes internalized approx. 94fg/cell.
Points are the mean of 3 separate experiments +/- sem.
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Intracellular Uptake of GEM-91 into Monocytes












FIGURE 3.11 Intracellular Uptake of GEM-91 into Monocytes. Cells were incubated with 3
concentrations of FAM-labelled GEM-91 for 4 hours after which they were treated with 0.25%
PI to quench the cell surface FAM-labelled GEM-91 enabling the intracellular GEM-91 to be
measured directly. After 30mins in culture with lOpM GEM-91 monocytes internalized
approx. 200fg/cell, increasing to approx. 800fg/cell after 4h in culture. The increase in
intracellular concentrations over 4h were concommitant with the decrease in extracellular
binding over this time period. Points are the mean of 3 separate experiments +/- sem.
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Intracellular Uptake of GEM91 into Neutrophils












FIGURE 3.12 Intracellular Uptake of GEM-91 into Neutrophils. Cells were incubated with 3
concentrations of FAM-labelled GEM-91 for 4 hours after which they were treated with
0.25% PI to quench the cell surface FAM-labelled GEM-91. After 30mins in culture with
lOpM GEM-91 monocytes internalized approx. 130fg/cell, increasing to approx. 460fg/cell
after 4h in culture. The increase in intracellular concentrations over 4h were concommitant
with the decrease in extracellular binding over this time period. Points are the mean of 3
separate experiments +/- sem.
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Intracellular Uptake of GEM-91 into
Leukocyte Subtypes





FIGURE 3.13 Intracellular Uptake ofGEM-91 into Peripheral Blood Leukocyte
Subtypes.
Leukocytes were incubated with 3 concentrations ofFAM-labelled GEM-91 for 4h
after which time they were treated with 0.25% PL This quenched the cell surface
bound fluorescence enabling intracellular fluorescence to be directly measured. It can
bee seen that at all the doses ofGEM-91 tested monocytes internalized more ODN




The object of the experiments described in this chapter was to investigate the uptake
characteristics of the naked, 25 base phosphorothioate ODN GEM-91 into peripheral
blood leukocyte subtypes in an attempt to determine the suitability of the monocyte as
a target for antisense therapy. Large differences between cell types have been
reported regarding oligonucleotide incorporation. Primary keratinocytes, for
example, have been shown to display nuclear accumulation of naked
phosphorothioate ODNs and specific inhibition of ICAM-1 expression (Nestle et al.,
1994). In the same study, however, endothelial cells smooth muscle cells and
fibroblasts did not show ODN accumulation in nuclei without the use of a lipid
carrier. In contrast to cell lines, freshly isolated PBLs represent a more
heterogeneous cell population not only with respect to cell type but also in terms of
the state of cell activation and differentiation, and so provide a more physiological
environment in which to investigate the uptake of ODN into monocytes. The data
presented in this chapter clearly demonstrated a dose- and time- dependent uptake of
ODN into PBLs in the concentration range O.l-lOpM over a 4 hour period. It was
apparent that this uptake comprised extracellular and intracellular components which
were both dose dependent, and that there was heterogeneous uptake between the
different PBL subtypes. In the total cell population, extracellular binding as measured
by biotin-labelled GEM-91 detected by PE-conjugated streptavadin, was found to be
dose dependent and non saturating in the range of concentrations tested (0.1-lOp.M).
The highest levels of extracellular association were detected at the earlier timepoints
with significant decreases being observed over time. After 30 minutes in the presence
of 10pM GEM-91 the mean concentration ofODN on the cell surface was 425 ±112
fg/cell. This concentration decreased to 115 ± 30 fg/cell over the 4 hour culture
period (fig 3.3). This decrease in extracellular binding was associated with a
concomitant increase in intracellular GEM-91 levels as measured by FAM-labelled
GEM-91 in conjunction with PI. The intracellular GEM-91 levels increased from 130
± 12.4 fg/cell after 30 minutes in culture to 458 ± 66.5 fg/cell after 4 hours These
intracellular levels were approximately equal to the extracellular levels achieved in the
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first hour. This pattern of ODN association strongly suggests that there is cellular
internalization of the ODN over the 4 hour period. The efficiency of this
internalization of GEM-91 varied between the PBL subtypes tested. After 2 hours in
culture at ODN doses of 0.1, 1 and 10pM the intracellular levels of GEM-91 in
monocytes were 100, 23 and 4 fold higher respectively than in lymphocytes. At this
timepoint, the intracellular ODN levels were similar in monocytes and in neutrophils
at all doses tested. However, after 4 hours in culture with the same three
concentrations of ODN, monocytes internalised approximately 45 times more ODN
than lymphocytes at the two lower doses and 10 times more at the 10p.M dose.
Furthermore, after 4 hours in culture at all doses tested, monocytes internalized twice
as much ODN as neutrophils. These results suggest that monocytes internalise ODN
preferentially over lymphocytes and neutrophils after a 4 hour incubation Indeed at
the highest dose ofODN administered (10pM), monocytes contained 828fgODN/cell
which equates to 5x10 molecules of DNA. Before 1997, only 4 studies had
examined uptake of ODNs in human PBLs and only one of these described
spontaneous uptake in primary monocytes. Pirrucello et al., 1994 investigated uptake
of a 27 base ODN at a concentration of 4pM into primary cultured monocytes by
confocal microscopy. They observed that after a 2 hour incubation, 75-85% of
monocytes and 42-61% of lymphocytes were ODN positive. No information was
given as to the actual quantity of ODN internalized by these cell types. Three other
studies have described uptake of ODNs in human PBLs. Marti et al., 1992 have
stated that incorporation ofODNs in PBMCs is one tenth of that in H9 cells (a human
T-lymphocyte cell line). No specification for mononuclear cell subtypes was made in
this study. Another group reported the opposite namely that uptake of ODNs in
PBMCs is more than two times higher than uptake in H9 cells (Iversen et al., 1992).
However, again mononuclear cell subpopulations were not examined in this study.
Zhao et al., 1996 compared uptake of three FITC labelled ODNs, two 20mers and
one 25mer in human PBMCs, bone marrow cells and a human promyelocytic
leukaemia cell line. The three ODNs were used interchangeably as no differences in
their uptake was seen. It was shown that uptake was heterogeneous between
different cell types in normal PBLs and in bone marrow cells, in that B-lymphocytes
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took up more than T-lymphocytes and myleoid/macrophages took up more than either
lymphocyte subtype. Interestingly, in contrast to my observations, neutrophils
exhibited a very low ODN uptake. In addition, it was observed that human leukaemic
cells took up more ODN than normal cells from the same patient. It was speculated
that this was due to the fact that leukaemic cells are more actively dividing than
normal cells. Zhao et al., 1996 also showed that ODN uptake is closely related to the
cell cycle in that activated cells take up more ODN than non-active cells. More
recently, during the course of my studies, Hartmann et al., 1998 have examined
spontaneous uptake of a FITC labelled 18 base phosphorothioate ODN by flow
cytometry and fluorescence microscopy. They have shown that in the presence of
lpM naked ODN incubated for 2 hours 100% of monocytes and B- lymphocytes
incorporated ODN compared with only 12% of natural killer cells and 1% of T-
lymphocytes. They observed that after 2 hours at a concentration of lp.M monocytes
internalize 4 times more ODN than lymphocytes. This is in contrast to the current
study where after a 2 hour incubation with lpM ODN monocytes internalized
approximately 20 times more ODN than lymphocytes in the absence of any cationic
lipids At the higher dose of lOpM ODN lymphocytes managed to internalize more
ODN, but monocytes still contained 4 times more than them. Hartman et al., 1998
did not investigate ODN uptake into neutrophils.
Experiments have been performed by groups aimed at tracking the progress of ODNs
through cells. These experiments have been carried out in haematopoietic cell lines
and not in PBLs. It has been reported that in HL-60 human promyelocytic leukaemia
cells, ODN appeared to localize in endosomes in which they are acidified and undergo
efflux relatively slowly (Tonkinson et al., 1994). However, in K562 human chronic
leukaemia cells, once internalized, ODNs move from the endosomal compartment into
the cytoplasm and from there into the nucleus. Hartmann et al., 1998 have
investigated ODN uptake into isolated primary monocytes and have shown that
complex formation of the ODN with the cationic lipid lipofectin, enhanced uptake and
improved intracellular distribution in monocytes 5-10 fold. This effect, however,
depended on the ratio of lipid to ODN and was effective only in a narrow
concentration range, namely a 1:1 ratio of ODN to lipofectin, as larger quantities of
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lipids are cytotoxic. For this reason, cationic lipid mediated ODN transfer is not
appropriate for systemic administration of ODNs but may be effective for locally
administered ODN where lower concentrations are required. In agreement with
Hartmann et al., we have shown that monocytes take up more ODN than
lymphocytes. Flowever, in the current study the differences are more striking,
monocytes internalizing more ODN compared with lymphocytes at IpM and lOpiM
after 2 hours and 4 hours in culture suggesting that sufficient monocyte loading with
ODN may be achieved at lower doses than previously thought and without the need
for cationic lipids. This suggests that monocytes may be good target cells for
antisense therapy. Hartmann et al., isolated peripheral blood mononuclear cells by
ficoll hypaque centrifugation which removed neutrophils, and resuspended their cells
in RPMI 1640 culture medium. In our study leukocytes were isolated by red-cell lysis
followed by resuspension in QBSF culture medium. It is possible that the presence of
neutrophils and/or platelets in the cell suspension may have increased the activation
state ofmonocytes through cell adherence causing them to take up more ODN, either
by increasing the density of cell surface receptors or by promoting the differentiation
ofmonocytes into the more phagocytotic macrophages. However, to fully investigate
the intracellular distribution ofODN within human PBLs to determine whether or not
the ODN reaches its mRNA target would require powerful microscopy carried out on
freshly isolated cells. It has been demonstrated by Beltinger et al., 1992 that at lower
concentrations (<lpM) ODNs enter cells mainly by receptor mediated endocytosis
whereas at higher concentrations fluid phase endocytosis becomes more obvious. It is
tempting to speculate that the higher levels of extracellular binding and internalization
of ODN seen in monocytes and neutrophils represents the presence of higher levels of
DNA binding proteins. This being so, it may be postulated that the decrease observed
in extracellular association of GEM-91 over time despite the continued presence of
ODN in the culture medium may be due to a down regulation in these binding
proteins or receptors. This may theoretically occur as a result of DNA binding and
subsequent receptor internalization or alternatively it may represent a change in cell
phenotype during culture with ODNs. It has been shown by many groups that certain
cell surface receptors are involved in receptor mediated endocytosis of naked DNA
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into cells including CDllb/CD18 (Mac-1) (Benimetskya et a/., 1997), which is
expressed primarily on monocytes and neutrophils but not on lymphocytes.
Therefore, it is possible that ODN may be entering monocytes and neutrophils
preferentially by receptor mediated endocytosis either via a specific receptor or by a
more generalised receptor mechanism.
In summary, I have shown that ODNs enter peripheral blood leukocytes in the naked
state without the use of a carrier molecule and that this uptake is dose and time
dependent. Furthermore, it has been shown that monocytes internalize more ODN
than either neutrophils or lymphocytes. Therefore, it is clear that monocytes represent
a potential target for ODN therapy. However, it is not clear from these studies
whether ODN is bioavailable intracellularly to act as an efficient antisense molecule.
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Investigation of Putative Antisense Receptors
Chapter 4
4.1 Introduction
1 have previously examined the uptake kinetics of a 25 base ODN into PBMC and
concluded that the uptake is both dose and time dependent. The changes in the
extracellular association of the oligo with monocytes and neutrophils were measured.
There was an initial high extracellular association of ODN and, despite the continued
presence of ODN in the culture medium a decrease in cell surface bound oligo was
observed over time. In addition, there was a concomitant increase in intracellular
ODN as the extracellular concentration decreased. From these observations it may be
speculated that the higher levels of ODN on the cell surface of monocytes and
neutrophils represents higher levels ofDNA binding proteins. If this were the case it
may be concluded that the decrease observed in the extracellular association of the
oligo over time despite the continued presence of ODN may represent a down
regulation of these binding proteins or 'receptors'. This may theoretically occur either
as a consequence of DNA binding and subsequent internalisation as in receptor
mediated endocytosis. Alternatively, it may be a consequence of changes in cell
phenotype during culture
4.1.1 Mechanisms ofOligonucleotide Uptake
Uptake of DNA appears to be a natural phenomenon that has been postulated to
represent a nucleic acid salvage mechanism for material excreted by apoptotic cells
(Bennett, 1993). A number of laboratories have examined ODN uptake using either
native, methylphosphonate or phosphorothioate DNA (Yakubov et al., 1989; Loke et
al., 1989; Geselowitz and Neckers 1992; Gao et al., 1992; Beltinger et al., 1995).
Methylphosphonate molecules are uncharged molecules that have been reported to
enter cells via passive diffusion (Miller, 1991). In contrast, native phosphodiester and
phosphorothioate molecules are large polyanionic molecules which cannot easily
passively cross cellular membranes. Therefore, it appears that ODN uptake is an
active process dependent on concentration, energy and temperature. This appears to
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be accomplished primarily through a combination of absorptive endocytosis and fluid
phase endocytosis which may be triggered in part by the binding of the ODN to
receptor-like proteins present on the surface of a wide variety of cells (Gao et al.,
1993; Beltinger et al., 1995). Studies by Beltinger et al., in K562 cells (human
leukaemia cell line) have demonstrated that the uptake mechanism is at least partially
concentration dependent, and that below a concentration of IpM, uptake of
phosphorothioate ODNs is predominantly via a receptor-like mechanism, whilst at
extracellular concentrations higher than this, adsorptive and fluid phase endocytosis
predominates. Furthermore, using electron microscopy, Beltinger et al., 1995 have
detected ODN in clathrin coated pits on the cytoplasmic membrane, within endosomes
and lysosomes as well as free in the cytoplasm. In addition, the ODN uptake can be
inhibited by an unlabelled competing ODN. This work strongly suggests that a
receptor mediated mechanism is involved in ODN uptake, and that, in K562 cells at
least, naked ODN is capable of reaching the cytoplasm and indeed the nucleus and
thus is likely to be available to bind to target mRNA.
4.1.2 Putative Oligonucleotide Cellular Receptors
The identity of cell membrane proteins that bind ODNs is at present unclear. Proteins
with molecular weights of 75-90 kDa have been found to bind ODNs in ITL60 cells
and have been termed nucleic acid binding protein-1 (NABR-1) (Yakubov et al.,
1989). Loke et al, 1989 have, using affinity chromatography, isolated an 80 kDa
surface protein that appeared to be responsible for nucleic acid transport.
Subsequently, Beltinger et al., 1995 investigated the binding of biotinylated
phosphorothioate ODNs to the cell membranes ofK562 cells and found ODN binding
proteins of 137-147, and 79-85 kDa, as well as species of lower molecular mass. In
preparations of purified renal tubular brush border membranes, Rappaport et al., 1995
identified a phosphorothioate ODN-binding protein of 97 kDa. However, none of
these putative binding proteins was further characterised. Guvakova et al., 1995 have
shown that phosphorothioate ODNs can bind to a large number of heparin binding
proteins, including basic and acidic fibroblast growth factor (bFGF and aFGF),
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platelet derived growth factor (PDGF) and vascular endothelial growth factor
(VEGF), as well as to the VEGF receptor. The affinity of phosphorothioate ODNs
for bFGF can be high (30nM), is dependent on ODN length and, to some extent,
ODN sequence as well. Kimura et al., 1994 reported that ligands for scavenger
receptors blocked ODN induction of interferon production on murine natural killer
(NK) cells and proposed that scavenger receptors bound ODNs
In 1997, Benimetskya et al., demonstrated using HL60 cells, the involvement of the
Mac-1 (CD 1 lb/CD 18) receptor in ODN uptake into cells. Mac-1 is a member of a
family of leukocyte integrins that are involved in leukocyte adhesion and migration,
and that are involved in the binding of polymorphonuclear leukocytes (PMN) to
endothelial cells and the extracellular matrix. Mac-1 is also found on monocytes,
macrophages and NK cells. Mac-1 is a heparin binding protein (Coombe et al., 1994;
Diamond et al., 1995) and is a cell surface receptor for a variety of ligands including
fibrinogen (Loike et al., 1991; Wright et al., 1988), C3bi (the cleaved third
component of complement) (Wright et al., 1983), intercellular adhesion molecule-1
(Diamond et al., 1991), factor X (Alteri et al., 1988) and fibrin (Loike et al., 1995).
Benimetskya et al., have demonstrated that both phosphodiester and
phosphorothioate ODNs bind to both the aM and (52 chains of Mac-1 on
polymorphonuclear leukocytes. They have also shown that there is a correlation
between this binding and the rate of intracellular ODN internalization and that ODN
binding can be inhibited by heparin and fibrinogen.
In the light of these experiments, we have investigated the effect of GEM-91 on
monocyte cell surface Mac-1 and CD 14 levels (another receptor found in abundance
on monocytes which has not been implicated in ODN binding). We have shown that
monocytes internalize ODN more efficiently than any other PBMC, and since
monocytes express high levels of both Mac-1 and CD 14, we have investigated the
relative contribution of these receptors in binding GEM-91.
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4.2 Materials and Methods
4.2.1 Blood Cell Collection and Isolation
Peripheral venous blood was collected and leukocytes isolated as previously
described.
4.2.2 Leukocyte Incubations
Leukocytes were adjusted to a concentration of 1x10' cells per mi in QBSF media.
Aliquots (2ml) were incubated in sterile polypropylene tubes at 37°C, 95% air 5%
CO2 for 0-4 hours. Cells were either treated with 5pM GEM-91 labelled with FAM,
5pM GEM-91 unlabelled, or sterile distilled water as a control. The 5pM dose of
GEM-91was chosen to conserve costs as it represented a compromise between the
highest (lOpM) and the intermediate (lpM) doses tested in chapter 3.
4.2.3 Preparation of Cells for Flow Cytometry
At timepoints of 0.5, 1, 2, 4 hours ,100ul aliquots of cells (lxlO6) were removed and
directly immunostained for CD14 and Mac-1 (CD 1 lb/CD 18) as described in chapter
2. To stain for Mac-1 (CD 1 lb/CD 18) 10pl of 70pg/ml stock solution of monoclonal
anti-human CD1 lb clone 44 conjugated with quantum red fluorochrome (Sigma
Chemical Co.) or a negative isotype control antibody (mouse IgGl conjugated with
quantum red, Sigma Chemical Co.) was added to lOOpl cells.
To detect the CD 14 antigen, which is a specific monocyte cell surface marker, lOOpl
cell aliquots were stained with monoclonal anti-human CD 14 clone UHM-1
conjugated with R-PE (Sigma Chemical Co.) or with the isotype control antibody
(IgGl conjugated with R-PE) as above.
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4.2.4 Flow Cytometric Analysis
Flow cytometry was carried out immediately, using the FL3 channel to detect CD1 lb
positive cells and the FL-2 channel to detect CD 14 positive cells. An average of
50000 cells were collected from each sample, typically containing 1500-2500
monocytes. Cell types were identified by virtue of their forward and side scatter
characteristics, cells in the monocyte gate being typically 95% CD 14 positive when no
oligo was added. The fluorescence channel gains were zeroed using the cells stained
with the negative isotype controls so that all cells fell in the first log decade. The
geometric mean fluorescence of the cells stained with the test antibody was recorded.
The geometric mean fluorescence of the cells after treatment with the ODN was
expressed as a percentage of the fluorescence of the untreated cells.
4.2.5 Statistical Analysis
All analyses were done on raw data and were carried out using a repeated measures
analysis of variance followed by a Bonferroni multiple comparisons post test. Where
data could not be matched due to varying numbers in each group, a one way analysis





4.3.1 Effect of Culture Conditions on Monocyte Cell Surface Mac-l(CDllb) and
CD 14 Levels
A 100% value was assigned to the CD1 lb and CD14 levels at baseline i.e. t=0.
After 0.5 hour in culture alone, the cell surface levels ofMac-1 decreased to 83 ± 5%
of baseline at Ih (p<0.01), 82 ± 6% of baseline at 2h (p<0.001), 73 +2 of baseline at
4h (p<0.001) (Fig 4.1a).
The cell surface CD 14 levels did not significantly decrease over the 4 hour culture
period compared with the t=0 baseline (Fig 4. lb).
4.3.2 Effect of GEM-91 on Monocyte Cell Surface Mac-l/(CDllb/CD18)
After 0.5 hours in culture with 5pM GEM-91, the cell surface levels of Mac-1 were
already significantly decreased with respect to the untreated cells at the same
timepoint and they continued to decrease in a time dependent manner over the
untreated cells at 1, 2 and 4 hours in culture. At t=0.5 the oligo treated cells had
CD1 lb levels 51 ± 4% of baseline, p<0.001, at t=l 38 + 3 % of baseline p<0.001, at
t=2, 31 ± 2.5% of baseline p<0.001 and at t=4, 24 ± 2% of baseline p<0.001 (Fig
4.1a).
4.3.3 Effect of GEM-91 on Monocyte Cell Surface CD14
Over a 4 hour culture period, the cell surface CD 14 levels on ODN treated cells were
not significantly different from the untreated cells at the same timepoint until t=4 at
which time they had fallen to 28 ± 4% of baseline p<0.001 (Fig 4. lb).
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Effect of GEM-91 on Mac-1 levels
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FIGURE 4.1 Effect of GEM-91 on Monocyte Mac-1 and CD 14 Levels. PBLs were incubated with
and without 5pM unlabelled GEM-1 for 4 hours. A. Monocyte cell surface Mac-1 levels decreased
significantly over the 4 hour culture period, but in the presence of 5pM GEM-91 for 4 hours the Mac-
1 levels decreased significantly further with respect to untreated cells. B. Cell surface CD 14 levels
did not significantly decrease until 4 hours into the culture period. In the presence of 5pM GEM-91
the cell surface CD 14 levels decreased significantly with respect to the untreated cells.
** p<0.01, *** pO.OOl, n=6.
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4.3.4 Association Between Baseline Mac-1 Levels and GEM-91 Binding to PBL
Cell Types
From figure 4.2 it can be seen that the cells having greatest cell surface Mac-1 levels
(monocytes and neutrophils) bound the greatest amount ofGEM-91 after 30 mins. In
addition, it can be seen in figure 4.3 that cell surface Mac-1 levels on monocytes and
neutrophils are higher than in lymphocytes.
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FIGURE 4.3 Mac-1 Levels on Peripheral Blood Leukocyte Subtypes and the Corresponding
GEM-91 uptake. The Y axis represents the mean channel fluorescence of the cells. In the case
ofMac-1 this is FL-2 Fluoresence. and in the case of GEM-91 it is FL-1 fluorescence. It can be
seen that monocytes and neutrophils which have the greatest density ofMac-1 receptors also have




In the previous chapter it was shown that uptake of GEM-91 into PBLs is dose and
concentration dependent over a four hour period and that the order of uptake
efficiency among PBL subtypes after 4 hours is lymphocytes < neutrophils <
monocytes. Many studies have been carried out that suggest that ODNs enter cells by
receptor mediated endocytosis via a variety of uncharacterised cell surface proteins
(Beltinger et al., 1995, Kimura et al., 1994). Recently, Benimetskya et al., 1997 have
demonstrated convincingly that the heparin binding integrin CD lib/CD 18 (Mac-1) is
a cell surface receptor for phosphodiester and phosphorothioate ODNs and is capable
ofmediating their internalization
Using monoclonal antibodies to Mac-1 and CD 14 directly conjugated with cy-5 and
PE respectively, the cell surface levels of these receptors on monocytes were
measured using flow cytometry with and without the addition of GEM-91. It has
been shown that after 4 hours in culture monocyte cell surface levels of Mac-1
decreased to 73% of those detected at baseline. Conversely, culture conditions did
not significantly decrease the cell surface CD 14 receptor levels. In addition to the
decrease in Mac-1 levels caused by culture alone, incubation with 5pM unlabelled
GEM-91 caused further time-dependent decreases in the receptor levels such that
after 30 minutes in culture, Mac-1 levels had significantly fallen and after 4 hours in
culture Mac-1 levels had fallen to 24 ± 2% (p<0.001) of those at baseline. In
contrast, in monocytes treated with GEM-91 CD 14 levels did not fall significantly
below levels in untreated cells until after 4 hours in culture. These results show that
GEM-91 causes a rapid pronounced decrease in monocyte cell surface Mac-1 levels
and an equally pronounced but slower decrease in cell surface CD 14 levels. When
FAM-labelled GEM-91 was incubated with PBMC in culture the highest levels of
fluorescence were seen in the cells expressing Mac-1 namely monocytes and
neutrophils. Lymphocytes had much lower associated GEM-91 (Figs 4.3 and 4.4).
Despite the fact that neutrophils have a higher density of Mac-1 receptors than
monocytes, it has been shown in the previous chapter and confirmed here that it is
monocytes which internalize more ODN. This may be due to the fact that monocytes
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have a greater density of cell surface receptors, in particular the CD 14 receptor and
these may be involved in ODN uptake. An alternative hypothesis might be that ODNs
upregulate the expression of another receptor on monocytes, but not on neutrophils
or lymphocytes, which results in an increased ODN binding. It has been suggested
that ODN uptake is related to the cell cycle in that activated cells take up more ODN
than non-active cells (Zhao et al., 1996; Benimetskya et ah, 1997). Zhao et ah, 1995
have shown that ODN uptake was stage specific during B-cell differentiation.
Because cell activation status may vary during cell maturation, it may be speculated
that during monocyte maturation into macrophages, increased expression of cell
surface receptors for ODNs may occur in addition to the increased phagocvtotic
ability of the cells contributing to an increased ODN uptake over and above that of
neutrophils and lymphocytes. This activation could feasibly occur in the artificial
conditions of cell culture.
The studies by Benimetskaya et. al., that demonstrate binding of ODNs to Mac-1 and
other heparin binding proteins on the cell surface suggest that these receptors may be
capable of internalizing ODNs. This observation in addition to the evidence from our
study that the cells with highest levels of Mac-1 have the greatest associated ODN
suggests that these receptors may be involved in uptake of ODN. Alternatively it is
also possible that ODN binding to cell surface receptors may elicit an intracellular
response initiating downregulation of the receptor or another response.
The present study shows that the extracellular presence of ODNs has an effect on
monocyte cell surface receptors. Mac-1 levels quickly decrease after 30 minutes in
the presence of ODN compared with CD 14 levels which do not significantly decrease
until 4 hours in culture with the ODN. This suggests that the ODN may be slowly
changing the phenotype of the monocyte by downregulating the expression of CD 14
and Mac-1. The effect of ODNs on the CD 14 receptor would be relevant to studies
concerning TF. The first step in the induction of TF by bacterial LPS is binding of the
LPS molecule to the CD14 receptor. The simple binding of the ODN to the CD14
receptor, or downregulation of the receptor, would reduce the potential for LPS
interaction with CD 14 inhibiting the induction of TF. Conversely, interaction of the
ODN with the CD 14 receptor may actually induce TF expression (see chapter 6) by
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setting in motion intracellular signalling pathways resulting in transcription of the TF
gene. Although the current experiments suggest that, in agreement with
Benimetskaya et al,. 1997, the Mac-1 and CD 14 receptors are somehow involved in
ODN uptake the results are far from conclusive. Studies examining ODN uptake in
the presence of neutralizing antibodies to Mac-1 and CD 14 or competitive ligands to
these receptors would be needed to clarify actual ODN binding to these receptors.
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Characterisation of Lipopolysaccharide Induction
of Tissue Factor InWhole Blood
Chapter 5
5.1 Introduction
Since monocytes are the only peripheral blood cell capable of expressing TF, there has
been considerable interest in measuring the procoagulant activity of these cells in
disease states. The results of these experiments have, however, been difficult to
interpret mainly because of the diverse methodology employed. Functional
approaches have utilized various methods for purifying monocyte populations, many
of which artefactually activate the cells (Muller et al., 1985). Some studies have used
clotting assays to quantitate TF activity (0sterud and Bjorklid, 1982), whilst others
have used chromogenic methods to quantitate the amidolytic activity of the TF/VIIa
complex (Carson et al., 1986). Interpretation is additionally complicated since some
authors measure TF after cell disruption (0sterud and Bjorklid. 1982) whilst others
evaluate intact cells (Surprenant and Zuckerman, 1989). Differences in the numeric
expression of procoagulant activity adds to the problem. An alternative approach has
been the use of flow cytometry (Luther et al., 1990; Carson et al., 1990), although it
is often unclear whether TF antigen levels correlate with procoagulant activity.
5.1.2 Adherent Monocytes versus Monocytes in Suspension
Most of the information on the regulation of TF expression in monocytes stems from
studies on adherent monocytes in cell cultures. LPS stimulation of adherent
monocytes is apparently mediated through the protein kinase C system (Ternisiera et
al., 1993) whereas observations by 0sterud show that protein kinase C inhibitors fail
to inhibit LPS induced TF activity in monocytes of whole blood. Furthermore, both
the phorbol ester, phorbol myristate acetate (PMA) and TNF-a induce TF in adherent
monocytes. In contrast, neither of these agents is capable of generating TF activity in
monocytes of whole blood, although they enhance several fold LPS induced TF
activity in these monocytes. 0sterud has postulated that many of the agonists that
apparently induce TF activity in adherent monocytes are merely enhancing the basal
activity in already activated cells. In addition, monocytes allowed to adhere to culture
plates for 24h do not express increased amounts of TF in response to LPS unless
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lymphocytes are present in the cultures (Levy and Edgington 1980; Levy et ai., 1981;
Schwartz et al., 1981; Lyberg., 1983). Therefore, under certain circumstances,
cellular co-operation is a prerequisite for TF expression in monocytes. Platelets and
serum growth factors have also been shown to augment TF expression in LPS treated
monocytes (Edwards and Perla 1984; Niemetz et al., 1974). These observations
clearly suggest that the function and control ofmonocyte TF expression may not fully
be appreciated by in vitro studies using isolated monocytes or monocytic cell lines.
5.1.3 Monocyte TF Induction In Whole Blood
This apparent difference in behaviour of monocytes in culture with those in
suspension led 0sterud to design an ex vivo whole blood model to investigate the
induction of TF in monocytes in their own environmental milieu, in an attempt to
decipher the intracellular co-operation involved (0sterud et al., 1982; 0sterud et al.,
1990). It has been shown that monocytes in whole blood appear to be activated
entirely through the phospholipase A2 (PLA2) pathway to generate products like
interleukins, TNFa and other cytokines as well as TF. In this system only two
agonists, LPS and immune complexes, have been shown to induce TF activity. Using
low dose LPS (2-5ng/ml) stimulated, anticoagulated whole blood as a test model,
0sterud has characterized TF induction on monocytes. He has concluded that
expression of TF activity is relatively constant in each individual tested, but varies
between individuals. He reported a 50-fold difference in LPS induced activity
between the highest and lowest responders (0sterud et al., 1994) but reported
virtually no difference in TF antigen as measured by ELISA between the highest and
lowest responders. This led him to speculate that the high TF activity induced in
monocytes of the high responder was due to an increase in the catalytic activity of TF
caused by an interaction between platelets and monocytes. In this whole blood
system, he has also shown that PMA (60ng/ml) or physiological concentrations of
TNF (5-10ng/ml) caused a 2 -3 fold enhancement of LPS-induced TF activity. In
contrast, neither of these agonists alone was able to induce TF activity in this system.
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It was postulated that the effects of these agonists were mediated by another cell type,
possibly granulocytes or platelets.
5.1.4 Role Of Platelets In Expression of Monocyte TF Activity
In 1974, Niemetz suggested that platelets enhance the procoagulant activity of white
blood cells (Niemetz et al., 1974). This was later confirmed in monocyte cell cultures
where isolated platelets added to the cultures enhanced LPS induced TF activity
(Lorenzet et al., 1985; Pinder et al., 1985). Furthermore, 12-Hydroxy-
eicosatetraenoic acid (HETE), a platelet product, was claimed to enhance LPS-
induced TF activity in adherent monocytes (Lorenzet et al., 1985). Osterud further
confirmed this platelet effect in his whole blood model. He removed platelets from
the white blood cells and then cross combined the white cells with either platelet rich
plasma (PRP) or platelet poor plasma (PPP). He subsequently stimulated the system
with LPS and observed a significant platelet enhancing effect on LPS induced TF
activity (0sterud et al., 1990). 0sterud then went on to demonstrate that the
variation in LPS induced TF activity between individuals was partly attributable to
platelets. Thus recombining platelet poor cells from high responders with platelets
from low responders lead to a marked reduction (60-70%) in LPS induced TF
activity. Accordingly, a significant rise in TF activity was observed when platelets
from high responders were recombined with cells from low responders. A mandatory
role for granulocytes in providing the platelet enhancement of LPS-induced TF
activity in monocytes has also been demonstrated by this group (Halvorsen et al.,
1993). In addition, exogenously added platelet activating factor (PAF) enhanced
LPS-induced TF activity in monocytes provided that both granulocytes and platelets
were present (0sterud et al., 1992). Furthermore, a PAF antagonist was shown to
suppress LPS induced TF activity in monocytes.
It is, therefore, apparent that in order to fully investigate TF induction by LPS in
monocytes, a whole blood model should be used to facilitate physiological cell
interactions. We have characterized TF induction by LPS in whole blood, examined
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the reproducibility of this induction both within subjects and between subjects and
have looked at the ODN association with PBLs in a whole blood environment.
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5.2 Materials and Methods
5.2.1 Blood Collection and Processing
Whole blood was collected from 6 healthy volunteers by clean venepuncture with a 21
gauge needle into sterile vacutainers (Sarsdtet) containing 3.2% trisodium citrate
anticoagulant.
5.2.2 Dose-Response and Timecourse of TF Induction on Monocytes by LPS
Blood aliquots (1ml) were placed in sterile 15ml polypropylene tubes (Falcon) and
treated with LPS from E. coli 0111:B4 (Sigma) (reconstituted in sterile distilled
water) to produce final concentrations of 0, lOpg/ml, lng/ml, lOOng/ml, lOpg/ml,
10Dug/ml. E. Coli stock solutions were made up such that 20pl volumes were added
to each sample to produce the desired final concentration. The samples were
incubated at 37°C with 95% air, 5% C02. Aliquots (lOOp.1) were removed at 2h, 4h,
6h, 24h, and were immediately indirectly immunostained for TF as described in
chapter 2. The primary monoclonal antibody cocktail to TF was kindly donated by
Prof. T.S.Edgington, Scripps Research Centre, La Jolla, CA.
5.2.3 Flow Cytometry
Fixed, stained, cells were analysed by flow cytometry as described in chapter 2.
Briefly, 50000 cells were collected and monocytes were identified by virtue of their
forward and side scatter characteristics and were periodically checked to be 95%
CD 14 positive. Isotype control stained cells were used to set the positive delineator
at 3% positive cells. Subsequently, cells falling within this marker were deemed to be
positive for TF. In addition, the geometric mean fluorescence of the TF stained cells
was recorded along with the geometric mean fluorescence of an isotype control at
each dose and timepoint.
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5.2.4 Person Specific TF Induction
6 normal healthy males were recruited to take part in a repeated study to look at
monocyte TF induction in individuals over a 3 month period. Blood was collected
from these subjects on 4 or 5 different occasions over a three month period. The
blood was stimulated with either lOOng/ml LPS or lOpg/ml for 2 hours and monocyte
TF levels measured as above by flow cytometry.
5.2.5 Association of GEM-9I with PBLs in Whole Blood vs Isolated Cells
As we were now using a whole blood model to look at TF induction in monocytes
with a view to it's inhibition with ASODNs we investigated the association of GEM-
91 to monocytes in whole blood compared with that in isolated peripheral blood
leukocytes. The ODN overall association was not differentiated into an intracellular
and an extracellular component as was the case in chapter 3, due to the expense of the
ASODN tested. Flowever. it was assumed that cell surface bound ODN would be
internalised to the same extent as in chapter 3. Blood was collected and leukocytes
isolated as described previously. Aliquots either of whole blood (500pil) or peripheral
blood leukocyte suspension in QBSF media (500pl of 1x10' cells) were incubated for
4 hours with either 0, 0.1, 1.0 or 5 pM final concentration of GEM-91. The whole
blood aliquots were then treated with red cell lysis solution as before and washed, as
were the isolated cells twice in PBS. The cells were then analysed by flow cytometry
as described above (50000 cells collected and geometric mean channel fluorescence




5.3.1 Dose Response and Timecourse of LPS Induction in Monocytes
After a 2h incubation with increasing doses of LPS, there was a dose dependent
increase in TF expression on monocytes in whole blood (Figs. 5.1 and 5.2). At
baseline there was a mean of 1.03 ± 0.26 % positive cells (geometric mean
fluorescence GMF 0.02 ± 0.02). A 2h incubation with sterile distilled water produced
3.27 ± 0.68 % positive cells (GMF 0.25 ± 0.13). On the addition of increasing
concentrations of LPS (lOpg/ml, lng/ml, lOOng/ml, lOpig/ml and 100p.g/ml) the TF
expression increased to 4.61 ± 1.91 % positive cells (GMF 0.61 ± 0.34), 23.12 ± 4.13
% positive cells (GMF 2.46 ± 0.91), 53.93 ± 8 % positive cells (GMF 8.96 ± 2.04),
66 04 ± 9.53 % positive cells (GMF 17.14 ± 4.77). At this timepoint the isotype
control antibody staining was consistently low. At 4h, 6h, 24h incubation times, the
cell morphology gradually changed, possibly due to monocyte differentiation into
macrophages, and it became increasingly difficult to distinguish monocytes from the
other peripheral blood leukocytes. The isotype control antibody also began to stick to
the cells and stain positive. This decline in monocyte quality over longer incubation
times suggested that a 2h incubation be used for all subsequent induction experiments
as this seemed to be the limit to our experimental system.
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5.3.2 TF Induction in Individual Subjects
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Six healthy volunteers were recruited to participate in a 3 month study to test the
reproducibility of the whole blood assay both within the same individual and between
individuals. Blood was taken from each individual on up to 5 occasions over a 3
month period and was treated with two concentrations of LPS for 2 hours. The
coefficient of variation was calculated for tests done on the same person over the
three month period (Table 5.1). In addition, mean values were calculated for each
dose on each individual and were compared with each other (Fig 5.3). All results are
expressed as percentage TF positive monocytes.
It was apparent that the at the higher dose of 10p.g/ml LPS there was a reproducible
intra-person induction of TF on whole blood monocytes. In 5 of the six subjects
tested repeatedly over the course of 3 months the cv < 10%, and in the individual with
large variability (KW), the isotype control stained samples were also high, suggesting
that this individual had particularly reactive monocytes. However, at the lower dose
of lOOng/ml LPS there was much more variation in the monocyte TF measured on the
same individual on different occasions, the cv being frequently greater than 20%.
Similarly, there was great variation in the TF induced by incubation with distilled
water alone in blood from the same individual tested on different days the cv ranging
from 18-80%.
Subject Isotype 0 LPS 100ng/ml LPS I0(j,g/ml
Control LPS
DS 1.57 (5) 34.5 (5) 11.1 (4) 8.88 (5)
SB 2.34 (5) 18.4 (5) 2.88 (5) 3.7 (5)
KW 21.5 (5) 77.1 (5) 29.3 (5) 16.2 (5)
RW 2.8 (5) 80.9 (5) 31.6 (4) 6.92 (5)
DF 2.51 (5) 51.0 (5) 16.6 (5) 9.41 (5)
RM 2.6 (4) 28.6 (4) 16.1 (3) 7.63 (4)
TABLE 5.1 Coefficients of Variation in Each Individual When Treated with 2 Concentrations of




With respect to inter-person variation, at the lOOng/ml LPS dose, there was a
maximum of a 1.75 fold difference in the lowest (36.3 ± 2.0% positive monocytes,
n=4) and the highest (63.7 ± 5.9% positive monocytes, n=3) responders. At the
higher dose of lOpg/ml LPS there was very little inter-person variation the lowest
responder having 61 ± 2.4% positive monocytes, n=5, and the highest responder
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5.3.3 Association of GEM-91 with PBLs in Whole Blood vs Isolated Leukocytes
5.3.3.1 Total Cells
In general, association ofGEM-91 with PBLs in whole blood was overall less than in
isolated cells for each cell type examined (Figs.5.4a-d). At O.lpM GEM-91 the total
fluorescence associated with the cells (GMF) was 2.52 ± 0.024 in whole blood vs
31.3 ± 11.9 in isolated cells. At the higher dose of l.OpM the total fluorescence
associated with the cells was 4.04 ± 0.2 for whole blood vs 56.9 ± 16 for isolated
cells. Finally, at 5pM GEM-91 the total cellular fluorescence was 15.86 ± 2.4 for
whole blood vs 60.4 ± 19 for the isolated cells. However, the pattern of ODN
association in the different cell types was the same in whole blood as in isolated cells,
with monocytes having the greatest association of ODN, followed by neutrophils and
finally lymphocytes having the least.
5.3.3.2 Lymphocytes
Lymphocytes took up very little ODN either in whole blood or in isolated blood cells.
At an ODN dose of O.lpM there was 7 fold less associated with lymphocytes in the
whole blood model than in isolated cells (GMF 1.4 ± 0.04 vs 7.1 ± 1.9). At the lpM
dose GMF was 2.4 ± 0.4 in whole blood vs 14.5 ± 2.9 in isolated cells and at the 5pM
dose, GMF was 6.8 + 1.4 in whole bloodvs 17.9 ± 2.8 in isolated cells.
5.3.3.3 Monocytes
The monocyte population had the greatest associated ODN both in the whole blood
setting and in the isolated cells preparation. At GEM-91 concentrations of 0.1 and
1.0 pM association with monocytes was 10 fold less in whole blood than in isolated
cells after a 4 hour incubation (GMF 12.3 ± 0.2 vs 131.3 ± 36.7 and 41.9 ± 1.3 vs
407.9 ± 68.8 respectively). At the 5 pM dose of GEM-91 association with
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monocytes in whole blood was 3.5 fold less than in isolated cells (GMF 140.4 ±11.8
vs 502.1 ±86.2).
5.3.3.4 Neutrophils
Oligonucleotide association with neutrophils was approximately 20 fold less in whole
blood than in isolated cells (GMF 3.2 ± 0.2 vs 63.1 ± 19) at a GEM-91 concentration
of 0.1 p.M. At a lpM dose, neutrophil associated ODN was 40 times less in whole
blood than in isolated cells (GMF 6.4 ± 1.2 vs 251 ± 90.5). At the 5 pM dose there
was a 12 fold greater ODN association with neutrophils in isolated cells compared
with neutrophils in whole blood (GMF 27.2 ± 3.8 vs 324.7 ± 27.2).
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FIGURE 5.4a Geometric Mean Fluorescence of untreated isolated cultured PBLs and PBLs
whole blood.
All the cell types tested had a low background fluorescence. Bars represent the mean of 4












FIGURE 5.4b Geometric Mean Fluorescence (GMF) of 0.1 pM FAM-labelled GEM-91
treated isolated PBLs or PBLs in whole blood. It can be seen that PBLs isolated from GEM-
91 treated whole blood have less associated ODN than GEM-91 treated freshly isolated PBLs
in culture. In both cases monocytes have the greatest associated ODN. Bars represent the
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FIGURE 5.4c Geometric Mean Fluorescence (GMF) of 1 .OpM FAM-labellcd GEM-91
treated isolated PBLs or PBLs in whole blood. PBLs extracted from GEM-91 treated whole
blood have less associated ODN than GEM-91 treated freshly isolated PBLs in culture. In
both cases monocytes have the greatest associated ODN. Bars represent the mean of 4
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FIGURE 5.4d Geometric Mean Fluorescence (GMF) of 5.0pM FAM-labelled GEM-91
treated isolated PBLs or PBLs in whole blood. PBLs extracted from GEM-91 treated whole
blood have less associated ODN than GEM-91 treated freshly isolated PBLs in culture.
Again, in both cases monocytes have the greatest associated ODN. Bars represent the mean of




Monocytes are the only peripheral blood mononuclear cell capable of expressing TF
when stimulated and as such represent an important source of systemic procoagulant
activity. Most of the information available on the regulation of TF expression stems
from studies on monocytes in culture (Muller et al., 1985; Luther et al., 1990).
0sterud is of the opinion that cultured, adherent monocytes do not accurately
represent the pathophysiological reactions and signal transductions involved in the
expression of TF in circulating blood in vivo, and for this reason, he believes that the
results of these studies provide information on a particularly artificial situation. In an
attempt to improve understanding ofmonocyte behaviour in their own environmental
milieu, 0sterud et al 1982, designed an ex vivo whole blood model to investigate
monocyte TF expression. In the decade that followed, 0sterud built up a picture of
the behaviour of monocytes in whole blood when stimulated to express TF. He
concluded that LPS was capable of inducing TF activity in monocytes in whole blood
and that although this induction of was relatively constant in each individual, there
was up to a 50-fold difference in LPS-induced activity between the highest and lowest
responders at concentrations of LPS between 2-5ng/ml (0sterud et al., 1994).
However, he also documented that there was virtually no difference between TF
antigen expression between the highest and lowest responders when measured by
Enzyme Linked Immunosorbent Assay (ELISA).
More recently Amirkhosravi et al., 1996 have developed a 2-colour whole blood
cytometric technique to measure cell surface TF antigen in monocytes in whole blood
using a pre- FITC-conjugated monoclonal antibody to TF in conjunction with a
fluorescently labelled CD 14 monoclonal antibody. Using small volumes of citrated
anticoagulated blood stimulated with lOpg/ml E. coli 0111 :B4 LPS they have shown
that monocyte TF antigen levels in normal subjects are low, 1.1 ± 0.95% making
small increases easy to detect. Percentage TF antigen positive monocytes following
LPS stimulation at 10p.g/ml for 1 hour was 34.6% ± 11.2%. Furthermore, they
observed that LPS-stimulated, TF antigen positive monocytes varied between subjects
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(21-68%) a 3 fold difference. This was in contrast to 0sterud's observation that
although TF activity varied by as much as 50-fold between the highest and lowest
responders, there was no measurable difference in TF antigen (0sterud et al., 1994).
This discrepancy may be due to the fact that 0sterud used a much lower LPS
concentration than Amirkosravi et al., (2ng/ml vs 10pg/ml), used heparin as
anticoagulant rather than citrate and measured clotting activity rather than antigen. It
may also be due to the fact that flow cytometry is a more sensitive method of
detecting cell surface antigens enabling smaller fluctuations in TF antigen to be
detected than is possible with ELISA. Amirkosravi et al., also demonstrated that
stimulated monocyte TF expression within individuals was relatively constant (cv=
5.4%) a fact also noted by 0sterud (1995a and 1995b).
In addition, Amirkosravi et al., has also shown that there is a strong positive
correlation between monocyte TF as measured in whole blood by flow cytometry and
procoagulant activity as measured by whole blood recalcification time using a
sonoclot analyser, suggesting that the expressed TF antigen is functionally active.
In the light of these conflicting reports, we have sought to characterize the time and
dose dependent induction of TF in a whole blood model using flow cytometry, which
appears to be the most sensitive method of detecting monocyte TF antigen
expression.
Therefore, the purpose of this study was 3 fold. Firstly, it was required to establish,
in my hands, the timecourse and dose-response relationship of LPS-induced TF
expression in monocytes in a whole blood setting. This was necessary to determine
an appropriate LPS dose and incubation time to provide optimal TF induction, whilst
maintaining sufficient monocyte morphology and integrity to facilitate flow cytometric
analysis. Secondly, it was necessary to assess the reproducibility of this whole blood
model of TF induction by LPS, both between different individuals, and in the same
individual tested on different occasions. We have developed an ex vivo whole blood
assay to investigate LPS induction of TF, designed to facilitate flow cytometric
measurement of TF antigen. The third aim of this study was to examine the




In agreement with Amirkhosravi et al., 1997, a low TF antigen level at baseline was
observed (1.03 ± 0.26% positive monocytes GMF 4.04 ± 0.45) making it easy to
detect the dose dependent increase in the percentage positive over the range of LPS
concentrations tested (0, lOpg/ml, lng/ml, lOOng/ml, 10p.g/ml and 100p.g/ml) after a
2 hour incubation (3.27 ± 0.68%; 4.61 ± 1.91%; 23.12 + 4.13%; 50.1 ±3.19%; 64.41
± 2.78% and 79.35 ± 3.81% positive monocytes) (Fig. 5.1a). However, incubation
times longer than 2h resulted in a breakdown of the dose-response relationship (Fig
5.1 b-d). As can be seen in figure 5.2b-d the samples immunostained with isotype
control antibody (control not designed to bind to TF) stained positive. As incubation
time with LPS increased, especially at the higher doses of LPS, monocyte morphology
was seen to deteriorate, making it difficult to distinguish them from lymphocytes on
the FACS plot. In addition, the monocytes became increasingly 'sticky', binding
control primary antibody and fluorescently labelled secondary antibody at random.
Consequently, it was decided that a 2 hour incubation with LPS was the limit to the
experimental set-up, and this time was chosen for subsequent stimulation experiments.
Similarly, Amirkhosravi, et al chose a 1 hour incubation with LPS in their set-up.
They observed a near maximal TF induction at this timepoint, and a corresponding
fast clotting time.
Six healthy male volunteers were recruited to take part in a 3 month study to
determine the reproducibility of the whole blood flow cytometric assay for monocyte
TF. Blood samples from each of the six individuals were taken between 3 and 5 times
over the 3 month period and were incubated in the absence and presence of LPS
(lOOng/ml and 10|ag/ml) for 2 hours. Monocyte TF antigen was then determined by
flow cytometry. Table 1 shows that the reproducibility of the assay within individuals
at 10p.g/ml LPS was much better than when the subjects were treated with the lower
dose of lOOng/ml LPS. The coefficients of variation (cv) were below 10% in all but
one case at the 10pg/ml dose whereas the cvs were often over 10% at the lower dose
of lOOng/ml. In the individual with the higher cv at 10p.g/ml, it can be seen that there
was a corresponding variation in the isotype control stained cells (cv=21.5%). This
suggests that this individual may have monocytes particularly susceptible to activation
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and thus background staining during these incubation conditions. 0sterud et al., 1992
have also reported a relatively constant induction ofTF activity within individuals.
However, his experiments were carried out at doses of LPS much lower (between 2-
5ng/ml) than our lowest dose of lOOng/ml. The lack of reproducibility at lOOng/ml
seen in the current study may be due to the fact that citrate was used as an
anticoagulant compared with heparin used by 0sterud. However, Amirkhosravi et al.,
1996 who have reported a 5% coefficient of variation within individuals at a dose of
10|ug/ml have reported that they observed no difference between the anticoagulants
heparin and citrate. 0sterud measured TF activity in lysed cells and not the TF
antigen on intact monocytes. In addition, the sensitivity of the flow cytometric
technique used in the current study, may make it easier to detect intra-person
fluctuations in TF antigen
With respect to inter-person variation, at the lOOng/ml LPS dose, there was a
maximum of a 1.75 fold difference in the lowest (36.3 ± 2.0% positive monocytes,
n=4) and the highest (63.7 ± 5.9% positive monocytes, n=3) responders. At the
higher dose of 10gg/ml LPS there was very little intra-person variation, the lowest
responder having 61 ± 2.4% positive monocytes, n=5, and the highest responder
having 78.11 ± 5.6% positive moncytes, n=5 (Fig 5.3). . Thus, in the current study
there was little sign of a high and low responder phenomenon at these doses.
Although both 0sterud et al., 1992 and Amirkhosravi et al., 1996 both observed a
dual responder phenomenon to varying degrees, 0sterud's 50 fold differences between
high and low responders were in TF activity and not in TF antigen when measured by
ELISA. Amirkhosravi et al., only observed a three fold difference (21-68%), in
contrast to 0sterud's 50 fold difference, but specifically in TF antigen. This is in
contrast to the current study which demonstrates, at most, a 1.75 fold difference in TF
positive monocytes between the highest and lowest responders. This may be due to
differences in red cell lysis methodology, or to the fact that Amirkhosravi et al., used a
1 hour incubation time compared with 2 hours in the current study. Furthermore,
Amirkhosravi used a directly conjugated monoclonal antibody to TF in contrast to our
indirect staining method. Biological variation or assay variation may also have
contributed to the variability seen at the lOOng/ml dose. Ultimately, the good
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reproducibility of TF induction within subjects and between subjects at the 1 Opg/'ml
dose of LPS after 2 hours suggests that these conditions provide a good model for
LPS induced TF antigen induction for use in subsequent experiments. Moreover, the
observation that TF antigen varies little between individuals, coupled with 0sterud's
studies demonstrating that this is amplified to a 50-fold difference in TF activity
between the highest and lowest responders, suggests that targeting TF antigen
expression may be an efficient strategy for inhibiting the procoagulant effects ofTF
Finally, since subsequent studies are to be carried out in whole blood, it was necessary
to characterize the association of GEM-91 ODN with monocytes in whole blood
compared with freshly isolated PBLs. It has been shown that isolated PBLs, when
incubated with FAM-labelled GEM-91, had more associated GEM-91 than leukocytes
incubated in whole blood treated with GEM-91 (Figs 5.4a-d). At 5pM dose ofGEM-
91, the total cellular fluorescence was 15.86 ± 2.4 for cultured cells compared with
60.4 ±19 for cells from whole blood incubations, a 4 fold difference. However, as in
isolated cells, there was a similar heterogenous association of GEM-91 between
different PBL subtypes, with monocytes having the greatest association, followed by
neutrophils and finally lymphocytes. At GEM-91 concentrations of 0.1 and l.OpM,
ODN association was 10 fold less in whole blood than in isolated cells after a 4 hour
incubation (GMF 12.3 ± 0.2 vs 131.33 ± 36.74 and 41.9 ± 1.3 vs 407.9 ± 68.8 n=4.
At the highest GEM-91 dose tested (5pM), monocytes from whole blood incubations
had 3.5 fold less associated ODN than isolated moncytes, (GMF=140.4 ± 11.8 vs
502.1 ± 86.2). In chapter 3, it was shown that in the presence ofODN, PBL subtypes
bound and internalized GEM-91 over a period of 4 hours. Due to financial
constraints it was not possible to measure intra- and extra-celluiar uptake kinetics of
the ODN again in whole blood. However, from the results of chapter 3, it can be
assumed that any associated GEM-91 could feasibly be internalized. There are a
number of possible reasons why cells isolated from whole blood incubated with GEM-
91 may take up less ODN than cultured cells. Oligonucleotides may complex with
plasma proteins in whole blood making less available to receptors on the cell surface.
However, it has been documented that cationic lipids are not required for some
ASODNs to have effect in vivo whilst in cultured cells the same ODNs require
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liposomes to facilitate their effects (Bennett et al, 1992; Dean et al., 1994; Stepkowski
et al, 1994). Therefore, it might be speculated that cultured cells, such as adherent
monocytes can be artifactually activated by culture conditions and so may take up
more ODN by the process of phagocytosis, resulting in intracellularly unavailable
ODN. In contrast, monocytes in whole blood may take up less ODN but by the active
process of receptor mediated endocytosis which may result in more bioactive ODN
being available to its target. It is not known how much ODN is required for an
antisense effect, but it is probable that even though whole blood monocytes take up
less than their cultured counterparts, they may still possess enough intracellularly
available ODN to have an antisense effect. Although anticoagulated, ex vivo whole
blood is a far from perfect physiological model, it represents a much more realistic
environment in which to study monocyte TF induction and its regulation, in so far as
it has a full complement of PBL subtypes, red blood cells, platelets and plasma
proteins all ofwhich are involved in LPS induced TF expression and ODN uptake into
cells.
In summary, this study has fully characterized the ex vivo whole blood model with
respect to LPS induced TF antigen expression. It has been confirmed that this model
ofTF induction by LPS provides a suitably physiological system in which to study the
antisense inhibition ofmonocyte TF by flow cytometry.
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Inhibition of Tissue Factor Induction on Monocytes by




The modification of the expression of specific mammalian genes for the purposes of
creating novel therapies with fewer side effects has long been an aim of the medical
profession. Over the past ten years advances have been made in gene targeting
strategies based on the technique of homologous recombination. This technique has
enabled genes to be altered on a routine basis producing cell lines and transgenic
organisms with defined genotypes, (Capecchi et al., 1989). Nevertheless, its general
application is considerably constrained by the fact that it requires the transfection of
large DNA constructs and so it is inefficient, expensive and restricted to a small
number of cell types. Moreover, the practicalities of applying genetic manipulation
techniques to gene therapy has been restricted by its low efficiency in that there is
generally less than one modified cell in every 100 000 treated cells (Vasquez and
Wilson, 1998). Parallel advancements in ODN technology offers several alternatives
for modifying gene expression. ODNs which bind specifically to DNA (antigene
ODNs) to RNA (antisense and ribozyme ODNs) and to proteins (aptamer ODNs)
have been developed (Hanania et al., 1995; Stull et al., 1995). Antigene strategies
focus primarily on gene targeting by homologous recombination or by triple helix
forming oligodeoxynucleotides (TFOs). TFOs hybridize in the major groove of DNA
by Hoogsteen or reverse Hoogsteen bonding and can disturb gene function by
preventing the binding of transcription factors (Maher et al., 1989; Helene, 1991a), by
inhibiting duplex unwinding (Helene et al., 1991b) or by inducing mutations in the
target gene (Wang et al., 1995; Ratajczak et al., 1992). This non-vector based
approach to manipulating gene function does not appear to be cell type specific but it
is constrained by the need for polypurine/polypyrimidine target sequences (Gewirtz et
al., 1996). Antisense and ribozyme ODNs can be used to direct the destruction of
specific RNAs or to prevent their translation (see later). Aptamer ODNs can be used
to interfere with or selectively stimulate the functions of particular proteins.
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ODNs are attractive molecules for therapeutic purposes because they can be easily
synthesized in large quantities by automated procedures. Furthermore, antisense
design does not require detailed knowledge of the structure of the target protein only
of the target mRNA. both in terms of sequence and secondary structure. Finally
ODNs can be designed to incorporate modified bases, backbone components and
reactive chemical species to confer stability, increase binding or improve functionality
such as in the case of phosphorothioate development (see chapter 3 for full discussion
of ODN modifications). As mentioned in chapter three, many methods of delivering
ASODNs to cells have been investigated including techniques whereby the ODN itself
is modified, as in receptor ligand conjugation (Stephens and Rivers, 1997), or the
target cells are treated to facilitate entry as in cell permeablization by electroporation
(Bergan et al., 1996; Flanagan et al., 1997) or chemically by streptolysin (Giles et al.,
1995a; Bergan et al., 1996; Flanagan et al., 1997). Antisense technology is well
advanced in its development as a genetic medicine with several antisense agents
already in clinical trial, and will be discussed in more detail below.
6.1.2 Mechanisms of Action of ASODNs
There are multiple antisense mechanisms by which ASODNs may regulate the
expression of target genes. The mechanism of action is dependent upon the design of
the ASODN. Oligonucleotides designed to bind the pre-mRNA across the boundary
between exons and introns (splice sites) may inhibit the splicing region. Kole et a/.,
1996 have demonstrated that uniformly modified 2'-0-methyl phosphorothioate
ODNs (ODNs with a modified sugar group), can alter the splicing of a thalassemic (3-
globin mRNA in mammalian cells. The ODN was used to mask a splice site so that an
alternative site was used. Similarly, Hodges and Crooke 1995, have reported that 2'-
O-methyl-phosphorothioate ODNs are capable of selectively blocking splicing of an
adenovirus transcript. Alternatively, binding of ODNs to the target mRNA may
inhibit gene expression through simple steric hindrance. The RNA-DNA duplex may
simply block the RNA from physically interacting with cellular components required
for translation of RNA into protein. For example, ODNs designed to bind the
126
Chapter 6
translation initiation codon may compete with the ribosome for the site and thus
inhibit translation. Several studies have demonstrated that ODNs are capable of
inhibiting translation in this way in in vitro translation assays including experiments by
Ochoa et al., in 1961. However, it has proved more difficult to prove this mechanism
in cell based assays. Alternatively, ODNs targeted to coding sequences downstream
of the initiation codon may inhibit the assembly and translocation of the ribosomes
along the mRNA. Baker et al., 1997 utilised uniformly 2' modified ODNs which do
not support RNase H activity (see later), to target the 5' terminus of ICAM-1 mRNA.
These ODNs very effectively inhibited ICAM-1 protein expression by markedly
changing the polysome profile of ICAM-1 mRNA shifting it from a higher molecular
weight polysome pool to a lower molecular weight pool. Another mechanism of
action ofASODNs is mediated by cleavage of the targeted mRNA by the endogenous
ribonuclease RNase H. This enzyme is an endogenous ribonuclease which is located
in the nucleus and in the cytoplasm and cleaves only hybridised mRNA/ODN
duplexes. There is a large body of evidence suggesting that reduction or cleavage of
the targeted mRNA is mediated by RNase H. This includes demonstration of a direct
reduction in mRNA (Stewart et al., 1996; Condon et al., 1996), detection of
appropriate cleavage products (Giles et al., 1995b), and use of modified ODNs that
do not support RNase H activity (Chiang et al., 1991; Monia et al., 1993).
6.1.3 Naked ASODNs versus Modified ASODNs
Many studies have been carried out both in vitro, in animal models and in clinical
trials demonstrating the effects ofASODNs on disease. There is some controversy as
to the best way of delivering ASODN to their target and these have been discussed
already. They include encapsulation of the ASODN in liposomes or conjugation of
the ASODN with cationic lipid to facilitate its entry into cells. This is thought to
increase uptake of ASODNs and improve intracellular bioavailability. However,
bearing in mind the cytotoxicity of cationic lipids, they are of little use in an in vivo
setting. A study by Nestle et al., 1994, has shown that cationic lipid is not required
for uptake and inhibitory activity of ICAM-1 phosphorothioate ASODNs in
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keratinocytes. Antisense phosphorothioate ODNs designed to hybridize to various
regions of the ICAM-1 mRNA selectively influenced cultured keratinocyte ICAM-1
expression in response to gamma interferon (INF-y). It was shown that keratinocytes
rapidly internalized antisense compounds within 30-60 minutes with approximately
30% of the cells possessing positive nuclei. Using flow cytometry, they also
demonstrated that IFN-y induced ICAM-1 expression was reduced by 50% by the
ASODN. Studies by Hartmann et al., 1996, have demonstrated that a
phosphorothioate ODN complexed with cationic lipid , designed to hybridise
specifically to the translation start site of TNF mRNA at a concentration of 2p.M
inhibited TNF induction by LPS in freshly isolated monocytes by up to 79% compared
with control ODNs. However, this group specify that certain steps in their
experimental protocol were crucial for efficient inhibition of TNF by ASODNs
including the serum-free incubation of ASODN and cationic lipid to prevent
interaction between ASODN and serum proteins which can lower the ratio of
available ODN (Srinivasan et al., 1995). This suggests that the use of cationic lipid in
vivo may not have the same effects as in a cell culture setting. Monia et al., 1996
have demonstrated inhibition of tumour growth in a xenograft model by an antisense
phosphorothioate ODN targeted to c-raf-1. A phosphorothioate ASODN targeted to
specifically inhibit c-raf-1 kinase produced dose dependent inhibition of tumour
growth over a range of concentrations (0.06-6mg/kg/day) for 21 days compared with
mismatched ODNs (ODNs with a scrambled antisense sequence). Interestingly,
cationic liposomes were required for the ASODN to have effects in cell culture
studies but not in the in vivo experiments. This observation is consistent with other
reports demonstrating that, although ODN transfection methods are required in vitro,
these procedures are not required to elicit antisense effects in vivo (Bennett et al,
1992; Dean et al., 1994; Stepkowski et al., 1994). In addition, Pawlowska et al.
1998, have investigated the ability of a naked 16mer antisense phosphorothioate
modified ODN to PAI-1 to increase fibrinolysis and modify experimental thrombosis
in rats. They have shown that intravenous infusion of the ASODN (l-5mg/rat)
produced a significant time and concentration dependent reduction in PAI-1 activity
of blood plasma compared with control ODNs. This 20-30% inhibition was enough
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to cause a profound delay in arterial occlusion time in rats treated with the ODN.
This study also strongly suggests that cell permeation barriers in vitro may not be a
problem in vivo.
6.L4 Chloroquine
Although there have been reports demonstrating that naked phosphorothioate ODNs
can enter peripheral blood leukocytes (Hartmann et al., 1998, Pirruccello et al.,
1994), and experiments have been carried out showing that this uptake is, at least in
part receptor mediated endocytosis (Beltinger et al., 1995, Benimetskya et al., 1997),
controversy exists as to the fate of ODNs once inside the cell. It is thought that
ODNs exert their effects either in the cytoplasm or in the nucleus. Although reports
by Beltinger et al., 1995 have detected phosphorothioate ODNs in both the cytoplasm
and nucleus they have also detected a high concentration of ODN in cytoplasmic
vesicles. How ODNs escape these vesicles and how rapidly this escape occurs is as
yet unclear. Chloroquine (CQ) is a widely used anti-malarial drug. It is a
lysosomatropic agent having its effect by accumulating in acidic food vacuoles and
lysosomes within malarial parasites with subsequent disruption of vacuole functions.
This is accomplished by raising the pH beyond the optimum required for parasite food
digestion. The acidic food vacuole in the malarial parasite has been likened to the
acidic phagolysosomes within mammalian cells (Ohkuma and Poole, 1978). It has
been shown that CQ causes swelling of lysosomes in the malarial parasite P.
falciparum (Yayon et al., 1984), similar to the effect seen in mammalian lysosomes
(Poole and Ohkuma 1981). Consequently, chloroquine has been shown to exert
similar effects in leukocytes as in the malarial parasite. It can enter cells and
accumulate in acid vesicles to a concentration estimated at 50nM as calculated on the
estimated volume of the vesicular compartments (Erbacher et al., 1996). Chloroquine
is known to interfere with the endocytosis process and causes a number of effects that
may influence the intracellular fate of ASODNs. Through its accumulation, it induces
the neutralization and swelling of acidic vesicles leading to membrane destabilization.
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In addition, by raising the pH of the lysosomes, it inhibits degradative enzymes which
require an acidic environment (Ohkuma and Poole, 1978; Poole and Ohkuma, 1981;
Maxfield 1982) and it inhibits vesicular transport thus reducing ligand delivery to the
lysosomes (Strous et al., 1985; Hedin and Thyberg, 1985; Stenseth and Thyberg,
1989). Chloroquine is also able to complex with DNA (Parker and Irvin, 1952). In
the light of these properties, it is possible to envisage several mechanisms by which
chloroquine could increase the efficacy of ASODNs. It could extend the effective
intracellular half-life of the ODN by avoiding the lysosomal degradation pathway and
reducing excretion or destabilize the endocytic compartments allowing more ODN to
escape. Erbacher et al., 1996 have demonstrated that addition of lOOpM CQ for 3 or
4 hours increased the transfection efficiency of a human hepatoma cell line (HepG2
cells) by a plasmid DNA/lactosylated polvlysine complex by neutralization and
vacuolization of the endosomal and lysosomal vesicles. In addition, Stewart et al.,
have demonstrated in a lung carcinoma cell line (A549 cells) that the inhibition of
ICAM-1 expression by a phosphorothioate ASODN complexed with fucose
conjugated poly-L-lysine was only observed in the presence of lOOpM chloroquine.
Therefore, we have examined the possibility of using CQ as a less cytotoxic way of
improving ASODN action in human monocytes.
6.1.5 Inhibition ofMonocyte TF Induction by ASODNs
To date, only one other group has investigated the use ofASODNs in the modulation
of TF expression. Stephens and Rivers, 1997, have used the published DNA
sequence of TF (Scarpati et al., 1987) as a template to design a thirty base
phosphorothioate ODN containing the rare tripeptide motif, Trp-Lys-Ser, which has
been predicted as a functional motif involved in the interaction with serine proteases.
They used CD 14 receptor mediated endocytosis as a means of delivering the TF
antisense ODN specifically to monocytes. They concluded that co-treatment of
isolated monocytes with the antisense TF molecule and LPS resulted in an 80%
suppression of TF activity compared with a control ODN. To our knowledge, there
have been no reports testing ASODN effects on peripheral blood leukocytes in ex vivo
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blood models. Furthermore, it is thought that phosphorothioate ASODNs may be
more efficacious in an ex vivo whole blood setting compared with isolated monocytes
in culture.
I have established a whole blood model to examine the induction of TF on monocytes,
and using this model have investigated the effect of several ODNs on the LPS induced
TF expression on monocytes in whole blood. I have tested the effect of Stephens and
Rivers' ODN as well as a truncated version and a mismatched version of it on LPS
induced TF in our system. In addition to the Stephens and Rivers ODN, I have
designed an ASODN targeted to hybridize around the start site of translation of the
TF mRNA and have tested this in my system when compared to the effects of GEM-
91. an ODN which does not bind to the TF mRNA. Bearing in mind the apparent
receptor mediated endocytosis mechanism ofODN uptake into cells, the effect of CQ
on the efficacy ofASODNs to TF has also been examined.
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6.2 Materials and Methods
6.2.1 Whole Blood Collection
Whole blood was collected from healthy volunteers by clean venepuncture with a 21
gauge needle into sterile vacutainers (Sarstedt, Germany) containing 3.2% trisodium
citrate anticoagulant.
6.2.2 Effect of Antisense ODNs on TF Induction in Monocytes
Antisense Sequence Description
ODN
AS1 AAAGCATTTGCTTTTCCAATCTCCTGACTT ODN used by Stephens and
Rivers (1997).
AS2 TTTGCTTTTCCAATCTCC Truncated version of AS1
AS3 TGTTTTAACCATACCTCATTGGATCACTCT Mismatched version of AS 1
ASJM GGGCCAGGCAGGGGTCTCCATGTCTACCAG In-house designed ODN
(hybridises at start-site of
translation of TF mRNA).
ASGEM91 CTCTCGCACCCATCTCTCTCCTTCT Control ODN not designed to
hybridise to TF mRNA
TABLE 6.1. Antisense ODNs Tested
Aliquots (500pl) of citrated whole blood were placed into sterile polypropylene tubes
and incubated directly with one of the above ODNs (1, 5 or 20pM final concentration
as noted in a volume of lOpl) or lOpl sterile distilled water as a control, for 4 hours at
37°C at 95% air 5% C02. After 4 hours, 5pl LPS from E. coli 0111:B4 (Sigma
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Chemical Co.), final concentration lOpg/ml or 5 ja.1 distilled water control, was added
for 2 hours to induce TF expression. In control experiments, each of the antisense
ODNs at each of the concentrations was added to whole blood and incubated for 4
hours to determine the effect of the ODNs alone on peripheral blood monocyte TF
expression.
6.2.3 Effect of Chloroquine on Antisense Inhibition of LPS Induced TF on
Monocytes
To examine the effect of the lysosomatropic agent chloroquine on the inhibition of TF
induction by ASODNs, lOpM chloroquine (Sigma Chemical Co.) made up in culture
medium, was added to whole blood aliquots in one of two regimes:
1. Chloroquine was added to a final concentration of lOpM concomitantly with the
antisense ODNs for 4 hours before LPS addition.
2. Chloroquine was added to a final concentration of lOpM after the first 3 hours of
antisense incubation, for 1 hour before LPS addition (Regime 2).
6.2.4 Immunostaining of Peripheral Blood Mononuclear Cells for TF Antigen in
Preparation for FACS Analysis
After treatment, lOOpl of whole blood was indirectly immunostained as described in
chapter 2. 33 pi of anti-tissue factor monoclonal antibody cocktail (30pg/ml stock
solution) (kindly donated by Prof. T.E.Edgington, Scripps Research Institute, La
Jolla, USA) in 67pl PBS was the primary antibody used. Whole blood lOOpl aliquots
were also added to tubes containing the same concentration of a negative control
antibody (from an SV40 large T antigen not expected to bind to TF) supplied along
with the anti-tissue factor monoclonal, or a phycoerythrin conjugated anti-CD 14




Flow cytometry was performed using a FACScan (Becton Dickinson, Oxfordshire)
running Cell Quest analysis software (Becton Dickinson). The monocyte population
was identified by its forward and side scatter characteristics and routinely contained
95% CD 14 positive cells. A total of 50000 cells was routinely collected which
yielded approximately 2500 monocytes per lOOpl blood sample. Monocyte cell
surface TF was detected in the FL2 orange channel which detects the fluorescence
emitted by phycoerythrin.
6.2.6 Data Analysis
Monocytes were gated as before by virtue of their forward and side scatter
characteristics, and were typically 95% CD14 positive. The positive delineator (Ml)
was set as described in chapter 2 to include 3% of the cells stained with isotype
control. All cells falling within this gate were subsequently deemed to be negative for
TF. In addition, having examined the TF profile of cells treated with LPS two other
markers were set: M2 was set to include cells with an intermediate fluorescence and
M3 was set to include cells with a high fluorescence. This was necessary because
some individuals had TF positive monocyte populations which expressed unusually
high induced TF levels (See Fig. 6.1).
The percentage of the total monocytes which fell inside each of these markers was
recorded for each sample. The Ml, M2, M3 profile of the sample treated with the
stimulatory LPS dose of 10p.g/ml was used as a reference, and the percentage of cells
within the corresponding markers in each test sample treated with ASODN was
expressed as a percentage change over the reference sample (See Fig 6.1 for a
worked example).
It is important to note that, as yet, it is not known whether an increase the number of
TF positive monocytes, or an increase in the amount of TF antigen on each monocyte
is a better measure of thrombogenicity. However, Amirkosravi et al., 1997 have
shown that the percentage of TF positive monocytes as measured by flow cytomtery,
is proportional to the monocyte procoagulant activity as measured by a functional
134
Chapter 6
clotting assay. For the purpose of this study, the percentage ofmonocytes expressing
TF was investigated and the ability of ASODNs to decrease the percentage TF
positive monocytes in each of three defined categories of TF positivity.
6.2.7 Statistical Analyses
Except in the case of the TF inductions by ASODNs (where the TF levels were not
high enough to have an M3 component), statistical analyses were performed on the
M3 data, although data is graphically displayed on all three markers. This was as
suggested by K. Peny of the University ofEdinburgh Medical Statistics Department.
All paired data was analysed by repeated measures analysis of variance followed by
the Dunett's post test, where each data set is compared with one control data set, in
this case the 10p.g/ml treated sample. Where data could not be paired due to different
sample sizes, a one way analysis of variance was carried out followed by a Dunett's
post test. Although the data is represented graphically as percentage change over
control, all statistics were carried out on raw data.
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6.3.1 Ml, M2, M3 Profile of TF-Induction on Monocytes
Subject %M1 %M2 %M3
1 15.37 31.07 54.07
2 18.45 60.21 22.89
3 31.31 34.38 31.39
4 24.73 64.83 10.97
5 15.33 66.07 18.77
6 12.38 46.42 42.79
7 20.33 70.17 10.67
8 19.1 70.64 10.26
Mean 19.6 55.5 25.2
Table 6.2 TF Positive (Ml, M2, M3) Profile ofMonocytes Treated with lOpg/ml LPS for 4h
(n=8). Numbers represent the % positive cells within each of the three markers. It can be
seen that certain individuals have a higher proportion ofmonocytes in M3 underlining the need
for three marker analysis.
6.3.1 Effect of ASODNs alone on Peripheral Blood Monocytes
Three of the ASODNs tested actually induced TF on monocytes in whole blood.
AS1, the Stephens and Rivers oligo, AS2 its truncated version and AS3 its
mismatched version at final concentrations of 1 and 5pM all produced significant
increases in the percentage of monocytes falling into the M2 marker when compared
with antisense untreated cells (4.44 ± 0.85 % vs 60 ± 7.152 % for lpM and 59 ±
3.52 % for 5pM AS1; 22.8 ± 4.9 % for lpM and 45 ± 4.9 % for 5pM AS2, and
finally, 76.42 ± 2.13 % for lpM and 71.9 ± 6.63 % for 5 pM AS3. ASJM and




ASODN % Monocytes in M2 n p value
OAS 4.4 + 0.85 8
1 (J.M AS 1 60 + 7.12 6 <0.01
5|+M AS1 59 + 3.52 6 <0.01
IpM AS2 22.8 + 4.9 6 <0.01
5|jM AS2 45.4 + 4.9 6 <0.01
1 !iM AS3 76.42 + 2.13 4 <0.01
5(j,M AS3 71.9 + 6.63 4 <0.01
1 (J.M ASJM 2.9 + 0.72 8 NS
5(j.M ASJM 5.1 ± 1.2 8 NS
20pM ASJM 5.4+1.3 8 NS
lpM ASGEM 4.2 + 2 8 NS
5pM ASGEM 7.62 + 1.41 8 NS
20uM ASGEM 5 ± 1.23 8 NS
TABLE 6.3. TF Induction By ASODNs
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6.3.2 Effect of AS1, AS2, AS3 on LPS Induced TF Expression on Peripheral
Blood Monocytes
AS1, the ASODN to TF designed by Stephens and Rivers significantly inhibited the
TF induction by LPS. The mean percentage change in TF positive monocytes treated
with lpM AS1 falling within the M3 marker was 42.2 ± 9.544 % inhibition (p < 0.01)
(Fig. 6.3) with respect to cells treated with LPS alone. Neither the truncated version
nor the mismatched version caused a significant inhibition in the cells falling in M3.
6.3.3 Effect of ASJM and AS GEM-91 on LPS Induced TF Expression on
Peripheral Blood Monocytes
ASJM, the in -house designed ASODN to TF designed to hybridise around the start
site of translation of the TF mRNA at neither lpM, 5pM or 20pM significantly
inhibited the TF induction by LPS. The percentage of monocytes falling in the M3
marker did not significantly change when the blood was pre-treated with this ASODN
compared with that pre-treated with distilled water (Fig 6 4)
6.3.4 Effect of Chloroquine Alone on TF Induction
Chloroquine alone did not significantly induce TF at either a 80|jM or 10p.M dose
when compared with LPS induction of TF. However, at 80pM final concentration,
chloroquine alone inhibited TF induction by approximately 70% after a 2h co-
incubation with LPS, and 60% after a 4h co-incubation with LPS (53.4 ± 5.5% TF
positive monocytes vs 15.37 ± 4.04 % after 2h co-incubation, 62.03 ± 6.06% TF
positive monocytes vs 23.58 ± 2.35 % after a 4h incubation). However, at a final
concentration of 10pM which is more in the range therapeutically tolerated by malaria
patients, chloroquine alone did not significantly inhibit LPS induced TF after a 4h co-
incubation with LPS (62.03 ± 4.91 % positive monocytes treated with LPS vs 65.28
±4.91 % positive treated with LPS+lOpM chloroquine. It was, therefore, decided
that a 10pM dose of chloroquine could be used in conjunction with the ASODN panel
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6.3.5 Effect of Chloroquine on AS1, AS2, AS3 Modulation of LPS Induced TF
Expression
It was postulated that the lysosomatropic agent chloroquine, at a concentration of
lOpM might increase the intracellular bioavailability of the ASODN by bursting
cytoplasmic endosomes thus releasing more ASODN into the cytoplasmic
compartment. On examining the percentage change in the proportion of monocytes
falling inside the M3 marker, it appears that addition of chloroquine at a final
concentration of 1 OpM significantly improved the inhibitory effects of AS 1 and AS2,
(ASODNs to TF) but not AS3 (mismatched version of AS1). Pre-incubation of blood
with 1 or 5 p.M AS1, or 1 or 5pM AS2 with lOpM chloroquine added simultaneously
for 4h produced significant mean % changes in the proportion of cells falling into M3;
45.5 ± 6.7 %, 42.5 ± 14.3, 32 ± 8.9 %, 43.1 ± 9.4 % inhibitions respectively when
compared with samples treated with LPS alone (n=6; p < 0.01). Chloroquine did not
significantly improve the inhibitory effect of the mismatched control AS3.
ASODN Mean % P Mean%Inhibition P n
Inhibition M3
M3 +CQ
lpM AS1 42.2 ±9.5 <0.01 45.5 ±6.7 <0.01 6
5pM AS1 -3.65 ±25.6 ns 42.5 ± 14.3 <0.01 6
I nM AS2 10.5 ± 12.7 ns 32.0 ±8.9 <0.01 6
5pM AS2 21.9 ± 11.5 ns 43.1 ±9.4 <0.01 6
lpM AS3 17.3 ±4.7 ns 28.0 ±7.18 ns 6
5M.M AS3 11.3 ± 11.7 ns 23.0 ±6.81 ns 6
TABLE 6.4 Inhibition ofMonocyte TF by AS1, AS2 and AS3 with and without the addition of CQ.
Raw data were analysed by a repeated measures analysis of variance followed by a Dunnett's post
test, where each group was compared with a control, in this case the lOag/ml LPS treated group
Negative values represent an induction rather than a inhibition.
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6.3.7 Effects of Chloroquine Administered in a Different Regime on ASJM and
ASGEM-91 inhibition of TF induction
It was postulated that the effects of chloroquine may be more pronounced on the
blood treated with ASJM if it was administered in a different regime. Blood was pre-
incubated with ASODN for 4 hours and chloroquine was added for the last hour of
the pre-incubation. This regime did not significantly improve the performance of the
ASODNs with only the lpM dose producing a significant inhibition; 41 ± 9%
inhibition with respect to samples not treated with ASODNs.
ASODN Mean % P Mean%Inhibition P Mcan%Inhibition P n
Inhibition M3 M3 +CQ
M3 +CQ Reg2
IpM ASJM 12.5+6.9 ns 37.0 ±7.7 <0.05 41.9 ± 9.01 <0.01 8
5pM ASJM -5.5 ±5.55 ns 13.9 ± 12.4 ns 21.5 ± 11.64 ns 8
20pM ASJM -1.36 ± 6.64 ns 30.9 ± 12.1 <0.05 32.0 ± 17.65 ns 8
lpM GEM-91 -0.51 ±2.9 ns 22.9 ±6.1 ns -7.24 ± 27.87 ns 5
5pM GEM-91 -13.32 ±4.27 ns 10.9 ± 7.8 ns 10.6 ±20.54 ns 5
20pM GEM-91 -15.55 ±2.99 ns 1.75 ±4.75 ns -4.92 ± 11.92 ns 5
TABLE 6.5 Inhibition of Monocyte TF by ASJM. GEM-91 with and without the addition of CQ
under Regime land Regime 2. Meaned data were analysed by a one-way analysis of variance
followed by a Dunnett's post test, where each group was compared with a control, in this case the
lOpg/ml LPS treated group. Negative values represent an induction rather than a inhibition.
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6.4 Discussion
It has been determined so far in this study that the monocyte appears to be a suitable
target cell for antisense therapy in so far as it internalizes ODNs more efficiently than
the other PBL subtypes. Bearing in mind that monocytes are the only PBLs capable
of expressing TF, the experiments outlined in the chapter set about investigating the
potential ofASODNs to TF at inhibiting the LPS-induced expression of this protein in
a whole blood model. Initially, an ASODN directed to the start site of translation of
the TF mRNA was designed. However, during the course ofmy preliminary studies,
Stephens and Rivers, 1996 reported the inhibition of TF activity (but not antigen),
using an ASODN to TF designed by them. Subsequently, their ODN was included in
the current studies as a comparison to the in-house designed ASODN to TF.
6.4.1 Induction of TF by ASODNs
Initially, the effect of an incubation with each of the ASODNs alone on whole blood
was investigated. It was shown that AS1, the ASODN to TF designed by Stephens
and Rivers, AS2, its truncated version and AS3 its mismatched version, all
significantly induced TF antigen on monocytes in whole blood after a 4 hour
incubation as measured by flow cytometry. AS1, and AS3 its mismatched version,
induced the most TF, the percentage ofmonocytes falling in the M2 marker was 60 +
7.12% and 59 ± 3.52% with lpM, and 5pM AS1 respectively and 76.42 ± 2.13 and
71.9 ± 6.63% with lpM and 5p,M AS3 respectively (P<0.01) when compared with
4.4 ± 0.85% for AS untreated blood. The truncated ODN, AS2, was less potent, with
22.8 ± 4.9 and 45.4 ± 4.9% monocytes falling in the M2 marker with luM and 5uM
AS2 respectively. In contrast, neither ASJM, the in-house designed ASODN, nor
GEM-91 significantly induced TF antigen on monocytes (Fig 6.2., Table 6.2) It
appears, therefore, that the TF inducing effect of the ODNs is not particular to
phosphorothioates; as is the case for other non-specific cardiovascular effects seen in
ex vivo whole blood (Shaw et al., 1997). This group have shown that
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phosphorothioates cause a decrease in partial thromboplastin time that is not sequence
specific, but rather is specific to the phosphorothioate linkage. The TF induction by
phosphorothioates seen in the current study may, however, be due to a combination
ofODN sequence and length effects. Although AS2 (18mer) the truncated version of
ASl(30mer), was less potent at inducing TF than AS1, the two longer ODNs ASJM
(30mer) and GEM-91(25mer), did not significantly induce TF. However, AS2, ASJM
and GEM-91 have in common that they contain fewer adenosines than AS1 and A3.
This observation suggests that the presence of adenosine may predispose the ODN to
TF induction. This could feasibly occur by interaction of the ODN with the LPS
receptor CD 14, setting into motion intracellular signals culminating in transcription of
the TF gene. It has been shown by Fan et al., 1991, that ligands of the Mac-1
receptor are capable of enhancing 2 to 8 fold the expression of TF. They have
postulated that engagement of Mac-1 by complementary iigands results in
transduction of cellular signals that enhance the expression of TF expression on
monocytes. As discussed in chapter 4, Benimetska et al., 1996 have shown that Mac-
1 is a cell surface receptor for ODNs. It might be speculated that binding of certain
ODNs to Mac-1 might induce intracellular signalling events to enhance any basal TF
expression occurring as a result of incubation conditions.
6.4.2 Inhibition Studies
The potential of 5 ASODNs at inhibiting LPS induced TF antigen expression on
monocytes in whole blood was then investigated. It was shown that incubation of
whole blood with AS1 at a concentration of lp.M significantly inhibited the TF
induction of TF by LPS producing a 42.2% reduction in the number of cells strongly
positive for TF, ie those cells falling in the M3 marker (Fig 6.3) (p<0.01, n=6) when
compared with the truncated version, and the mismatched version of the ODN.
Neither ASJM nor GEM-91 produced a significant inhibition in TF induction by LPS
(Fig 6.4). Stephens and Rivers have investigated the effect of AS1 as well as a
mismatched, a sense and an irrelevant control ODN, all of which were linked to a
CD 14 monoclonal antibody conjugated with poly-L-lysine carrier complex, on TF
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activity in freshly isolated, lysed monocytes. They concluded that co-incubation of
the ASODN to TF, but not the control ODNs, with LPS resulted in a marked
suppression of TF biological activity by 80.4 ± 2.2% when compared to monocytes
treated with LPS in the absence of TF ASODN. They also conclude that the CD 14-
poly - L-lysine carrier system is required for the ODN to have its effect. In the
current study, I have shown a significant inhibition of TF antigen by a naked version
of Stephens and Rivers ASODN (AS1), at the IpM dose, but not at the 5uM dose.
This may be due to the fact that the ASODN is already at its maximal dose at IpM
and any further increase in the dose ofODN may cause increased TF induction by the
ODN to interfere with the inhibition. In their study, Stephens and Rivers do not
attempt to measure TF antigen, and so it is not certain whether the ASODN is
reducing TF activity by actually decreasing translation of the protein. I have
attempted to improve the efficacy of the ODNs tested by incubating them in
conjunction with the lysosomatropic anti-malarial agent chloroquine. Chloroquine has
been shown to improve intracellular bioavailability of ODNs (Loke et al., 1989)
possibly by inhibition of intracellular recycling of ODNs or by releasing ODN from
intracellular acid vesicles. At a lOpM dose CQ did not on its own inhibit TF
induction and so this dose was chosen for co-incubation experiments (Fig 6.5). It has
been shown that co-incubation of lOpM CQ with 1 or 5 pM AS1 or AS2 for 4 hours
before LPS stimulation, caused a significant inhibition in TF antigen induction.
Incubation with 1 and 5pM AS1 produced a 45.5 ± 6.7% and 42.5 ± 14.3% inhibition
in the percentage of monocytes falling in the M3 marker compared with samples
treated with LPS alone Similarly, co-incubation of whole blood with 1 and 5pM
AS2, the truncated ODN, resulted in a 32 ± 8.9 and 43.1 ± 9.4% reduction in the
percentage of monocytes strongly positive for TF. Pre-incubation with the control
mismatched ODN AS3 did not result in an inhibition which reached significance
(Fig.6.6, Table 6.3). However, it was evident that in some individuals this control
ASODN did cause some inhibition of TF antigen induction, especially in the presence
of CQ. This suggests that the effects seen with these ODNs are not purely antisense
effects but are enhanced by non-specific interactions.
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The in-house designed ODN ASJM, which was designed to hybridize around the start
site of translation of the TF mRNA gave less promising results in the absence of CQ
than AS1. Without the addition ofCQ, no significant inhibition of TF was seen any of
the three doses tested. It was clear that some individuals did respond, but the
inhibitions seen were not reproducible and so did not reach significance. In the
presence of CQ, the effect of ASJM was improved, resulting in a significant reduction
in the percentage of strongly TF positive monocytes (Fig 6.7, Table 6.5). It was
thought that the CQ might further improve the inhibitory effects of the ODNs if
administered in a different regime. When CQ was added to the whole blood for the
final hour of ODN pre-incubation only, there was a slight improvement in ASJM
effect at the lpM dose, resulting in a 41 ± 9% inhibition in TF (Fig 6.8, Table 6.6).
This improvement was not seen at the higher doses. In addition, GEM-91 which was
used as a control ODN in this part of the study did not elicit any significant inhibition
of TF. It is, therefore clear that CQ does help the efficiency of ODN action. The
mechanism for this cannot be determined from this study but is likely to be a result of
CQ bursting intracellular vesicles, thus releasing any sequestered ODN. As CQ is
already used therapeutically as an antimalarial agent at doses around 10pM, this study
suggests that it might be feasible to administer CQ with ASODNs as less toxic
alternative to cationic lipids for increasing intracellular bioavailability.
The most important observation in this study is that although each of the ODNs tested
significantly inhibited TF antigen induction under certain circumstances, there was
never a total inhibition by any of the ODNs and the inhibitions seen were not dose
dependent. There are a number of possible reasons why the efficacy of the ODNs was
so erratic. It is possible that the ODNs were not consistently reaching their
intracellular targets. It has been documented that ODNs taken up by receptor
mediated endocytosis often become sequestered in intracellular acid vesicles (Loke et
al., 1989; Bennett et a/., 1992) meaning that although they find their way into the cell,
they do not reach their target mRNA. Although we have shown that CQ improves
the efficiency of ASODNs in some individuals and at certain ASODN doses, it does
not consistently do so. Secondly, it is possible that the ASODN is reaching the
proximity of the mRNA to be inhibited, but that the precise target site is inaccessible.
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The internal structures of target mRNAs and their associations with cellular proteins
create physical barriers, which render most potential binding sites inaccessible to
ASODNs. For Watson-Crick binding to occur, nucleic acid drugs must be
complementary to exposed regions of their target mRNA. In the current study the
start site of translation of the TF mRNA has been targeted which theoretically should
be accessible for ODN binding. However, other sequences in the mRNA may be
better ODN binding regions and so mRNA targeting is essentially a hit or miss
process. Currently, effective nucleic acid drugs are being selected from large pools of
candidate sequences. Although the microarray technique used by large drug
companies, whereby multiple sequences are screened to find the best match for an
antisense molecule, improves the binding efficiency of ASODNs, the ability to
determine which regions of a given mRNA molecule are accessible has been a
significant impediment to the design of effective ASODNs. Recently, Peng Ho et
al., 1998 have described an RNA mapping technique to identify accessible sites on
mRNA molecules, whereby the RNA transcript of interest is probed with a library of
semi-random chimeric ODNs. Regions of the RNA accessible for hybridization with
members of the ODN library were cleaved using RNase H. Subsequent sequencing of
the newly created RNA ends using primer extension analysis identified potentially
effective sites for the targeting of antisense ODNs. The expense of techniques like
this is likely to limit them to large corporations.
In the current study, control ASODNs were used in an attempt to determine whether
the effects of the ODNs tested were true antisense effects or were due to non-specific
ODN effects. The observations described in chapter 4 show that ODNs are capable
of causing a reduction in monocyte cell surface CD 14 and Mac-1 receptors, both of
which are receptors for LPS and are involved in LPS induced stimulation of TF
expression (Ingalls and Golenbock, 1995; Fenton and Golenbock 1998). Although
neither the control ODN used in conjunction with Stephens and Rivers antisense
molecules, namely a mismatched version of the true ODN, nor the GEM-91 ODN
which was used as a control ODN in studies with the in-house designed ASJM
produced any significant inhibition ofTF it was clear that in some individuals a degree
of inhibition, albeit irreproducible, occurred (Figs 6.3-6.8). In addition, binding of the
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ODNs to the TF antigen itselfmay have inhibited antigen detection by the monoclonal
antibody, resulting in an apparent reduction in the protein. Taken along with the
apparent erratic inhibitions seen with some of the ASODNs tested, and the lack of
extensive control ODNs used it is impossible to conclude that any effects seen are true
antisense effects. Non-specific antisense effects have been well documented
throughout antisense literature and sometimes produce surprisingly therapeutic
results. Nevertheless, these non-specific effects have hampered the ability of some
groups to conclude that important therapeutic observations were due to antisense
mechanisms. This has underlined the need for exhaustive and expensive control
ODNs to be used in experiments. Inside cells it is not possible to improve specificity
by raising the temperature or changing the ionic strength, strategies which are
commonly used in vitro to minimise non-specific binding of ASODNs. One approach
to improve specificity has been to deploy multiple antisense compounds, each directed
against a different site in the same target RNA, and thereby achieve complete target
inhibition by 'triangulation'. In addition, efforts have been made to exploit the fact
that not all portions of an RNA molecule are equally exposed. For example, if a
target sequence occurs in an accessible region of the target mRNA but in a protected
region of a bystander, the target will be preferentially destroyed by RNase H. Thus
identification of antisense molecules complementary to vulnerable regions on the
target mRNA may be a way of improving specificity. However, the complexity of
RNA molecules makes this a difficult prospect.
The results of this study illustrate the great potential for TF inhibition by ASODNs.
Inhibitions of as much as 43% were seen in the presence of lp.M naked AS1, and in
the region of 30-45% in the presence of AS1, AS2 ASJM in the presence ofCQ were
observed. However, the lack of dose dependency and the fact the control ODNs also
caused a degree of inhibition suggests that these inhibitions were not entirely sequence
specific. Furthermore, the observation that some of the ODNs tested actually induced
TF, suggests that an equilibrium between TF inhibition and induction may have been
occurring, possibly explaining the lack of dose dependency. It may also have been
possible that the doses of ODN chosen were at the top of the dose response curve.
Perhaps an exploration of lower ODN doses might have yielded more promising and
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specific results. It should also be noted that during the course of this study, although
there was no evidence of an overall high responder phenomenon, a few individuals
were seen to possess a population ofmonocytes 'super positive1 for TF on stimulation
with LPS (Table 6.2). In these individuals, this population of monocytes was most
readily inhibited by ASODN. This raises the question of whether it is therapeutically
beneficial to simply reduce the number of cells expressing high TF antigen, thus
increasing the number of intermediately expressing cells. Bearing in mind that TF is
the cellular receptor for factor Vila, it could be envisaged that those cells highly
positive for TF would bind factor Vila more readily making them more thrombogenic.
To date there have been no reports indicating that monocytes having a higher TF
antigen concentration are more thrombophilic than those with more intermediate
levels. If this were the case, reduction of TF on these cells in particular by ASODNs
would be of great therapeutic benefit.
It is obvious that monocytes are a useful target cell for ASODN therapy, and the
potential for inhibiting inducible TF is great. The results of this study suggest that
inhibition of TF is possible, but much work needs to be done in designing a more
specific, accessible and efficacious ODN to the TF mRNA.
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Tissue Factor Induction onMonocytes: Potencies of a
Panel ofDifferent Lipopolysaccharide Molecules
Chapter 7
7.1 Introduction
Studies of LPS inductions of clotting activity most often utilize E. coli LPS. It is
clear, however, that LPSs are a complex set of molecular species the activities and
functionality of which vary greatly and are dependent on their structures and bacterial
source.
7.1.1 Bacterial Lipopolysaccharides
Bacterial lipopolysaccharides (LPS) are complex glycolipids that are integral
components of the outer membrane of all Gram-negative bacteria and which induce a
series of acute pathophysiological reactions in higher organisms (Table 7.1).
However, in addition to toxic effects, LPSs also induce effects considered to be
beneficial (Table 7.1).





Limulus amoebocyte lysate gelation
Induction of endotoxin intolerance
Adjuvant activity




Activation of procoagulant activity (tissue factor)
Activation ofmacrophages
Induction of tumour necrosis factor
Induction of interleukin-1
Induction of interferon
Induction of nonspecific resistance to infection
Protection against irradiation
Mitogenicity ofB lymphocytes
TABLE 7.1. Biological Effects of Bacterial LPSs. (Taken from Lindberg et al., 1990)
Structurally, most types of LPS are composed of three distinct regions: the lipid A
hydrophobic, the core oligosaccharide (composed of the structurally distinct inner
'lipid A proximal' region which consists of 3-deoxy-D-manno-2-octulosonic acid (2-
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keto-3-deoxyoctonate; Kdo) and L-glycero-D-manno-heptose residues, and the outer
core which consists of D-glucose and/or D-galactose and A-acetyl-D-glucoseamine
regions) and the O-polysaccharide which consists of long chains of repeating
oligosaccharide units (Fig 7.1). This general structure is typical of the LPS of
Escherichia coli and related enterobacteria and is often referred to as the smooth or
S-form chemotype. Enterobacterial mutants which have lost the O-polysaccharide
region of their LPS molecule are described as rough and produce a rough or R-form
chemotype in which the core oligosaccharide is the terminal region However, many
Gram-negative species naturally produce a rough form of LPS which is often termed
the lipooligosaccharide (LOS). R-mutants of Salmonella species and E. coli which
produce only partial core oligosaccharide are termed deep-rough mutants (Fig 7.2).
Such partial structures exist in nature, for example the full LOS/LPS of Chlamydia
species consists of lipid A and a 3-deoxy-D-manno-2-octulosonic acid (Kdo)
oligosaccharide only, which is similar to the deep-rough structure of the Re
chemotype - with which it cross reacts serologically (Brade et ai, 1987; Hoist et al,
1993).
7.1.2 Structural and Antigenic Heterogenicity
The O-polysaccharide structure of S-form LPS determines the O-serotype of the
strain and in E. coli alone there are over 160 different known serotypes. The core
oligosacharide can be structurally and serologically divided into two regions, the inner
and outer core. In E.coli there are five recognised core structures which show much
similarity to each other and to that of Salmonella species. The outer cores consist of
five hexoses (D-glucose, D-galactose and D-glucosamine) in different arrangements
and configurations, but showing an overall degree of similarity (Fig 7.1). The inner
part of the core is much more conserved containing the Kdo and heptose
trisaccharides as well as phosphate substituents. There is little variation between
closely related species. The lipid A region is much more conserved and within a
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FIGURE7.1SchematicRepresent tionofA. SmoothandB.RougLPS.Adaptedfr mindberg etal.,1990.
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FIGURE 7.2 Chemical structures of Salmonella R-mutants.
Kdo=3-deoxy-D-waw«o-2-octolosonic acid, Hep=heptose, Glc=
D-glucose, Gal=D-galactose, GlcNAc=A'-acetyl-D-glucosamine.
Adapted from Poxton, 1995.
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7.1.3 Function of LPS
The minimal structure of the LPS molecule which is essential for the viability of the
bacterium is equivalent to the Re-form LPS (Rietschel et al., 1990). The lipid A of
LPS is the sole lipid found in the outer leaflet of the bilayer of the outer membrane,
and the number and arrangement of the substituent fatty acids results in a membrane
of extremely low fluidity. It functions as a permeability barrier to hydrophobic
molecules and is, therefore, structurally and physiologically important The long O-
polysaccharide chains in the pathogenic bacterium confer resistance to the lytic action
of serum complement by preventing the insertion of an active membrane attack
complex into the bacterial envelope. Most R-mutants or naturally rough bacteria are
thus sensitive to the lytic action of normal serum.
7.1.4 Endotoxin
Endotoxin is the name given to bacterial LPS which is present within the circulation.
The lipid A region is responsible for the endotoxicity of the molecule but is never
found separated from the Kdo, the Re-like structure being the smallest found
naturally. Thus the minimum structure needed for endotoxicity is similar to that
required for bacterial survival. The host is continuously being exposed to endotoxin
and as a result, several mechanisms have evolved for detoxifying large and small
amounts of LPS. For example, on leukocytes, there are three classes of LPS
receptors. CD 18 binds to LPS present on bacteria and promotes their phagocytosis
without stimulating any secretory reponse (Wright and Jong 1986). Scavenger
receptor (acetyl-iow density lipoprotein) recognises dispersions of LPS and is
involved in pinocytosis and subsequent degradation of LPS. Finally, LPS-binding
protein (LPB), an acute phase protein (Wright, 1991) which is thought to be involved
in the neutralization of LPS, mediates the secretory responses of leukocytes through
binding to CD 14 (Wurfel et al., 1994). The LPS/LPB complexes act primarily on
monocytes/macrophages through the CD 14 receptor inducing the secretion of TF in
addition to a range of proinflammatory cytokines.
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7.1.5 Bacteroides fragilis LPS
The gram-negative bacterium Bacteroides fragilis is the most commonly isolated
anaerobic species in many infectious processes arising from faecal contamination such
as intraabdominal absesses and peritonitis (Gorbach and Bartlett 1974). Anaerobes in
general constitute approximately 99% of the faecal bacterial mass and, of this amount,
Bacteroides species constitute 20-30% of species isolated (Duerden et al., 1991).
Bacteroides species are numerically more abundant in the gut outnumbering members
of the family Enterobacteriaceae such as Escherichia coli by about 1000 fold
(Delahooke et al., 1995) and as such they constitute a large pool of biologically active
LPS. Bacteroides fragilis has been the most extensively studied of the Bacteroides
species (Lindberg et al., 1990; Williamson et al., 1984). It has been well documented
that Bacteroides fragilis LPS is generally less endotoxic than enterobacterial LPS
(100-1000 fold less) has a different fatty acid structure and is monophosphorylated
(Lindberg et al., 1990). Early studies on the endotoxic activity of the LPS of
Bacteroides fragilis were done in the 1970s by Sveen et al., 1977, Sveen, 1997 and
Kasper et al., 1976. It was concluded that the endotoxic activity of B. fragilis was
lower than that seen with the LPS of Salmonella More recently, the biological
activity of B. fragilis LPS has been reassessed by examining the lipid A molecule. It
has become apparent that the phosphate groups on the glucosamine residues are
important as are the number and structure of the fatty acids linked to the amino sugars
(Fig 7.1), (Kotani et al., 1985; Rietschel et al., 1987a; Rietschel et al., 1987b).
Loppnow et al., 1986, have shown that absence of the phosphate group on the non-
reducing glucosamine of the LPS (substance 505) reduced pyrogenicity in rabbits by
100-fold compared with its phosphorylated E. co/z-like derivative (substance 506). In
addition, the pyrogenic activity in rabbits of a fully phosphorylated substance with
four instead of six fatty acids (substance 406) was reduced by > 10-fold and the
substance had lost its ability to induce interleukin 1 in monocyte cultures. Moreover,
fiither studies by Loppnow et al., 1988 in which a characterised LPS of B. fragilis,
NCTC 9343, was used demonstrated that, compared with the LPS of Salmonella
minnesota Re595, its ability to induce interleukin 1 was reduced by 100- to 1000 fold.
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In addition, the ability of the LPS of B. fragilis to stimulate a release of
prostaglandins PGE2 and PGF2ot was slightly reduced from that of the LPS from S.
minnesota Re595. The LPS ofB. fragilis NCTC 9343 lacks the phosphate group on
the non-reducing glucosamine and has an average of 5 branched and long chain (CI 5-
C17) fatty acids (Weintraub et al., 1989) and so this has been concluded to be the
cause of the low endotoxicity.
However, recent studies by Delahooke et al., 1995 have shown that the biological
activity of B. fragilis LPS is dependent on the extraction method. The phenol-
chloroform-petroleum method used in earlier studies results in an LPS of low
endotoxic activity. However the aqueous phenol method used by Delahooke et al.,
produces a product with biological activities equivalent to that of enterobacterial LPS.




7.2 Materials and Methods
7.2.1 LPS Molecules Tested
Four of the LPS molecules tested were isolated and extracted by Prof. Ian Poxton,
Department of Medical Microbiology, University of Edinburgh and were kindly
donated in the lyophilised form. The Escherichia coli 018K~ LPS and the
Bacteroides fragilis LPSs were extracted using the aqueous phenol method (Westphal
and Luderitz 1954) as described by Hancock and Poxton, 1988 and the Salmonella
minnesota Re595 and Ra60 strains were isolated using the phenol-chloroform-
petroleum method (Galanos et al., 1969). All native LPSs were made free from
protein contamination by treatment with proteinase K (20p.g/ml) at 65°C for 2 hours
Proteinase K was removed by two washes with pyrogen free water at 100,000 x g.
Escherichia coli 011LB4 LPS was extracted by the trichloroacetic acid method
(Staub et al., 1965) and was purchased from Sigma. This latter LPS contains more
protein than the other LPSs and so will be less pure (Poxton, personal
communication).
7.2.2 TF Inducing Ability of a Panel of Different LPS Molecules
Whole blood samples from a total of six healthy volunteers were collected into citrate
coated tubes (Sarstedt). Aliquots of 500p.l were placed in sterile polypropylene tubes
and were treated with a range of concentrations of the 5 different LPS molecules
(reconstituted in sterile, pyrogen free distilled water) to be tested (0.1pg/ml-10p.g/ml)
(see table 7.1). The blood samples were incubated for 2 hours at 37°C in an
atmosphere of 95% air 5% C02. After this time, 100pl aliquots of blood were
indirectly immunostained for tissue factor as described in chapter 2, and the fixed cells
subsequently analysed by flow cytometry. The percentage TF positive monocytes was
recorded for each dose of each of the LPS molecules tested and dose response curves
plotted. From these curves the ED30 value was calculated. This is defined as the dose
of LPS required to produce 30% positive monocytes.
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7.2.3 Incubation of E. coli 018K LPS with an Excess of Bacteroides fragilis LPS
To test the hypothesis that B. fragilis LPS masks the TF inducing ability of E. coli
018K" LPS, 500pl aliquots of blood were incubated with a range of concentrations of
B. fragilis LPS (0. lpg/ml-lOug/ml) either in the presence of a Ing/ml dose of E. coli
018K" LPS or sterile distilled water for 2hrs at 37°C 95% air, 5% C02. Aliquots
(lOOpl) of blood were then indirectly immunostained for tissue factor and analysed by
flow cytometry. The percentage TF positive monocytes was recorded both in the























7.3.1 Potencies of a Panel of LPS Molecules at Inducing MonocyteTissue Factor
Antigen
Whole blood was incubated with increasing doses of 5 different LPS molecules and
the dose of LPS required to produce 30% positive monocytes was calculated (ED30).
The results revealed the following increasing order of LPS potencies: B.fragilis was
the least potent at inducing TF (ED30 300ng/ml). The LPS from E. coli strain
0111 ;B4 was more potent (ED30 0.2 ng/ml). The LPS from E. coM 018K~ strain and
the S. minnesota strain Ra60 were of similar potency (ED30 0.07ng/ml) and the
smallest deep rough LPS Re595 from S. minnesota was slightly more potent (ED30
0.03ng/ml) (Table 7.3 and Fig. 7.3)
LPS Approximate ED30 For TF Induction
(ng/ml)
E. coh 011LB4 0.2
E. coli 018K 0.07
S. minnesota Ra60 0.07
S. minnesota Re595 0.03
B. fragilis 300
TABLE 7.3 Potencies of LPS Molecules Tested at Inducing TF Antigen on Monocytes in Whole
Blood. ED30 is defined at the dose of LPS required to produce 30% positive monocytes.
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Potencies of 5 Different LPS Molecules at Inducing TF
Antigen on Monocytes in Whole Blood
♦ 0111:B4 —♦—018K —A— Re595
-•— Ra60 —■— B. fragilis
90 T
0 10"4 10"2 10° 102 104
LPS Dose (ng/ml)
FIGURE 7.3 Potencies of 5 Different LPS Molecules at Inducing TF Antigen on Monocytes in
Whole Blood. It can be seen that B. fragilis LPS is the least potent (ED30 300ng/ml).
Salmonella minnesota Re595 LPS was the most potent (ED30 30pg/ml). ED30 is defined as the




7.3.2 Effect of B. fragilis on TF Induction by E. coli 018K LPS
A set dose of Ing/ml E. coli 018K LPS was added to whole blood and incubated in
the presence of increasing concentrations of B. fragilis LPS. When added in excess.
B. fragilis LPS was able to mask the TF inducing ability of E. coli 018K" LPS (Fig
7.4). At a dose of 1 ng/ml, E. coli 018K" LPS produced 70% TF positive monocytes
which was gradually reduced by a maximum of 65% to 45% TF positive monocytes




Effect of B. fragilis LPS on TF Induction by
018K E. coli LPS
■ B. fragilis E. coli + B. fragilis
B. Fragilis Concentration (ng/ml)
FIGURE 7.4 Effect of B. fragilis LPS on TF induction by E. coli 018KLPS.
Increasing concentrations ofB. fragilis LPS were added to whole blood containing a set dose
of lng/ml E. coli 018K" LPS. The presence of an excess ofB. fragilis LPS resulted in a 65%





Bacterial LPSs or endotoxins are vital components of the outer cell walls of Gram-
negative bacteria. A variety of pathophysiological responses in various tissues and
organ systems occur during endotoxaemia including the induction of procoagulant
proteins such as TF and proinflammatory cytokines such tumour necrosis factor alpha
(TNF-a) on peripheral blood monocytes. Over stimulation of the clotting and
immune systems by excessive LPS leads to symptoms of endotoxic shock or systemic
inflammatory response syndrome (SIRS) a condition characterized by disseminated
intravascular coagulation and multiple organ failure (Bone et al., 1993). Therefore,
bacterial LPSs have been a focus of research for several decades.
The purpose of this preliminary study was to investigate the TF inducing capability of
a range of different bacterial LPS molecules. The five different molecules chosen
were: E. coli 0111 :B4 LPS, which is a standard LPS used in many studies requiring
induction of TF (including Stephens and Rivers, 1996, Stephens et al., 1996,
Amirkosravi et al., 1996, Yang et al., 1995, Steinemann et al., 1994); E. coli 018K"
LPS which is the commonest O-type found in septicaemia; two Salmonella mutant
LPSs S. minnesota Ra60 LPS which is a full core rough LPS and S. minnesota Re595
LPS a deep rough LPS; and finally B. fragilis LPS which is a smooth LPS from one
of the commonest inhabitants of the gut.
It has been concluded that the endotoxic activity ofB. fragilis is lower than that seen
with the LPS of Salmonella (Sven et al., 1977; Kasper et al., 1976). Recently, the
apparent reduced biological activity of B. fragilis LPS has been associated with the
structure of the lipid A molecule. It has become apparent that the phosphate groups
on the glucosamine residues are important as are the number and structure of the fatty
acids linked to the amino sugars (Kotani et al., 1985; Rietschel et al., 1987a;
Rietschel el al., 1987b). It has been shown that LPS from B. fragilis NCTC 9343 is
less potent at inducing IL-1 in monocyte cell cultures than LPS from S. minnesota
Re595 and at stimulating the release of prostaglandins PGE2 and PGF2a (Loppnow et
al., 1988). The LPS ofB. fragilis NCTC 9343 lacks the phosphate group on the non-
172
pr 7v. ncipiv^i
reducing glucosamine and has an average of 5 branched and long chain (CI5-CI7)
fatty acids and so this has been concluded to be the cause of the low endotoxicity
(Weintraub et al., 1989).
Studies by Delahooke et al., 1995 have demonstrated that the stimulation of TNF-a
production by Bacteroides fragilis LPS in isolated human mononuclear cells is
between 2 and 4 fold less than that by E. coli 018K" LPS. This group have also
shown that this induction of TNF-a is through a CD 14 independent mechanism, as it
is not blocked by anti-CD 14 monoclonal antibodies. In the current study 1 have
shown that B. fragilis LPS is 1500 times less potent at inducing TF antigen on
monocytes than E. coli 0111:B4 (ED30 200pg/ml vs 300ng/ml), 3000 times less
potent than E. coli 018K" LPS or S. minnesota Ra60 LPS (ED30 lOOpg/ml vs
300ng/ml), and 10,000 times less potent than S. minnesota Re595 LPS (ED30 3 0pg/ml
vs 300ng/ml) where ED30 is defined as the dose of LPS required to produce 30% TF
positive monocytes. To my knowledge, there are no other studies comparing the
potencies of different LPSs at inducing TF antigen on monocytes. It is possible that
the extraction methods used to produce the LPS molecules might effect their TF
inducing ability. However, this is unlikely as the least potent B. fragilis LPS was
extracted using the aqeous phenol method, which has been shown by Delahooke et
al., to produce LPS of a high biological activity, in contrast to the more potent Re595
LPS and Ra60 LPS which were extracted using the less effective phenol-chloroform-
petroleum method. The diminished potency of B. fragilis LPS at inducing TF
compared with the others tested is much more pronounced in my study than that seen
by Delahooke et al., for TNF-a production. This may be due the the fact my studies
were carried out in a whole blood model rather than in isolated cells. Although anti-
TNF-a antibodies have not been shown to attenuate procoagulant responses in
experimental and clinical experiments (Salat et al., 1996) TNF-a has been shown to
enhance LPS induction of TF in monocytes and endothelial cells (Parry and
Mackman, 1994). In vitro studies have shown the tissue factor gene to be under the
control of a cA-acting NFkB site (Oeth et al., 1994; Parry and Mackman 1994) and
TNF-a directly contributes to activation of this transcription factor leading to
upregulation of TF expression (Parry and Mackman 1994). It is possible that the
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diminished induction of TNF-a by B. fragilis coupled with the reduced capacity ofB.
fragilis to directly induce the TF protein resulted in the significantly lower TF antigen
expression on monocytes seen with B. fragilis LPS in my study. In a recent study by
Lynn et al., 1993, CD 14 and serum were shown not to be absolutely necessary for the
activation of mononuclear phagocytes by bacterial LPS. They suggested that a CD 14
independent pathway may be of importance in local sites of infection where the
concentration of LPS may be high, such as in faecal contamination of the peritineum.
Delahooke et al., have shown that in peritoneal macrophages from C3H/HeJ (LPS
non-responders) and C3H/FIe N (LPS responders) mice TNF release after stimulation
with both B. fragilis and E. coli LPS appeared to occur through a CD14-independent
pathway. The current study does not provide any evidence that B. fragilis LPS is
acting via a CD 14 independent pathway. Studies using CD 14 neutralizing antibodies
would be required to confirm this.
Studies by Loppnow et ah, in monocytes isolated from rabbits have demonstrated
that, compared with the LPS ofSalmonella minnesota Re595, the ability ofB. fragilis
LPS to induce interleukin 1 was reduced by 100- to 1000 fold (Lopponow et ah,
1988). Similarly, in the current study, I have demonstrated that B. fragilis LPS is
1500 times less potent than S. minnesota Re595 LPS at inducing TF antigen on
monocytes. The deep rough structure of S. minnesota Re595 is very similar to the
structure of Chlamydial LPS, which has been implicated in the pathogenesis of
coronary heart disease and in the aggravation of atherosclerosis (Leinonen et ah,
1993). The results from the current study show that, of all the LPSs tested, S.
minnesota Re595 LPS was the most potent at inducing TF on monocytes in their
whole blood environment. It is possible that this increased ability to induce TF may
contribute to the pathophysiology of Chlamydia induced cardiovascular disease.
It has been shown by Delahooke et ah, that an excess of Bacteriodes LPS blocked the
effects of E. coli LPS on human mononuclear leuckocytes and TITP-1 (monocytic)
cells. Whether this was due only to the configuration of LPS in solution or due to an
effect at the cellular level was not known. There is a well documented synergistic
relationship between E. coli and B. fragilis, whereby B. fragilis inhibits the
phagocytic killing of E. coli (Onderdonk et al., 1976; Rotstein et ah, 1989).
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Furthermore, Magnuson et al., have shown that B. fragilis NTCT 9343 LPS inhibits
E. coli LPS-induced human endothelial cell adhesiveness for neutrophils (Magnuson
et al., 1989). In the current study I have shown that B. fragilis LPS inhibited the
induction of TF antigen on monocytes by E. coli 018K" LPS by 65%. It is known
that Bacteroides species outnumber E. coli in the gut by at least 1000-fold. The
results of the present study, taken with the observations from the studies mentioned
suggest that ifBacteroides LPS is the main inducer of TF in situations where bacteria
or their products translocate from the gut into the blood stream, B. fragilis should be
targeted rather than E. coli. It is not yet known if the observations seen in vitro will
occur in vivo. However, if this is the case, it is not unlikely that the Bacteroides LPS
may serve a protective role against E. coli LPS induced monocyte TF expression.
Infection with Chlamydia pneumoniae has recently been shown to be associated with
atherosclerosis. Fryer et al., 1997 have shown that Chlamydia pneumoniae can infect
cultured human endothelial cells and stimulate a four-fold increase in the expression of
TF and platelet adhesion thus providing a link between infection with C. pneumoniae
and procoagulant activity. In addition, the C. pneumoniae organism has been
detected in atherosclerotic plaques from coronary arteries (Kuo et al., 1995), carotid
arteries and the thoracic and abdominal aorta (Ong et al., 1996). In the current study
I have shown that of all the LPSs tested, S. minnesota Re595 LPS was the most
potent at inducing TF expression on monocytes. Bearing in mind that the structure of
Chlamydia LPS is similar to that of S. minnesota Re595 LPS (they cross react
serologically) (Brade et al., 1987; Hoist et al., 1993) it is possible that in patients
infected by C. pneumonia, Chlamydia LPS may be responsible for the increased
thrombogenicity of the atheroscerotic plaque
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8.1 General Discussion and FutureWork
The main aim of this study was to investigate the potential of the monocyte as a
therapeutic target for the inhibition of the procoagulant protein tissue factor. Tissue
factor is the major in vivo activator of blood coagulation leading to thrombin
generation and fibrin deposition. Although TF is constitutively expressed in many
extravascular cells, peripheral blood cells do not normally express TF. Monocytes
and endothelial cells can be induced to express TF in response to a variety of agonists
such as LPS and TNF- a and, as a result, play an important role in the
pathophysiology of coagulation disorders such as disseminated intravascular
coagulation.
Antisense oligonucleotides are short lengths of single stranded DNA which bind to
DNA or mRNA and prevent the trascription or translation of target proteins. As
such, antisense therapy provides the promise of specific inhibition of particular target
proteins. The experiments described in chapter 3 investigate the potential of the
monocyte as a target for antisense therapeutics, with the view to specific inhibition of
the TF protein. Using the 25mer phosphorothioate ASODN GEM-91 I have shown
that there is heterogeneous uptake of ODN between PBL subtypes with monocytes in
particular internalizing ODNs more efficiently than other cell types. In addition, I
have demonstrated that uptake is dose and time dependent. After 4 hours in culture
with 10p.M ASODN, monocytes internalized approximately 45 times more ODN than
lymphocytes and twice as much as neutrophils, and at this dose uptake was not yet
saturated. Indeed at this dose monocytes contained 828fg ODN/cell which equates to
5xl07molecules of single stranded DNA. It is not known exactly how many copies of
ASODN are required to produce complete inhibition of target mRNAs but this
amount is likely to be in excess. However, from this study the intracellular fate of the
ODN was not determined. It has been noted that ASODNs have their effects mostly
in the cytoplasm where they come into contact with their target mRNA (Wagner et
al., 1995). Although I have shown that monocytes internalize ODN more efficiently
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than other PBL subtypes, it is unclear as to whether the ODN reaches the cytoplasm
and its target mRNA. Studies have been carried out which conclude that ASODN
uptake is, at least in part, receptor mediated, whereby ODNs bind to a cell surface
receptor and are internalized into 'receptosomes' from where they may or may not
escape into the cytoplasm (Beltinger et al., 1995). Other groups have demonstrated
that ODNs must be conjugated with a carrier molecule or encased in a liposome to
facilitate entry into cells and improve intracellular bioavailability (Hartmann et al.,
1998). These carriers have been shown to be cytotoxic at certain concentrations and
so may not be appropriate for systemic administration of ODNs. In agreement with
Hartmann et al, I have shown that monocytes internalize more ODN than other PBL
subtypes. However, in my study the differences are more striking, suggesting that
sufficient monocyte loading may be achieved at lower doses than previously thought
and without the need for carrier molecules. This suggests that monocytes are
potentially good target cells for antisense therapy. It was not possible in the current
study to examine the intracellular fate of ASODNs within the monocyte. Using
confocal and electron microscopic techniques, it has been suggested by some groups
that ODNs localize to intracellular acid vesicles (Loke et al., 1989; Stein et al., 1993;
Bennett et al., 1992) whilst others have observed ODNs in the nucleus and free in the
cytoplasm (Beltinger et al., 1995). Further microscopic studies will be required to
fully investigate the intracellular distribution of ASODNs in monocytes and to track
the movement ofODNs from the cell surface to the target mRNA.
Having shown that monocytes internalize more ODN than other PBL subtypes, an
investigation into a possible mechanism for this was investigated. The pattern of
uptake of ODNs into monocytes was strongly suggestive of a receptor mediated
mechanism. It has been demonstrated by many groups that ODNs enter cells by a
receptor mediated mechanism and a number of candidate receptors have been
investigated. Benimetskya et al., 1997 have convincingly demonstrated that the Mac-
1 (CDllb/CD18) receptor binds ODNs in neutrophils. This receptor is found in
greatest abundance on monocytes and neutrophils and is a likely candidate for ODN
uptake in monocytes. In addition it was thought that the monocyte cell surface
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marker CD 14 may also be affected by ODN molecules In chapter 4, the effect of
ODN on monocyte cell surface Mac-1 and CD 14 was investigated It was shown that
fluorescently labelled ODN association was greatest in the cells which had highest cell
surface Mac-1 and CD 14 receptor levels, namely monocytes and neutrophils.
Furthermore, it was demonstrated that incubation of PBLs with ODN for 30 minutes
resulted in a significant decrease in the monocyte cell surface levels of Mac-1 which
decreased further over the 4 hour incubation period. This mirrored the rate of
internalization of ODN described in chapter 3. CD 14 levels also significantly
decreased, but not until after 4 hours in the presence of GEM-91. Although it is clear
from these studies that the ODN was causing a downregulation of Mac-1 and CD 14,
it is not clear what form this downregulation is taking. It is possible that the ODNs
were simply binding to Mac-1 and CD 14 preventing antibody recognition of the
receptors by flow cytometry. However, the uptake kinetics of ODN described in
chapter 3, suggest that once bound to the cell surface, ODNs are indeed internalized.
This possible receptor mediated endocytosis would be responsible for a decrease in
cell surface receptors. Alternatively, the ODN may be causing a change in monocyte
cell phenotype by signalling a downregulation in receptor number. Both the Mac-1
and CD 14 receptors are involved in the LPS induction of TF on monocytes, and so
any effect of ODNs on these receptors could contribute to any modulation of
ASODNs on TF expression If ODNs are indeed ligands for these monocyte
receptors, it is possible that they could initiate intracellular signalling pathways
resulting in the expression of TF or other inducible proteins. Benimetska et ai, have
shown that upregulation of cell surface Mac-1 by TNF-a increased the binding of
ODNs. During the course of this study I attempted to demonstrate an increased ODN
association with monocytes after upregulation ofMac-1. However, this proved to be
outwith the limits ofmy experimental design. Although an upregulation in Mac-1 was
demonstrable with TNF-a, further treatment of isolated PBLs with ODN resulted in a
loss ofmonocyte morphology, and so flow cytometric analysis was not possible. To
further clarify the role of Mac-1 in ODN uptake in peripheral blood monocytes,
experiments using Mac-1 neutralizing antibodies are required. By examining ODN
uptake in the presence of a Mac-1 neutralizing antibody, or in the presence of a
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known ligand for Mac-1 such as fibrinogen a more conclusive effect of the importance
of this receptor in ODN uptake could be determined
Having determined that monocytes effectively internalized ODN. it was concluded
that it may be possible to inhibit induced TF expression on monocytes by ASODNs to
TF. The observations of over a decade of studies by Osterud et al. have concluded
that TF induction in monocytes is strongly influenced by cellular cooperations
between monocytes, neutrophils and platelets in whole blood. Therefore, I decided
that monocytes should be studied in the context of ex vivo whole blood in an attempt
to provide as physiological a model as possible in which to investigate TF induction
and its regulation. To this end it was necessary to characterize the induction of TF by
LPS in monocytes in ex vivo whole blood to determine the dose and time of
incubation of LPS which provided a suitable and reproducible TF induction. It was
decided to combine the methods of 0sterud and Amirkhosravi et al., to produce a
suitable system. The final protocol involved the incubation of citrated whole blood
with 10jug/ml LPS for 2 hours, after which time it immunostained for TF and analysed
by flow cytometry. During the course of this study it was shown that, in agreement
with the work of 0sterud and Amirkoshravi, there was little variation in the TF
antigen inducing ability of different individuals when treated with 10p.g/ml LPS.
0sterud has, however, noted that TF activity varies dramatically between the highest
and lowest responding individuals by as much as 50-fold. These results suggest that
low TF antigen levels may translate into much higher TF activities, and emphasize the
case for therapeutically targeting TF antigen levels by antisense ODNs in preference
to activity inhibition with, for example factor Vllai.
In chapter 6 studies aimed at the inhibition of TF induction using specifically designed
ASODNs are described. I initially designed a 30 base phosphorothioate ASODN
targeted to bind around the start-site of translation of the TF mRNA (ASJM) in an
attempt to inhibit translation of the protein, as I believed that was likely to be an
accessible site on the mRNA. This ODN alone did not produce any significant
inhibition of LPS induced TF antigen. During the course of these experiments a study
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by Stephens and Rivers was published in which they reported an 80% inhibition of TF
activity in isolated monocytes with a specifically designed ASODN to TF (AS1).
This ODN, in addition to a truncated version of it (AS2), were used in the current
study to investigate inhibition of TF antigen. At the lp.M dose a significant (42 %)
inhibition was seen in TF antigen when compared with ASODN untreated cells.
Neither the truncated ODN nor the mismatched version had an effect. In an attempt
to produce specific antisense effects, Stephens and Rivers' ODN was designed to
contain the rare tripeptide motif Trp-Lys-Ser, which had been predicted as a
functional motif involved in the interaction with serine proteases,. My studies initially
demonstrated that AS1 and its truncated and mismatched counterparts actually
induced TF on monocytes whereas ASJM and GEM-91 did not. Despite this fact.
AS1 was better at inhibiting TF than ASJM. This may have been due to the fact that,
through it's possible increased interaction with either the CD 14 or Mac-1 receptors,
AS 1 gained better entry to the cell by receptor mediated endocytosis. The concurrent
induction of TF may have been an unfortunate by product of this interaction, which
was not picked up by Stephens and Rivers. The increased efficacy of AS 1 is unlikely
to be wholly a consequence of AS1 superior design, as in the presence of the
lysosmatropic agent chloroquine, both AS1 and ASJM inhibited TF antigen induction
to roughly the same extent 45 ± 6.7% vs 37 ± 7.7 % and in regime 2 ASJM produced
a 41.9 ± 9.01% inhibition. This suggests that the disappointing results seen without
CQ were more likely to be due to diminished intracellular bioavailability which was
improved in the the presence of the lysosomatropic agent. However, it has been
reported that the efficacy of ASODNs is better in vivo than in vitro (Moma et
al.,1996) so it is possible that the effects of these ODNs could be improved if
administered systemically in vivo. It would be interesting to investigate the potential
of systemic administration ofASODNs to TF in an animal model of sepsis, to see how
they compare with monoclonal antibodies to tissue factor, which have been shown to
decrease mortality in many animal models of DIC (Taylor et al., 1991; Dackiw,
1996). If efficacious, ASODNs to TF would represent a potentially much less toxic
and more specific inhibition of TF. ASODNs to TF could also have applications for
more localized therapies. Expression of TF has been shown to increase around the
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sites of balloon angioplasty (Weiss et al., 1989). Local administration of ASODNs to
TF, perhaps by coating the balloon, would offer potential specificity as well as rapid
inhibition of induced TF only, around the site of injury.
Although in the current study the control ASODNs chosen were less efficacious than
the ASODNs to TF, it was obvious that some inhibition was occurring with these
control molecules. Ideally, several controls should be deployed alongside the specific
ASODN containing increasing numbers of specific base mismatches. Although a
random mismatched ODN was deployed with AS1 and was shown to have a lesser
effect (Table 6.4), financial constraints meant that a complete range of control ODNs,
for ASJM was not synthesized. In order to conclusively prove that the inhibitory
effects seen were indeed true antisense effects, a study using a more sophisticated
panel of control ODNs, each control perhaps containing an increasing number of base
mismatches, would be required. According to Branch, 1998, the concept that an
antisense molecule can selectively knock out a single gene remains, as yet,
unconfirmed. The original concept that ODNs are exquisitely specific and easy to
design has been marred by the discovery of numerous mechanisms of action leading to
non-antisense effects. As discussed already these include binding of the ODN to the
target protein preventing its recognition; binding of the ODN to a receptor causing
induction of the target protein or indeed another unrelated protein; or binding of the
ODN to a non-target RNA ultimately resulting in a decrease of the target protein.
Although these non-specific effects may be useful therapeutically, their
unpredictability makes them difficult to investigate as the rules for rational drug
design cannot be applied, leaving non-antisense effects to be monitored empirically.
Although the issue of their ultimate specificity remains, there is growing evidence that
antisense molecules can be useful pharmacological tools when applied carefully
(Crooke and Bennett, 1996). In addition, certain non-antisense effects of ASODNs
promise to be valuable therapeutically. The time and expense necessary to screen
large numbers of potential antisense molecules and to monitor their in vivo effects,
limits their investigation to the pharmaceutical industry. It has been shown in this
study that there is merit in targeting the monocyte to inhibit TF induction, but whether
or not the inhibitory effects are true antisense effects remains to be seen.
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Throughout the course of these studies, E. coli 0111 :B4 LPS has been used to induce
TF on monocytes. However, in reality, LPS from a number of different bacteria
might challenge the host. Bacteroides species are numerically more predominant (by
at least 10J fold) in the gut than members of the family Enterobacteriaceae such as E.
coli, and as such they represent a potentially large pool of biologically active LPS. It
is possible that TF might be induced on monocytes/macrophages by LPS from
Bacteroides fragils if it were to enter the bloodstream, such as in the case of DIC
caused by gut rupture. Furthermore, it has been demonstrated that B. fragilis LPS is
between 100 - 1000 fold less endotoxic than other LPSs (Lindberg et al., 1990). In
the light of studies by Delahooke et al., 1995 which have shown that B. fragilis is
between 2 and 4 fold less potent at inducing TNF-a in macrophages than E. coli LPS,
I have investigated the TF antigen inducing potential of a panel of five different LPS
molecules. 1 have demonstrated that B. fragilis LPS is 1500 times less potent at
inducing TF than E. coli 0111:B4 LPS and 3000 times less potent than E. coli 018K
LPS. From this study it was not clear why the B. fragilis LPS was less potent than
the E. coli LPSs. It is possible that, in contrast to E. coli LPS, Bacteroides LPS was
acting via a CD 14 independent mechanism resulting in the activation of an alternative
signal transduction pathway for inducing TF antigen. In order to fully test this
hypothesis, it would be necessary to carry out these experiments in ex vivo whole
blood in the presence of a CD 14 neutralizing antibody. It has already been shown by
Delahooke et al., that monoclonal antibodies to CD 14 did not block the TNF-a
inducing ability of Bacteroides fragilis in isolated human mononuclear leukocytes. It
is, therefore, likely that B. fragilis LPS will also induce TF via a CD 14 independent
pathway. This being the case, it is interesting to speculate what this alternative
pathway might be. It is possible that B. fragilis LPS might induce TF via a different
receptor such as the Mac-1 receptor, or via a different intracellular signalling
mechanism. Interestingly, in this study I have also shown that in the presence of an
excess of B. fragilis LPS, the TF antigen inducing ability of E. coli 018K LPS is
reduced by about 65%. This is in agreement with the observations of Delahooke et
al., for TNF-a induction. These observations are particularly interesting considering
that B. fragilis outnumbers E. coli species in the gut by about 1000 fold. If
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Bacteroides species are the main inducers of TF in conditions whereby the blood
stream is contaminated by faecal matter, greater efforts should be made to target this
bacterium with immunotherapy instead ofE. coli. Furthermore, it is also possible that
if the B. fragilis LPS has the same inhibitory properties in vivo as I have seen in ex
vivo whole blood, this bacterium could serve an important protective role. The
mechanism for this masking of the effects ofE. coli by B. fragilis LPS is unknown. It
might be speculated that ifB. fragilis LPS acts via a CD 14 independent pathway, this
mechanism, whilst causing the induction of less TF antigen, might also set in motion
an inhibitory second messenger system to block the effects of E. coli LPS.
Alternatively, it is possible that B. fragilis LPS might induce the transcription of a
repressor protein which blocks the CD 14 receptor to E. coli LPS. It is also possible
that this CD 14 independent TF induction might be more susceptible to inhibition by
ASODNs. This would also be an important further investigation.
In summary, I have shown that the monocyte is a feasible target cell at which to direct
antisense therapy aimed at the inhibition of aberrant TF induction. I have had limited
success at inhibition of TF antigen with both published and in-house designed naked
ASODNs but these limitations are likely to be surmountable ifmore time and money
were available to carefully design a more specific and bioavailable antisense molecule.
Unfortunately, this sort of fine tuning is limited to the pharmaceutical industry.
Antisense therapeutics is now a fast moving field with the approval of the first
antisense drug 'Vitravene' (for the treatment of patients with cytomegalovirus) taking
place in 1998, just seven years after the programme was initiated and nine years after
serious investment in the antisense technique began. This suggests that this form of
therapy is becoming widely accepted and is entirely feasible in vivo. The important
point now is to identify novel but sensible target proteins which are easily detected
and have a paramount role in disease. I believe that inhibition of the TF protein by
antisense therapeutics is well worth further investigation as this protein is suitably
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Extracellular gem-91 uptake raw data
GEM-91 Dose Level (plVlj
Cell Type Time(h) 0.1 1.0 10.0
Total Cells 0.5 31.9 ± 10.5 58.5 ± 17.2 425.2 ± 112
1.0 29.2 + 5.84 100 + 30.4 284 + 65.2
1.5 17.9 + 4.75 71.8 + 12.3 258 + 63.0
2.0 11.0 + 4.10 38.9 + 11.3 132 + 41.4
4.0 5.93+3.33 19.9 ± 1.93 115+29.6
Lymphocytes 0.5 0.54 + 0.55 1.7 + 0.11 69.3 ± 9.65
1.0 1.65+0.14 8.43 + 3.18 76.4+ 11.2
1.5 0.01+0.27 2.69+ 1.27 60.6 ± 8.59
2.0 0.54 + 0.41 2.85+0.51 49.7+ 14.7
4.0 0.30 + 0.49 2.11 ±0.2,1 56.5 ± 12.4
Monocytes 0.5 53.2 + 9.90 115 + 31.6 499 ± 70.6
1.0 55.1+4.34 264 + 79.5 555 +60.8
1.5 51.4 + 9.56 229 + 6.62 531 +54.8
2.0 25.0 + 12.0 132 + 20.8 468 ± 54.7
4.0 16.4 + 3.89 30.9 + 20.6 63.5 + 26.5
Neutrophils 0.5 31.3 ± 10.0 58.4+ 17.0 357 + 47.8
1.0 20.8 + 2.40 99.9 + 30.5 282 + 66.6
1.5 16.9 + 4.95 71.5+ 12.2 264 ± 60.8
2.0 12.4 + 6.23 38.7+ 10.9 142 + 48.1
4.0 5.93+3.16 20.2 + 2.26 135 +26.3
Append B1 Extracellular association of GEM-91with total leukocytes and lymphocyte, monocyte and
neutrophil subtypes at concentrations between 0.1-lO.Op.M up to 4 hours.




Intracellular gem-91 uptake raw data
GEM-91 Dose Level (pM)
Cell Type Time(h) 0.1 1.0 10.0
Total Cells 0.5 17.7 ± 1.35 62.0+11.6 130+12.4
1.0 31.2 + 7.66 65.8 + 8.05 129 + 34.1
2.0 62.2 + 7.61 151 ± 52.3 276 ± 86.6
4.0 87.5 ± 12.3 280 + 15.5 458 + 76.2
Lymphocytes 0.5 0.40 + 0.40 17.3 ± 11.9 20.9 + 5.20
1.0 0.60 + 0.17 15.9+11.4 68.2 + 20.4
2.0 0.60 + 0.30 8.80+ 1.73 93.8+ 12.1
4.0 3.70 + 3.70 12.5+4.87 89.9 + 30.7
Monocytes 0.5 32.6 + 4.69 117 + 22.6 208 + 3.83
1.0 40.9+ 11.3 88.5 ± 7.86 395 + 73.7
2.0 62.0 ± 27.0 191+60.6 365 ±121
4.0 172 + 65.5 506 ± 44.1 828 + 211
Neutrophils 0.5 19.2 + 1.48 64.0+ 10.0 130 + 12.0
1.0 24.4 + 24.4 80.9 + 7.28 217 + 40.7
2.0 59.1 +59.1 196 + 35.4 363 +40.4
4.0 77.0 ± 9.46 301 ± 1.4 460 + 56.1
Append. B2 Intracellular uptake of GEM-91 into total leukocytes and lymphocyte, monocyte, and neutrophil
subtypes at concentrations between 0. l-lOpM up to 4 hours.
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